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Zusammenfassung
Ziel dieser Arbeit war die Analyse der ERBB-Rezeptor anhängigen Signalwege
in unterschiedlichen Brustkrebszelllinien und die Etablierung sensitiver Metho-
den für die quantitative Untersuchung von Signalnetzwerken. Zunächst wurde
ein automatisiertes Protokoll für die reproduzierbare Zellstimulation mit Wachs-
tumsfaktoren entwickelt. Des Weiteren wurden Proteinarrays dahingehend an-
gepasst, dass sie für die umfangreiche Analyse von phosphorylierten Proteinen
eingesetzt werden konnten, wobei zwei Plattformen angewandt wurden: Micro-
spot Immunoassays und Reverse Phase Protein Arrays. Für die Datenanalyse
wurden in Zusammenarbeit mit der Bioinformatik-Gruppe der Abteilung ver-
schiedene Algorithmen entwickelt. Experimente in den ERBB2 überexprimie-
renden Zelllinien HCC1954 und SKBR3 zeigten, dass die therapeutischen Anti-
körper gegen ERBB2, Trastuzumab und Pertuzumab, die ligandenabhängige
Aktivierung der ERBB Signalkaskaden nicht wirkungsvoll verhindern konnten,
und auch durch die Kombination beider Antikörper konnte keine stärkere Inhi-
bition erzielt werden. Im Gegensatz dazu reduzierte die Kombination eines
der Antikörper mit dem EGFR Inhibitor Erlotinib signifikant die Liganden
induzierte Aktivierung der ERBB Signalkaskaden. Zusätzlich führte die An-
wendung der Kombination von Trastuzumab mit Erlotinib auf proliferierenden
Zellen zu einer Reduktion der Phosphorylierung des ribosomalen Proteins S6
und des Zellzyklusregulatorproteins RB und damit zu einem Zellzyklusarrest.
Daher konnte die Kombination von Erlotinib mit Trastuzumab als potentielle
Therapiemöglichkeit für Patientinnen mit ERBB2-positivem Brustkrebs postu-
liert werden. Der Vergleich der ERBB Signalkaskaden in den Zelllinien MCF7,
SKBR3, HCC1954 und BT474 zeigte, dass S6 ein guter Indikator für den Akti-
vitätsstatus des Signalnetzwerks ist, da S6 durch Signale der ERBB Rezeptor-
abhängigen PI3K- und der MAPK-Signalkaskaden aktiviert wird. Während
diese beiden Signalkaskaden bedingt durch verschiedene Expressionsmuster der
Rezeptoren und durch onkogene Mutationen in den Zelllinien unterschiedlich
auf die Therapeutika reagierten, spiegelte die Phosphorylierung des Proteins S6
den Einfluss exogener Signale am zuverlässigsten wider.
xiii

Summary
This work was focused on the quantitative analysis of time-resolved in vitro
measurements of ligand-induced ERBB signalling in breast cancer cell lines, as
well as the development of experimental methods suitable for the large-scale
analysis of signalling networks. First, an automated protocol for the highly
reproducible stimulation of cell lines with growth factors was developed. In
parallel, protein microarray technologies were advanced to the quantification of
phosphoproteins and resulted in two different assay formats: microspot immuno-
assays and reverse phase protein arrays. In collaboration with the bioinforma-
tics group, data analysis tools were developed for both platforms. Experiments
in ERBB2 overexpressing cell lines, HCC1954 and SKBR3, demonstrated that
both ERBB2 targeting monoclonal antibodies, trastuzumab and pertuzumab,
did not efficiently prevent ligand-induced signalling in vitro. Moreover, the
combination of both antibody therapeutics did not result in improved efficacy.
However, combining a single therapeutic antibody with the EGFR inhibiting
small molecule erlotinib significantly downregulated ligand-induced signalling.
Furthermore, treatment of proliferating cells with the combination of trastu-
zumab and erlotinib resulted in a dephosphorylation of the ribosomal protein
S6 and the cell cycle regulator protein RB resulting in cell cycle arrest. Thus,
the combination of erlotinib with trastuzumab could be postulated as potential
therapy for the treatment of ERBB2-positive breast cancer patients. A compa-
rative analysis of ERBB signalling in four cell lines, MCF7, BT474, HCC1954,
and SKBR3, revealed that the phosphorylation of the ribosomal protein S6 is
a strong predictor to analyse the activation status of signalling networks since
the S6 protein integrates signals from the MAPK as well as the PI3K pathway,
the two major pathways downstream of ERBB receptors. Due to differential
ERBB receptor expression or additional oncogenic mutations, therapeutics af-
fected ERK1/2 and AKT signalling to different extents in the four cell lines
whereas the S6 phosphorylation reflected reliably the cellular response on exo-
genous perturbations.
xv

1 Introduction
1.1 Breast cancer
Cancer is one of the two leading causes of death in western countries. Cancer
development is a multistep process and therefore, the cancer risk increases with
age. Chromosomal aberrations like copy number variations, translocations, gene
amplifications or deletions, and accumulation of mutations are the major causes
of cancer. Six essential alterations in cell physiology lead to malignant growth:
self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, eva-
sion of apoptosis, limitless replicative potential, sustained angiogenesis, and
tissue invasion and metastasis (Hanahan and Weinberg, 2000). While lung can-
cer is the most frequent cancer in men with 1.09 million new cases in 2008 (16.5%
of all diagnosed cancer cases), breast cancer is by far the most frequent cancer
type among women with an estimated 1.38 million new cases in 2008 (23% of all
diagnosed cancer cases) as delineated by the World Health Organization data-
base (Globocan). Risk factors are among others an increased hormone level
caused by childlessness, early menarche, late menopause or hormonal contra-
ception. Mutations of the tumour suppressor genes BRCA1 and BRCA2 are
linked to hereditary breast cancer (Hall et al., 1990). Physical activity and low
alcohol consumption reduce the cancer risk. Breast cancer is a heterogeneous
disease with respect to molecular alterations, cellular composition, and clinical
outcome. Based on hierarchical clustering of gene expression data, the first mo-
lecular profile of breast cancer was published by Perou et al. (2000). Further
analysis of the “intrinsic” gene expression pattern led to the identification of
five subtypes with significant clinical implications: luminal A, luminal B, basal
epithelial-like, ERBB2-positive, and normal breast-like (Sorlie et al. (2001); Fig.
1.1). Both luminal breast cancer subtypes exhibit a high expression level of the
oestrogen receptor (ER) while the basal epithelial-like subtype is characterised
by a high level of basal epithelial markers but a low level of ER/luminal-related
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Figure 1.1: Cluster of breast cancer subtypes
Hierarchical clustering of 115 tumour tissues and seven non-malignant tissues.
(Figure from Sorlie (2004).)
transcripts. Breast cancer samples related to the ERBB2-positive subtype ge-
nerally have a high expression level of genes lying in the ERBB2 amplicon at
chromosome 17q22.24. The normal breast-like subgroup shows the highest si-
milarity with non-epithelial cells. However, it is still under discussion whether
the normal breast-like type presents an important distinct molecular subtype
or is due to poor sample quality (Sorlie, 2004). A significant correlation has
been observed between the overall survival and chemotherapy sensitivity of the
patients and the molecular subclasses (Fig. 1.2). Kaplan Meier survival analysis
demonstrated that luminal subtypes are associated with the best clinical out-
come. However, a subgroup of ER-positive breast cancer patients, the luminal
B subtype, has a high proliferation rate and exhibits similarities in the gene
expression level when compared to ER-negative breast cancer patients (Sorlie,
2004). Therefore, tumours classified as luminal B are associated with a poor cli-
nical outcome. Additionally, the luminal B subtype is characterised by a lower
expression level of ER/luminal specific genes which may sometimes lead to resis-
tance against adjuvant hormone therapy. ERBB2 belongs to the ERBB family
of receptor tyrosine kinases and is overexpressed in 20–30% of breast tumours.
The ERBB2-positive subtype is associated with poor prognosis (Slamon et al.,
1987) and a short overall survival (Sorlie et al., 2001). The basal breast-like
subtype is often associated with the clinical triple-negative tumours which are
negative for expression of ER, progesterone receptor and ERBB2. Comparable
to the ERBB2-positive subtype, this subtype is also associated with poor prog-
nosis and worse outcome (Dent et al., 2007).
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Figure 1.2: Survival depending on breast cancer subtypes
Overall (A) and relapse-free (B) survival analysis of 49 breast cancer patients,
uniformly treated in a prospective study. (Figure from Sorlie et al. (2001)).
1.2 Breast cancer therapy
Standard cancer treatment like chemotherapy and radiation target highly proli-
ferating cells by inhibiting cell division or DNA replication. Besides the tumour
cells, healthy tissue such as bone marrow, hair follicles, and the digestive tract
are strongly affected. Targeted therapies were developed to overcome these se-
vere side effects by blocking exclusively the growth and spread of cancer by
disturbing the function of tumour specific molecules and leaving healthy tissue
unaffected. Targeted therapeutics mainly fall into the following four catego-
ries: tyrosine kinases inhibitors, angiogenesis inhibitors, proteasome inhibitors,
and immunotherapeutics. The first targeted therapy was developed against the
ER, which is often overexpressed in breast cancer (Ward, 1973). Several so-
called selective oestrogen receptor modulators (SERMs) like Tamoxifen, which
interfere with the binding of oestrogen to its receptors, are approved for ER-
positive breast cancer. Tamoxifen, the first ER-targeting therapeutic agent, was
already approved in 1977 for the treatment of advanced breast cancer in postme-
nopausal women. Herceptin®(trastuzumab), a monoclonal antibody targeting
ERBB2, was clinically approved in 1998 for metastatic ERBB2-positive breast
cancer in combination with conventional chemotherapy. A further targeted drug
for breast cancer therapy is lapatinib, a dual specific tyrosine kinase inhibitor
against EGFR and ERBB2, which is approved since 2007 for the treatment of
triple positive breast cancer (ER+, EGFR+, ERBB2+) and of advanced me-
tastatic ERBB2-positive breast cancer that has progressed after trastuzumab
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treatment applied in combination with capecitabine, a cytostatic agent. Mean-
while, these therapeutics face similar problems as conventional therapeutics like
insufficient efficacy. Only one third of the patients respond to trastuzumab
therapy and in the end almost all patients develop resistance within the first
year of treatment (Esteva et al., 2002). Targeting a single molecule or a single
pathway allows the tumour cells to find ways to circumvent drug interference.
A strategy to overcome this escape mechanism is to couple toxic substances to
tumour-targeting antibodies and thus deliver these directly to the cancer cell
(Alley et al., 2010, Krop et al., 2010). Another possibility is the treatment of
cancer cells with proapoptotic peptides. These peptides are guided by a second
peptide which specifically binds to the vasculature of the tumour (Arap et al.,
2002, Zurita et al., 2004). This reduces side effects as well as the likelihood to
develop resistance due to target-independent and immediate induction of apop-
tosis. Today, it is common clinical practice to determine the receptor status in
breast cancer to decide for the most appropriate treatment. Only patients with
ER-positive tumour are treated with Tamoxifen and ERBB2-positive patients
with trastuzumab. However, as not all patients respond to a targeted therapy,
it is important to be able to predict which patient will benefit from a certain
targeted therapy. A step further will take targeted therapy to personalised me-
dicine which aims at finding the most suitable treatment for a certain patient
at the right time.
1.3 ERBB receptor family members
Receptor tyrosine kinases (RTKs) are a group of transmembrane spanning re-
ceptors which regulate transduction from extracellular signals into a cellular
response. This group of signalling proteins frequently harbours oncogenic mu-
tations or are overexpressed in several cancer entities (Hynes and Lane, 2005).
RTKs are divided into 20 groups based on their structure as summarised by
Blume-Jensen and Hunter (2001) such as the epidermal growth factor receptor
(EGFR) family. The EGFR (or ERBB) family consists of four members, EGFR
(ERBB1, HER1) (Ullrich et al., 1984), ERBB2 (HER2, HER-2/neu) (Yama-
moto et al., 1986), ERBB3 (HER3) (Kraus et al., 1989, Plowman et al., 1990)
and ERBB4 (HER4) (Plowman et al., 1993), which show a high homology to
each other. The receptors evolved by two gene duplications from a single recep-
tor in invertebrates to four receptors in vertebrates (Stein and Staros, 2000).
4
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1.3.1 Structure of ERBB receptors
The receptors comprise five regions: an extracellular domain, a transmembrane
domain, a juxtamembrane domain, a kinase domain, and a C-terminal regula-
tory domain. The extracellular domain is further subdivided into four distinct
subdomains. In the ligand unbound state, these domains exist in a tethered
conformation, and the dimerisation loop is buried. Upon ligand binding, the
conformation of these domains changes into an active state. Activated receptors
expose the dimerisation loop and are now able to form homo- and heterodimers.
The dimerisation as such is independent of the ligand and entirely mediated by
receptor interaction (Ferguson et al., 2003, Garrett et al., 2002). The extracellu-
lar domain of the ERBB2 is radically different from the other family members.
Due to a unique interaction between domain I and III, the receptor resembles
the ligand bound conformation (Garrett et al. (2003); Fig. 1.3). Because of
this active conformation, the ERBB2 is the preferred dimerisation partner of all
other family members (Graus-Porta et al., 1997) and enhances signalling (Ka-
runagaran et al., 1996). Furthermore, ERBB2 has no known ligand (Lemmon,
2009).
Figure 1.3: Conformation of EGFR and ERBB2
The figure shows the conformation of ERBB2 in comparison with the ligand
unbound conformation of EGFR (A) and with the EGF bound conformation (B).
(Figure adapted from Franklin et al. (2004).)
1.3.2 ERBB receptor ligands
The EGF-family of peptide growth factors consists of 11 ligands. These ligands
are EGF, transforming growth factor alpha (TGF-α), heparin-binding EGF-like
5
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Figure 1.4: The ERBB receptors and their ligands
The figure shows the four ERBB receptors and the 11 ligands grouped according
to their binding specificity.
growth factor, (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin
(EPR), epigen, and four heregulins (HRG1-4), also called neuregulins. Like the
receptors, the ligands evolved from a single ligand in C. elegans (Citri and Yar-
den, 2006). All ligands contain a conserved EGF-like domain and are synthesised
as transmembrane precursor molecules (Harris et al., 2003). Release of the li-
gands is mediated by matrix-metalloproteases (Black et al., 1997). The growth
factors are specific for one or two receptors and are divided into four groups
based on their specificity. The first group binds specifically to the EGFR, the
second group binds to EGFR and ERBB4, the third group binds to ERBB3 and
ERBB4, and the fourth group binds specifically to ERBB4 (Fig. 1.4). ERBB
ligands are monomeric and induce conformational changes of only the single cor-
responding receptor. Binding of EGF to EGFR results in EGFR homodimers or
EGFR/ERBB2 heterodimers. Binding of HRG1 can result in ERBB3/ERBB2,
ERBB3/ERBB4, ERBB4/ERBB4 and ERBB4/ERBB2 dimers. Thus, ligand
binding induced receptor activation opens a variety of different dimerisation op-
tions. However, several ligands induce certain preferred receptor combinations
(Pinkas-Kramarski et al., 1996). While TGF-α preferably leads to the forma-
tion of homodimers, EGF induces EGFR/ERBB2 heterodimers (Lenferink et al.,
1998), and stimulation with HRG1 mainly results in ERBB2/ERBB3 dimers.
6
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1.3.3 ERBB receptor activation
Receptor dimerisation leads to transphosphorylation of specific tyrosine residues
located in the kinase or the C-terminal regulatory domain. Phosphorylation re-
sults in full kinase activity of the receptor. Additionally, the phosphotyrosine
residues in the C-terminal tail serve as docking sites for adaptor proteins contai-
ning SRC-homology 2 (SH2) or phosphotyrosine binding (PTB) domains. Figure
1.5 shows the phosphorylated residues of the four ERBB receptors and the cor-
responding adaptor molecules. These proteins serve as linkers which pass on the
signal from the receptor to distinct downstream signalling pathways. Among the
ERBB receptors, there are two receptors with special properties. First, ERBB2
has no own ligand, it enhances and prolongs signalling by exploiting different
mechanisms. ERBB2 modulates the dissociation of the receptor-ligand complex
of its heterodimerisation partner (Karunagaran et al., 1996). It has also been
reported that ERBB2 containing heterodimers evade endocytosis (Wang et al.,
1999). While EGFR homodimers are degraded, heterodimers with ERBB2 are
recycled back to the cell surface (Lenferink et al., 1998). Overexpression of
ERBB2 causes constitutive activation of ERBB2 and ligand-independent acti-
vation of EGFR (Worthylake et al., 1999). Second, the ERBB3 receptor has a
dead kinase domain (Guy et al., 1994) and is exclusively activated via trans-
phosphorylation. Therefore, ERBB2 and ERBB3 receptors are active only in
the context of ligand-activated ERBB heterodimers. ERBB2/ERBB3 dimers
are the most prevalent and potent dimers in terms of inducing cell growth and
transformation and are therefore regarded as the most tumourigenic heterodimer
(Holbro et al., 2003, Wallasch et al., 1995). Members of this family are dere-
gulated in many cancer entities like lung, colon (EGFR), or breast (ERBB2).
Thus, ERBB signalling presents one of the most studied and targeted pathoge-
nic signalling network in biology. As described before, the four receptors carry
binding sites for a diverse set of SH2 domain containing proteins (Fig. 1.5).
These proteins bind to the receptors with different affinities and contribute to
the diversity of signalling output. EGFR and ERBB4 mainly possess GRB2 and
Shc binding sites which recruit RAS and result in an activation of the mitogen-
activated protein kinase (MAPK) pathway. Other direct targets of the EGFR
are STAT5 and PLCγ . ERBB3, on the other hand, has at least six binding
sites for p85, the regulatory subunit of the phosphoinositide 3-kinase (PI3K).
The binding sites on ERBB2 are much more promiscuous (Jones et al., 2006)
and this receptor is therefore able to activate both major pathways. Another
7
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Figure 1.5: Summary of systematic interaction profiling of ERBB re-
ceptors
Shown are cytoplasmic phosphotyrosine residues of each receptor. The kinase
domains are designated as dark oval. Underlined and coloured residues mark
identical sequence regions between the receptors. Most interaction partners are
found at the c-terminal end outside the kinase domain. (Picture from Schulze
et al. (2005))
factor contributing to the diversity of signalling pathways is the difference in
dissociation constants for each adaptor molecule. Jones et al. (2006) showed
that the receptors bind different sets of adaptor molecules dependent on the
abundance of a certain protein. The ERBB3 network is nearly unaffected by
the concentration of adaptor molecules while EGFR and ERBB2 act more pro-
miscuous at high protein expression levels. The overexpression of EGFR and
ERBB2 in many cancer types could therefore result in signalling via alternative
pathways and not only by inducing stronger signals.
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1.4 ERBB signalling pathways
Downstream of the ERBB receptors are two major signalling pathways, the
MAPK and the PI3K pathways. The MAPK pathway mainly drives cell proli-
feration while PI3K activation drives cellular survival and anti-apoptotic signals.
Figure 1.6 gives an overview on the major keyplayers of MAPK and PI3K si-
gnalling and the crosstalk between the two pathways and the major proteins are
described in the glossary.
Figure 1.6: ERBB signalling pathway
Schematic overview of downstream proteins involved in ERBB receptor mediated
signalling. The arrows do not necessarily represent direct interactions between
the proteins.
The guanine nucleotide exchange factor SOS binds to the adaptor molecule
GRB2 and is thereby recruited to the activated membrane receptors. RAS, a
small membrane-bound monomeric GTP-binding protein, is activated through
the SOS-mediated exchange of GDP to GTP. Activated RAS interacts with se-
veral effector proteins like RAF and PI3K. The MAPK cascade consists of three
components existing in several isoforms. After activation by RAS, RAF translo-
cates into the cytoplasm and phosphorylates the MAPK kinase MEK1/2 which
9
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then leads to the activation of ERK1/2. Signal amplification occurs via the
RAF-mediated phosphorylation of MEK1/2, as MEK1/2 is expressed in sub-
stantially higher amounts compared to RAF (Santen et al., 2002). MEK1/2 is
a dual specific kinase which phosphorylates ERK1/2 at a threonine and a tyro-
sine residue separated by just a single amino acid and phosphorylation on both
amino acids is essential for full ERK1/2 activity. Next, p90RSK is phosphory-
lated by ERK1/2. The ERK1/2 pathway is deregulated in about one third of
all human cancers. Overexpression of the receptors can result in a constitutive
activation of this pathway. Besides, members downstream of the receptor are
also frequently mutated, especially RAS and B-RAF (Dhillon et al., 2007).
The PI3K consists of two subunits, the regulatory p85 and the catalytical p110
subunit. The p85 subunit directly binds to phosphotyrosines of the activa-
ted receptors, mainly ERBB3, and directly leads to activation of the lipid ki-
nase. Next, PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2)
to produce phosphatidylinositol-3,4,5-trisphosphate (PIP3). This is an impor-
tant second messenger molecule which recruits proteins like PDK1 and AKT to
the cell membrane. PDK1 phosphorylates AKT at position T308. AKT then
releases inhibition of mTOR by phosphorylating PRAS40 and TSC2. mTOR
exists in two complexes: mTORC1, which is rapamycin sensitive, and mTORC2,
which is rapamycin insensitive. mTORC2 was identified as PDK2 which phos-
phorylates AKT at position S473 (Sarbassov et al., 2005). The interplay of
PDK1, AKT, and mTORC1 results in phosphorylation of p70S6K which then
phosphorylates several effectors associated with translation like the ribosomal
protein S6 and eIF4B. A negative regulator of this pathway is PTEN, which de-
phosphorylates PIP3 and thereby inhibits growth signals and prevents tumour
formation. The PI3K pathway is deregulated by activating mutations within
different domains of the p110 subunit. Another factor is loss of PTEN which
also results in constitutive activation of the PI3K pathway.
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1.5 Therapies targeting ERBB receptors
As members of the ERBB receptor family are frequently overexpressed in dif-
ferent cancer entities, mainly due to genomic amplifications, they quickly moved
into the focus for development of targeted therapy. In principle, two different
molecular strategies, monoclonal therapeutic antibodies and small molecules
inhibiting receptor tyrosine kinases, are exploited to produce target specific in-
hibitors. Nowadays, therapeutics of both categories are clinically approved, and
combinatorial therapies are under investigation. Figure 1.7 shows the mode
of action of the monoclonal antibodies trastuzumab and pertuzumab, and the
small molecule drug erlotinib.
Figure 1.7: Mode of action of trastuzumab, pertuzumab, and erlotinib.
The antibody trastuzumab (a) binds to domain IV of ERBB2 extracellular do-
main. The antibody pertuzumab (b) binds to domain II, the dimerisation loop
of ERBB2 and sterically blocks dimerisation. Erlotinib (c) inhibits ATP binding
to EGFR tyrosine kinase domain and thereby prevents downstream signalling.
(Picture adapted from Baselga and Swain (2009)).
1.5.1 Antibody therapeutics
Trastuzumab is a humanised monoclonal antibody against ERBB2. It was ini-
tially approved for the therapy of patients with metastatic breast cancer with
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overexpressed ERBB2 in combination with conventional chemotherapy. Its anti-
tumour activity is multifaceted, and the mode of action has not been fully un-
derstood. Trastuzumab leads to cell cycle arrest in the G1-phase caused by
upregulation of cyclin-dependent kinase (CDK) inhibitor p27 which results in
decreased CDK activity (Ye et al., 1999). It has been described that tras-
tuzumab inhibits both the PI3K and MAPK pathways which in turn leads to
upregulation of p27 (Yakes et al., 2002). The inhibition of AKT has been shown
to be due to an upregulation of PTEN (Nagata et al., 2004). As a humanised
IgG1, trastuzumab is bound by the Fcγ receptor III (RIII) and thereby induces
antibody-dependent cytotoxicity (ADCC) in vitro (Cooley et al., 1999) and in
vivo (Clynes et al., 2000). Trastuzumab binds to the juxtamembrane region of
the ERBB2 receptor (Cho et al., 2003). For that reason, it prevents shedding of
the receptor (Molina et al., 2001). Proteolytic cleavage of the receptors results in
a truncated ERBB2 called p95. This truncated receptor is constitutively active
(Christianson et al., 1998) and no longer subjected to regulation. Initially, it
was thought that trastuzumab also leads to an increase in ERBB2 endocytosis
or degradation but meanwhile it has been shown that it does not downregulate
ERBB2 from the cell surface (Austin et al., 2004). There is still controversy
whether the unchanged abundance of ERBB2 is due to endocytosis resistance
(Hommelgaard et al., 2004, Longva et al., 2005) or due to enhanced recycling
and decreased endocytosis (Austin et al., 2004). Additionally, it was reported
that trastuzumab treatmentalso reduced the VEGF receptor expression and led
to a vasculature resembling the normal phenotype in vivo (Izumi et al., 2002).
Pertuzumab (Omnitarg®) is another humanised monoclonal antibody against
ERBB2 (Adams et al., 2006). At the moment, phase III clinical studies are
ongoing (NCT01120184). Pertuzumab binds to domain II, the dimerisation
domain, and thus prevents binding of ERBB2 to other ERBB receptors (Franklin
et al., 2004). It has been reported that pertuzumab is able to inhibit formation
of ERBB2/ERBB3 dimers (Agus et al., 2002) and thus to prevent the formation
of the most tumourigenic dimer. Pertuzumab has demonstrated its activity in
vitro and in vivo in several tumour entities expressing different levels of ERBB2,
including ovarian (Mullen et al., 2007, Takai et al., 2005), breast, prostate (Agus
et al., 2002), lung (Sakai et al., 2007) and colorectal cancer (Pohl et al., 2009).
In contrast to trastuzumab, which is only active in ERBB2 overexpressing cells,
pertuzumab is able to inhibit growth also in cells with normal ERBB2 expression
(Sarup et al., 1991).
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1.5.2 Small molecule therapeutic agents
Erlotinib (Tarceva®) is a selective inhibitor of the tyrosine kinase domain of
EGFR. It is clinically approved since 2005 for the treatment of non-small cell
lung cancer (NSCLC) and since 2007 for the treatment of pancreatic cancer.
Currently, it is evaluated in several phase II clinical studies for treatment of
breast cancer (Dickler et al., 2009). Like many other small molecules targeting
the ATP binding site of the receptors, it is not absolute specific for the EGFR
but also inhibits other kinases (Karaman et al., 2008).
1.5.3 Resistance to targeted therapies
Targeted therapies aiming at the inhibition of one single molecule are suscep-
tible to resistance. Various breast tumours exhibit innate or acquired resistance
towards ERBB2-targeting therapies and resistance is linked to alterations of
the PI3K pathway. PTEN is a negative regulator of the PI3K pathway and is
the most commonly lost tumour suppressor in human cancer (Liu et al., 2008).
In breast cancer, loss of PTEN is associated with poor prognosis (Depowski
et al., 2001) and trastuzumab resistance (Nagata et al., 2004). Other factors
associated with resistance are gain of enzymatic function mutations of the p110
catalytical subunit of PI3K which results in constitutive activation (Saal et al.,
2005) and has been shown to be oncogenic in vivo (Bader et al., 2006). Both al-
terations result in constitutive activation of the PI3K pathway and are therefore
reported to correlate with similar prognostic factors (Perez-Tenorio et al., 2007).
Additionally, downregulation of p27 is associated with trastuzumab resistance
(Nahta et al., 2004). Upregulation or activation of other receptor tyrosine ki-
nases like the IGF-IR (Lu et al., 2001, Nahta et al., 2005), ERBB3 (Sergina
et al., 2007, Wang et al., 2008), or MET (Shattuck et al., 2008) are associa-
ted with resistance in breast cancer and other cancer entities (Engelman et al.,
2007). Studies indicate that the truncated form of ERBB2 which lacks the ex-
tracellular domain causes resistance (Xia et al., 2004). One possible explanation
is that trastuzumab is not able to bind to the truncated form. Additionally, it
has been proposed that trastuzumab instead binds to the shedded extracellular
domain and is thereby neutralised (Leary et al., 2009). Finally, the upregulation
of ERBB ligands is able to counteract ERBB receptor inhibition. It has been
reported that TGF-α is upregulated in tumours which are resistant to therapy
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(Valabrega et al., 2005). Chakrabarty et al. (2010) showed that cell lines har-
bouring both amplified ERBB2 and mutant PI3K revealed higher levels of HRG
which results in autocrine activation of ERBB3 and ERBB4. Consistent with
this, Eckstein et al. (2008) reported that amphiregulin expression is associated
with cisplatin resistance. Overall, overexpression and mutations of kinases or
upregulation of receptor ligands were mainly associated with therapy resistance.
Many diseases like cancer are correlated with alterations of protein abundance
and function. All cancers carry somatic mutations but only a subset are so-called
driver mutations which are implemented in tumour development and confer
growth advantage (Pleasance et al., 2010). However, large-scale sequencing stu-
dies revealed that the signature of somatic mutations is highly variable. At least
350 cancer genes have been identified so far (Futreal et al., 2004). Another study
identified driver mutations in 120 of 518 protein kinase genes (Greenman et al.,
2007). An important subclass of mutations confers therapy resistance. Some
mutations already exist in resistant subclones and convert to driver mutations
once the selective environment changes due to initiation of therapy (Stratton
et al., 2009). Although mutations, changes on the transcriptome level, and the
fine tuning by micro RNAs influence of cellular behaviour, only transient pro-
cesses like protein phosphorylation mainly reflect the activity status of a cell.
Thus, sequencing and measuring mRNA or miRNA levels are not sufficient to
provide information on protein abundance and posttranslational modifications
(Tibes et al., 2006). Minor changes of protein abundance, modification or acti-
vation can result in a deregulation of the cellular balance between proliferation,
differentiation, migration, and apoptosis. Technologies, which allow to measure
and quantify small changes in a time-resolved manner, open new possibilities to
develop novel therapeutical strategies. The identification of cellular profiles in
response to targeting therapeutics may contribute to predict sensitivity or re-
sistance to a certain drug if similar activation profiles can be found in tumours.
Consequently, methods for the high throughput analysis of proteins are required
to gain insights into the tightly regulated network of cellular signal transduction.
14
1.6 Protein Microarrays
1.6 Protein Microarrays
Protein microarrays are a reliable tool for the quantitative analysis of protein
expression and activation of signalling networks (Grubb et al., 2003, Wulfkuhle
et al., 2008). Two different approaches were established in the division.
phosphospecific
capture antibody
sample
incubation
detection
antibody
secondary
antibody
Figure 1.8: Schematic overview of the MIA approach
Capture antibodies are immobilised on nitrocellulose coated glass slides. This
antibody binds to the target protein in the lysate which is than detected with a
second specific antibody. The complex is visualised by a NIR-labeled secondary
antibody.
The first format is the microspot immunoassay (MIA) (Korf et al., 2008a) which
allows the determination of several phosphoproteins in parallel from only small
sample amounts. A scheme of the procedure is shown in figure 1.8. In gene-
ral, the MIA is a miniaturised sandwich enzyme-linked immunosorbent assay
(ELISA). Two specific antibodies are targeting different epitopes of the same
protein. This increases sensitivity and specificity and enables the detection
of phosphorylation events of lowly abundant proteins. Capture antibodies are
immobilised on nitrocellulose coated glass slides, and a certain set of capture
antibodies is spotted on 16 identical subarrays per slide. Six of these subar-
rays are then incubated with a dilution series of recombinant phosphoproteins
of known concentration to generate antibody specific calibration curves for each
phosphoprotein. The remaining 10 subarrays are incubated with the protein
lysates of interest. With the help of a calibration curve, the concentration of
phosphoprotein in the lysate is calculated. Applying MIA allows to determine
the absolute quantity of the assessed phosphoproteins. MIAs are a very sensitive
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tool, as small amounts of the target phosphoprotein are captured from a sample.
A valid antibody pair detects proteins in the pg/ml range, and depending on
the abundance of the target protein, only 10–50 µg/ml total protein is needed
for the quantification of the target phosphoprotein.
Nitrocellulose-coated slide with two subarrays
Lysate-Spot
Target-specific
1. antibody
NIR-labeled
2. antibody
Scanned slide
Figure 1.9: Schematic overview of the RPPA approach
Protein lysate is immobilised on nitrocellulose coated glass slides. A specific
antibody binds to its target and is visualised by a NIR-labeled secondary antibody.
The second approach are reverse phase protein arrays (RPPAs) (Paweletz et al.,
2001). Here, the protein lysates are directly immobilised on nitrocellulose coa-
ted glass slides, and more than 2000 samples can be analysed in parallel on one
slide. With only a few µl of protein lysate, at least 100 arrays can be printed
and analysed. To increase sensitivity, this approach was adapted to detection
in the near-infrared range (Loebke et al., 2007). Figure 1.9 shows the work-
flow of the RPPA. Each array is incubated with a different primary antibody
recognising the target protein or phosphorylation site of interest. This complex
is visualised by a near-infrared labeled secondary antibody. For normalisation,
single arrays are also incubated with total protein dyes. By analysing the si-
gnal intensities of individual spots, RPPAs allow the relative quantification of
proteins or phosphoproteins within the set of printed lysate samples.
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1.7 Aim of the study
The overall aim of the study was the quantitative and time-resolved analysis of
ERBB signalling on the systems level in breast cancer cell lines. As prerequisite,
experimental methods had to be developed to produce and analyse biological
samples on a large scale and to generate data for quantitative modelling. To ob-
tain high quality, quantitative data, protocols had to be adapted to the protein
microarray format allowing the targeted analysis of signalling processes. For pro-
tein microarray data analysis, appropriate tools had to be developed in parallel.
The first aim was to delineate the interplay between signalling processes invol-
ving the ERBB3/PI3K and the EGFR/MAPK pathways. The second aim was
to examine the impact of the targeted therapeutics trastuzumab, pertuzumab,
and erlotinib on ligand-induced pathway activation in ERBB2 overexpressing
cell lines to elucidate quantitative differences between all possible combinatorial
treatments for the identification of an optimised treatment strategy. Quantita-
tive data will feed into data-driven modelling of network dynamics to identify
new points of therapeutic intervention.
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2.1 Materials
2.1.1 Chemicals
The chemicals applied in this thesis were purchased from the following compa-
nies if not described otherwise:
AppliChem (Darmstadt) Baker (Groß-Gerau) BioRad (München)
Fluka (Seelze) Gerbu (Gaiberg) Merck (Darmstadt)
PAA (Pasching) Roth (Karlsruhe) Sigma (Steinheim)
2.1.2 Equipment
2470 Arrayer Aushon, Billerica
5100 Cryo 1◦C Freezing Container Thermo Scientific, Karlsruhe
7900HT Sequence Detection System Applied Biosystems, Darmstadt
Biomek®FX Beckman Coulter, Krefeld
FACScalubur™ BD, Heidelberg
Incubation chamber Metecon, Mannheim
Incubator BBD 6220 Heraeus, Hanau
Laminar flow workbench (Hera-safe) Heraeus, Hanau
Multichannel pipette Biohit, Rosbach
Multipette plus Eppendorf, Hamburg
NanoDrop ND-1000 UV/VIS NanoDrop Technologies,
spectrophotometer Wilmington
Odyssey®Infrared Imaging System LI-COR Bioscience, Lincoln
pH meter Hanna Instruments, Kehl
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Pipetteboy Integra Biosciences, Fernwald
Pipetteman Gilson, Langenfeld
PTC-225 Peltier Thermo Cycler MJ Research
Mini-Protean®II eletrophoresis cell BioRad, München
Spectra MAX 190 Molecular Devices, Ismaning
SonoPlus Bandelin, Berlin
Trans-Blot®SD Transfer Cell BioRad, München
Tube rotator VWR, Darmstadt
Centrifuges Biofuge fresco, Heraeus, Hanau
Multifuge 4KR, Heraeus, Hanau
Sigma 4K15C, Qiagen, Hilden
Sorvall RC 5B Plus, Langenselbold
2.1.3 Consumables
10 cm plates TPP, Darmstadt
6 and 15 cm plates Greiner Bio-one, Frickenhausen
6-well plates Nunc, Langenselbold
96-well plates Greiner Bio-one, Frickenhausen
Cell culture flasks T25, T75, T175 Greiner Bio-one, Frickenhausen
Cell scraper TPP, Darmstadt
Combitips Eppendorf, Hamburg
Filtertips (RPT) Starlab, Ahrensburg
Pasteur pipettes WU, Mainz
Polypropylene columns (5ml) Qiagen, Hilden
Reaction tubes (1.5ml, 2ml) Eppendorf, Hamburg
Serological pipettes BD, Heidelberg
Tubes (15ml, 50ml) Greiner Bio-one, Frickenhausen
2.1.4 Miscellaneous
Complete, Mini Roche, Mannheim
Fast Green, FCF Sigma, Steinheim
Lipofectamine™2000 Invitrogen, Darmstadt
Lysozyme Sigma, Steinheim
ONCYTE ®Nitrocellulose slides Grace Biolabs, Bend
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peqGold prestained Protein-Marker IV Peqlab, Erlangen
peqGold prestained Protein-Marker V Peqlab, Erlangen
PhosSTOP Roche, Mannheim
PVDF membrane Millipore, Eschborn
0.45 µm Immobilon-FL
SwellGel Immobilized Pierce, Bonn
Glutathione Discs
Tween®20 Sigma, Darmstadt
Whatman paper (0.34mm) Whatman, Dassel
2.1.5 Kits
BCA Protein Assay Kit Pierce, Bonn
RevertAid™H Minus First Strand Fermentas, St.Leon-Rot
cDNA Synthesis Kit
RNeasy®Mini Kit Qiagen, Hilden
2.1.6 Recombinant proteins
AKT1/PKBα, active, 14-372 Millipore, Schwalbach
ERK1 (MAPK3), PV3311 Invitrogen, Karlsruhe
2.1.7 Growth Factors
Growth factors were diluted in PBS containing 0.1% BSA to a final concentra-
tion of 100 ng/µl.
Betacellulin (BTC) R&D Systems, Wiesbaden
Epidermal growth factor (EGF) Sigma, Steinheim
Heregulin-β1 (HRG1-β) Biocat, Heidelberg
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2.1.8 Kinase inhibitors and targeted therapeutics
Table 2.1: Inhibitors, therapeutics, and corresponding concentrations
inhibitor company target stock applied
erlotinib Roche EGFR 12,7mM 1µM
gefitinib Asta Zeneca EGFR 50mM 10 µM
LY294002 Calbiochem PI3K 50mM 10µM
PD98059 Calbiochem MEK1 20mM 10 µM
pertuzumab Roche ERBB2 25mg/ml 10µg/ml
rapamycin US biological mTORC1 50mM 10nM
trastuzumab Roche ERBB2 24,7mg/ml 10µg/ml
Pertuzumab 10 mM histidine, 240 mM sucrose, 0.02% Tween®20
Trastuzumab 5 mM histidine, 60 mM trehalose, 0.1 mg/ml Tween®20
Erlotinib 6% Captisol
Small molecule inhibitors were dissolved in DMSO.
2.1.9 Buffers, media, solutions
0.25% trypsin EDTA solution GIBCO, Invitrogen, Darmstadt
7-amino-actinomycin D Calbiochem, Darmstadt
ABsolut™QPCR ROX (500nM) Mix ABgene, Schwerte
Antibody Diluent with Background Dako, Glostrup
Reducing Components
DMEM (41966) GIBCO, Invitrogen, Darmstadt
DMEM (31053) GIBCO, Invitrogen, Darmstadt
DPBS GIBCO, Invitrogen, Darmstadt
Fetal Bovine Serum GIBCO, Invitrogen, Darmstadt
HEPES, 1M GIBCO, Invitrogen, Darmstadt
l-glutamine, 200mM GIBCO, Invitrogen, Darmstadt
Mammalian Protein Extraction Pierce, Bonn
Reagent (M-PER)
MEM Non-essential amino acids (100x) GIBCO, Invitrogen, Darmstadt
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Nuclease-free Water Ambion, Darmstadt
Odyssey®Blocking Buffer Licor Bioscience, Bad Homburg
OptiMEM GIBCO, Invitrogen, Darmstadt
Ponceau S solution Sigma, Steinheim
Roti-Load1 Roth, Karlsruhe
Rotiphorese Gel 30 Roth, Karlsruhe
RPMI 1640 (A10491) GIBCO, Invitrogen, Darmstadt
RPMI 1640 with GlutaMAX™(61870) GIBCO, Invitrogen, Darmstadt
RPMI 1640 without phenol-red (11835) GIBCO, Invitrogen, Darmstadt
Sodium pyruvate, 100mM GIBCO, Invitrogen, Darmstadt
TEMED Serva Electrophoresis, Heidelberg
10x PBS (pH 7.4) 1.37M NaCl
27mM KCL
18mM KH2PO4
100mM Na2PO4
10x TBS (pH 7.6) 1.37M NaCl
200mM Tris
SDS-PAGE
Table 2.2: Composition of polyacrylamid gels
stacking gel running gel
15% 12.5% 7.5%
Acrylamide 1.33ml 10ml 8.3ml 5ml
4x gel buffer 2.55ml 5ml 5ml 5ml
10% SDS (w/v) 100µl 200µl 200 µl 200 µl
10% APS 100µl 100µl 100 µl 100 µl
TEMED 5µl 6.7µl 6.7µl 6.7µl
ddH2O 6ml 4.7ml 6.4ml 9.7ml
4 x stacking gel buffer 5 M Tris-HCl; pH 6.8
4 x running gel buffer 1.5 M Tris-HCl; pH 8.8
1 x running buffer 25 mM glycine + 0.1% SDS (w/v)
APS 10% in H2O
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Western blotting
Cathode buffer 40mM aminohexanoic acid, 20% methanol
Anode buffer I 300mM Tris Base, 20% methanol
Anode buffer II 25mM Tris Base, 20% methanol
Washing buffer 0.1% Tween®20 in TBS (TBST)
Blocking buffer Rockland Blocking Buffer 1:2 in TBS
5mM sodium fluoride
1mM sodium vanadate
Secondary antibody buffer Washing buffer + 0.02% SDS (w/v)
Microspot immunoassay
Assay buffer 1% BSA
0.5% NP-40
0.02% SDS (w/v)
50mM Tris HCl, pH 7.4
150mM NaCl
1mM EDTA
5mM sodium fluoride
1mM sodium vanadate
1 complete mini/10ml
Blocking buffer 5% milk (w/v)
0.5% NP-40
50mM Tris HCl, pH 7.4
150mM NaCl
1mM EDTA
Washing buffer 0.1% Tween®20 in PBS (PBST)
Reverse phase protein array
Blocking buffer Odyssey®Blocking Buffer 1:2 in PBS
5mM sodium fluoride
1mM sodium vanadate
Secondary antibody buffer Washing buffer + 0.5% BSA
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Protein expression
Stock solutions IPTG (1M)
200mM DTT
200mM EDTA, pH 8.0
200mM PMSF
1M NaCl
1M Tris-HCl, pH 8.0
1M MgCl2
1M IPTG
ampicillin (100mg/ml)
kanamycin (30mg/ml)
lysozyme (50mg/ml)
Benzonase (250U/µl)
LB medium 10 g tryptone
5 g yeast extract
10 g NaCl
ad 1 l ddH2O, autoclave
LB agar 1.5% agar in LB medium
Lysis buffer 20mM Tris-HCl, pH 7.5
500mM NaCl
1% NP-40
1mM EDTA
1mM DTT (add freshly)
Elution buffer 10mM reduced l-glutathione
50mM Tris-HCl, pH 8.0
In vitro phosphorylation
Kinase assay buffer 50mM Tris-HCl, pH 7.5
10mM MgCl2
1mM EGTA
0.01% Triton X-100
200µM ATP (added freshly)
2mM DTT (added freshly)
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2.1.10 Antibodies
Table 2.3: Antibodies used for RPPA and Western blot analysis
target protein phosphosite company catalog number
AKT CST 9272
AKT Santa Cruz sc-1619-r
AKT S473 CST 9271
AKT T308 CST 9275
Cyclin D1 CST 2922
EGFR CST 2646
EGFR Santa Cruz sc-03
EGFR Y992 CST 2235
EGFR Y1045 CST 2237
EGFR Y1068 CST 2236
EGFR Y1086 CST 2220
EGFR Y1148 CST 4404
EGFR Y1173 CST 4407
ERBB2 Neomarkers AB-17
ERBB2 Y877 CST 2241
ERBB2 Y1112 Millipore 04-294
ERBB2 Y1139 abcam ab53290
ERBB2 Y1221/2 CST 2243
ERBB2 Y1248 Millipore 06-229
ERBB3 Neomarkers AB-2
ERBB3 Y1197 CST 4561
ERBB3 Y1222 CST 4784
ERBB3 Y1289 CST 4791
ERBB4 Santa Cruz sc-283
ERBB4 CST 4795
ERBB4 Y1162 Epitomics 2295-1
ERK1/2 Santa Cruz sc-94
ERK1/2 Millipore 06-182
ERK1/2 T202/Y204 CST 4370
ERK1/2 T202/Y204 CST 9106
GAB1 CST 3232
GAB1 Y307 CST 3234
GSK3α/β Santa Cruz sc-7291
GSK3α/β Y279/216 Epitomics 2309-1
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Table 2.3: Antibodies used for RPPA and Western blot analysis
target protein phosphosite company catalog number
MEK BD 610122
MEK S217/221 Sigma M7683
MET CST 3127
MET Y1003 CST 3135
MET Y1234/35 CST 3077
mTOR CST 2972
mTOR S2448 CST 2971
mTOR S2481 Millipore 09-343
NFkB Santa Cruz sc-109
NFkB S536 CST 3033
RSK CST 9355
SDHA Santa Cruz sc-59687
p27 BD 610241
p38 CST 9212
p38 T180/Y182 CST 9211
p70S6K BD 611261
p70S6K CST 2708
p70S6K T389 CST 9206
p70S6K T389 CST 9234
p70S6K T241/S424 Epitomics 1135-1
p90RSK S380 CST 9341
p90RSK T359S363 CST 9344
PDK1 CST 3062
PDK1 S241 CST 3438
PDK1 S241 CST 3061
PI3K/p85 abcam ab40755
PI3K/p110 abcam ab32569
PKCα abcam ab32376
PKCα S657/Y658 abcam ab23513
PKCα S657 Millipore 06-822
PLCγ abcam ab41433
PLCγ S1248 CST 4510
PRAS T246 CST 2997
PTEN CST 9552
PTEN T366/S370 Epitomics 2195-1
cRAF S259 CST 9421
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Table 2.3: Antibodies used for RPPA and Western blot analysis
target protein phosphosite company catalog number
cRAF S289/296/301 CST 9431
RB S807/811 CST 9308
S6 S235/236 CST 4858
SRC CST 2123
SRC Y416 CST 2101
STAT3 Santa Cruz sc-482
STAT3 S727 CST 9134
STAT3 Y705 CST 9131
STAT5 CST 9310
STAT5 Y694/699 Millipore 05-495
Microspot Immunoassay
Table 2.4: Capture antibodies
target protein phosphosite company catalog number
pAKT1 S473 Millipore 05-669
pAKT1 S473 BD 558368
pAKT1 T308 BD 558316
pAKT1 T308 CST 5106
pERK1/2 T202/Y204 Sigma M9692
pERK1/2 T202/Y204 CST 9106
pSTAT3 S727 BD 612543
Table 2.5: Detection antibodies
target protein company catalog number dilution
AKT1 Santa Cruz sc-1619-r 1:400
ERK1/2 Millipore 06-182 1:800
ERK1/2 Santa Cruz sc-94 1:800
STAT3 CST 9132 1:500
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Secondary antibodies
Table 2.6: Secondary antibodies
reactivity host species company label
mouse goat Invitrogen Alexa Fluor®680
rabbit goat Invitrogen Alexa Fluor®680
goat rabbit Invitrogen Alexa Fluor®680
mouse goat Pierce DyLight 680
mouse goat Pierce DyLight 800
rabbit goat Pierce DyLight 680
rabbit goat Pierce DyLight 800
2.1.11 siRNAs
Table 2.7: Applied siRNA from Dharmacon
gene symbol siRNA ID antisense sequence 5’-3’
EGFR J-003114-10 UAUUCCGUUACACACUUUGUU
EGRF J-003114-11 AUAUUCGUAGCAUUUAUGGUU
EGFR J-003114-12 AACUGCGUGAGCUUGUUACUU
EGFR J-003114-13 AGUUAUUGAACAUCCUCUGUU
ERBB2 J-003126-17 UAACCUGUGAUCUCUUCCAUU
ERBB2 J-003126-18 GUAUUGUUCAGCGGGUCUCUU
ERBB2 J-003126-19 CAGUACUCGGCAUUCCUCCUU
ERBB2 J-003126-20 UUGGUUGUGAGCGAUGAGCUU
ERBB3 J003127-10 UAUUGGUUCUCAGCAUCGCUU
ERBB3 J003127-11 UGUCCCGUGAGCACAAUCUUU
ERBB3 J003127-12 CACUUCUCGAAUCCACUGCUU
ERBB3 J003127-13 UUAUAGUUCAACAUGACGAUU
ERBB4 J003128-10 UAUUCGAGUCAAUUCUUGCUU
ERBB4 J003128-11 UAACUAGGUAUCUUUGAGGUU
ERBB4 J003128-12 AAUUUGUCAAUGUUACUGGUU
ERBB4 J003128-13 AAUGUAUACACUCCAGAGCUU
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2.1.12 Taqman Gene Expression Assays
The assays used for Taqman analysis listed in table 2.8 were purchased from
Applied Biosystems, Darmstadt.
Table 2.8: Taqman Gene Expression Assays
gene
symbol
assay ID gene name
EGFR Hs00193306_m1 Epidermal growth factor receptor
ERBB2 Hs00170433_m1 v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2
ERBB3 Hs00176538_m1 v-erb-b3 erythroblastic leukemia viral oncogene
homolog 3
ERBB4 Hs00171783_m1 v-erb-b4 erythroblastic leukemia viral oncogene
homolog 4
MET Hs00179845_m1 met proto-oncogen
GAPDH Hs99999905_m1 glyceraldehyde-3-phosphate dehydrogenase
2.1.13 Cell culture
All human breast cancer cell lines were purchased from the American Type
Culture Collection (ATCC), LGC Prochem, Wesel.
BT474 HTB-20 ductal carcinoma
HCC1954 CRL-2338 ductal carcinoma
MCF7 HTB-22 adenocarcinoma
SKBR3 HTB-30 adenocarcinoma
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Growth media
BT474 DMEM
10% FBS
10% NCTC-135
10 µg/ml insuline bovine
HCC1954 RPMI 1640
10% FSB
MCF7 RPMI 1640 with GlutaMAX™
10% FSB
1 x NEAA
1mM sodium pyruvate
insuline bovine
SKBR3 DMEM
10% FBS
1 x NEAA
Starvation media
BT474 DMEM (phenol-red free)
10% NCTC-135
HCC1954 RPMI 1640 (phenol-red free)
1mM HEPES
1mM sodium pyruvate
MCF7 RPMI 1640 (phenol-red free)
1 x NEAA
1mM sodium pyruvate
SKBR3 DMEM (phenol-red free)
1x NEAA
2mM l-glutamine
1mM sodium pyruvate
Freezing medium
10% DMSO
20% FBS
70% growth medium
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2.2 Methods
2.2.1 SDS-PAGE
Discontinuous sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) was used to separate proteins based on their molecular weight and
were performed according to Laemmli (1970). SDS, an anionic detergent,
and β-mercaptoethanol denature and dissociate the protein into subunits.
β-mercaptoethanol reduces disulfide bonds while SDS binds to hydrophobic re-
gions, unfolds the protein structure and leads to negatively charged proteins
whereby the number of incorporated detergent molecules depends mainly on
the size of the protein. This results in a uniform charge to mass ratio of 1.4 g
SDS per g protein and proteins move in the electric field with a velocity depen-
ding on their size and subjected to the sieving effect of the polyacrylamide gel.
Polyacrylamide gels consist of a stacking gel and a separating gel. The stacking
gel has a large pore size and is used to concentrate the proteins before reaching
the separating gel. Protein separation is achieved in the alkaline separating gel
with small pore size. Depending on the size of the target protein, gels with
differing acrylamide concentrations leading to different pore sizes can be used
for optimal resolution.
For sample preparation, protein lysates were mixed 1:4 with 4 x sample buffer
and heated for 5min at 95◦C. 20 µg protein per sample was loaded and the
gel was run at 120–150V between 1.5–2 h, depending on the size of the target
protein.
2.2.2 Western blotting
The proteins resolved by SDS-PAGE were transferred onto a PVDF membrane
by electrophoretic transfer. A semidry approach was employed which consists of
three different buffers, anode buffer I, anode buffer II, and cathode buffer. First,
the PVDF-membrane was activated in 100% methanol and equilibrated in anode
buffer II. Whatman paper was soaked in the three buffers and assembled with
the gel and the membrane as shown in figure 2.1. The proteins were transferred
for 1 h at 25V. For proteins above 150 kDa, the transfer was prolonged for
10min. The transfer of proteins was controlled by staining the membran with
Ponceau-S solution, a reversible organic stain. Destaining was achieved with
ddH2O. The membrane was blocked for 1 h with blocking buffer at RT.
32
2.2 Methods
4 whatman paper in anode buffer I
2 whatman paper in anode buffer II
6 whatman paper in cathode buffer
PVDF membrane
SDS gel
Figure 2.1: Western blot assembly
2.2.3 Immunological protein detection
The antibody against the target protein was diluted 1:1,000 in blocking buf-
fer. The membrane was exposed to the primary antibody dilution over night
at 4◦C. Following the incubation, the membrane was washed 4 x 5min with
washing buffer. Afterwards, the membrane was incubated with a 1:10,000 se-
condary antibody dilution for 60 min in a dark box to avoid light exposure.
Depending on the host species of the primary antibody, anti-mouse or anti-
rabbit secondary antibodies labeled with DyLight 680 or DyLight 800 were
used. After washing a second time for 4 x 5min, the membrane was scanned
using the Odyssey®Infrared Imaging System (Odyssey) at 700 and 800 nm allo-
wing the detection of two different proteins on the same Western blot if primary
antibodies from different species were used, even if the molecular weight of both
proteins was highly similar.
2.2.4 Preparation of recombinant phospho-STAT3
Induction of recombinant GST-tagged STAT3 expression
Bacteria were streaked from glycerol stock onto a LB-plate and incubated over
night at 37◦C. The next day, 50–60 colonies were collected per plate and
inoculated in 10ml LB medium containing 1% glucose, 15µg/ml kanamycin,
and 100µg/ml ampicillin. Cultures were grown at 30◦C over night at 220 rpm.
500ml LB medium containing 1% glucose, 15 µg/ml kanamycin, and 100µg/ml
ampicillin were inoculated with 10ml starter culture. Growth was monitored
every hour until the optical density at 600 nm (OD600) reached 0.8. A 1ml
aliquot was taken for pre-induction control. Protein expression was induced
with 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubation was
continued at 30◦C for 4 h. Again, a 1ml aliquot was saved as post-induction
control. The cell suspension was cooled down and the cell pellet was harvested
by centrifugation at 8,000 x g for 10min and stored at -20◦C.
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Protein extraction
The frozen cell pellet was resuspended in 10ml lysis buffer for protein extraction.
Lysozyme (200µg/ml lysis buffer) was added to the suspension and incubated for
15min on ice. Afterwards, phenylmethanesulfonylfluoride (PMSF) was added
to a final concentration of 100 µM. After sonication for 3 x 10 sec with 50–60%
power setting, benzonase (25U/ml lysis buffer) and 5mM MgCl2 were added,
mixed thoroughly, and incubated for further 20min on ice. For loading of total
protein on SDS-PAGE, 60 µl of the total protein extract solution was mixed with
20µl 4 x sample buffer and stored at -20◦C. To prepare the soluble fraction,
protein lysate was centrifuged at 28,000 x g for 20min at 4◦C and cleared from
the insoluble particles. A 60µl aliquot of the supernatant was mixed with 20µl
4 x sample buffer and stored for SDS-PAGE analysis representing the soluble
protein fraction. The supernatant was used for protein purification.
Protein purification
For protein purification, 10ml of the supernatant yielded by the protein ex-
traction procedure was poured into a purification column and mixed with two
SwellGel Immobilized Glutathione Discs. After sealing the column with a lid,
the slurry was incubated for 60min at room temperature on an end-over-end
shaker to allow binding of the recombinant fusion protein to the affinity resin.
Next, the lid was removed, the tip at the bottom of the column was opened,
and the flow-through containing the unbound material was collected for ana-
lysis. The slurry was washed 2 times for 10min each with 10ml PBS. Both
washing fractions were collected for further analysis. After sealing the column
tip, 300 µl elution buffer was added and incubated for 5 min. The eluate was
captured and the elution procedure was repeated 5 times.
In vitro protein phosphorylation of GST-STAT3 at S727
To phosphorylate STAT3 at serine 727 in vitro, the protein kinase ERK1 was
used. 2 µl ERK1 active were mixed with 98µl kinase-assay-buffer. 10 µg GST-
STAT3 was added to the ERK1 active dilution and kinase-assay-buffer was
added to a final concentration of 25µg/ml GST-STAT3, mixed, and incubated
for 2 h at 30◦C. To proof phosphorylation, GST-STAT3 and phosphorylated
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GST-STAT3 were analysed on Western blot using phosphospecific antibodies.
Phosphorylated GST-STAT3 was aliquoted and stored at -20◦C.
2.2.5 Protein microarrays
Printing of antibodies for microspot immunoassays (MIA) and of lysates for
reverse phase protein arrays (RPPA) was carried out using the Aushon 2470
Arrayer. This Arrayer is a pin tool spotter which can be equipped with up to 48
solid pins in different alignments. Each pin dips into a single well of a 384-well
plate containing the samples. Due to the characteristics of the pins, a small
droplet of liquid remains at the tip of the pin. The volume is dependent on the
size of the pin. The droplet is then delivered to the slide. Here, the pins had a
diameter of 185µm. This resulted in 1.6 nl per spot with an average spot diame-
ter of 250 µm. To achieve a consistent spot morphology, 0.05% Tween®20 were
added to all samples, antibodies and lysates. Tween®20, like any other deter-
gent, lowers the interfacial surface tension and results in a consistant dispersion
of the lysate within the spot. For each spotting run, the arrayer generates a so
called gal-file which contains the layout of the array and informations regarding
the location of each sample on the array.
2.2.6 Microspot Immunoassay
The MIA approach was used to quantify phosphoproteins in cell lysates. The-
refore, phosphospecific monoclonal mouse antibodies were used as capture anti-
bodies while polyclonal rabbit antibodies were applied as detection antibodies
to bind the captured protein at a different epitope, which is not phosphoryla-
ted. In our approach, we only used commercially available antibodies, listed in
table 2.4. Each slide was divided into 16 subarrays on which the same set of
antibodies was immobilised. Six subarrays were used to create a serial dilution
curve, the remaining ten subarrays were used for sample incubation. Figure 2.2
shows the image of a slide with 16 subarrays after performing the detection.
Immobilisation of antibodies
The first step of the MIA procedure was the immobilisation of antibodies on
nitrocellulose coated glass slides. To print 16 subarrays per slide, the 2 x 4 pin
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Subarray 1-6: serial dilution Subarray 7-16: samples
Figure 2.2: MIA slide image
The slide was divided into 16 subarrays (blue). Onto each subarray, three capture
antibodies were immobilised in six replicates (white). The slide was incubated
with a six-fold serial dilution on subarrays 1-6 and 10 different samples on sub-
arrays 7-16 (red).
and 9 x 9µm pin spacing configuration of the 2470 Arrayer was used. With
this configuration, each capture antibody could be spotted on eight subarrays
in parallel. Because spotting was carried out with 8 pins, 3–5µl of antibody
dilution were transferred into 8 wells of one 384-well plate. Figure 2.3 shows
the pipetting scheme for three capture antibodies. Prior to spotting, the 384-well
plates were centrifuged for 1min at 700 x g. For low abundant proteins or weak
antibodies, two depositions per spot were carried out to double the amount of
antibody on the nitrocellulose surface. This resulted in a higher signal intensity.
With 3 µl of antibody per well, 36 slides were spotted within 3 h. The spotted
slides were stored at 4◦C for several weeks.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
A 1 2 1 2 1 2 1 2 3 3 3 3
B
C 1 2 1 2 1 2 1 2 3 3 3 3
D
Figure 2.3: Antibody pipetting layout
Shown is the distribution of three capture antibodies on a 384-well plate for the
spotting procedure. Each antibody is dispensed into eight wells.
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Sample preparation
For the incubation procedure, the recombinant phosphoproteins and the protein
cell lysates had to be denaturated. Therefore, the probes were mixed with 10%
SDS to a final concentration of 1% and heated for 5min at 95◦C. To stop the
denaturation process, the samples were chilled on ice and centrifuged shortly.
To create a standard curve, the recombinant proteins were diluted with assay
buffer to generate a six-step two-fold serial dilution. According to the protein
of interest, the samples were diluted with assay buffer to a final concentration
of 10–50µg/ml. The concentration of the target protein in the diluted sample
has to lie within the range of the dilution series to ensure exact quantification.
Incubation of microspot immunoassays
Ahead of the incubation with the probes, the spotted slides were blocked with
blocking buffer for 2–4 hours at 4◦C. Before addition of the samples, the slides
were mounted into the incubation chamber to create an independent wells on
each of the 16 subarrays. 150 µl PBST per well was pipetted with a multichannel
pipette to prevent drying. To start the process, the PBST of the first six wells
was aspirated off and 200 µl of the standard dilution was transferred into the
wells. Afterwards, the PBST from the the last ten wells was aspirated and 200µl
of diluted sample was transferred per well. The slides were incubated over night
at 4◦C on a rocking platform. The next day, all samples were aspirated off and
150µl assay buffer was pipetted per well using a multichannel pipette. Slides
were washed 3 x 5min on a rocking platform. After the final washing step, the
incubation chamber was disassembled and the slides were placed into a dark box
and washed for further 5min. The following incubation steps were performed
in the dark box. Primary antibodies were diluted in assay buffer as listed in
table 2.5 and incubated for 2 h at 4◦C on a rocking platform. Subsequently, the
slides were washed four times in PBST. The Alexa Fluor®680-labeled goat anti-
rabbit secondary antibody was diluted 1:5,000 in assay buffer and incubated for
30min at 4◦C on a rocking platform. Afterwards, the slides were washed four
times in PBST, one time with ddH2O, and dried vertically in a slide chamber
on paper tissue for at least 30min and stored in the dark.
37
2 Materials and methods
Image analysis
The dried slides were scanned using the Odyssey with a laser excitation of
685 nm and a resolution of 21µm. The images were analysed using the Gene-
Pix Pro5.0 software. The software used the gal-files for spot identification and
to link the sample annotation to the detected signal intensities. Outliers were
flagged and thus discarded from further analysis. The signal intensities of all
spots were saved as gpr-files (GenePix result-files).
Data analysis using QuantproReloaded
The analysis of the MIA was performed using the in-house developed R-based
software tools Quantpro (Korf et al., 2008b) or QuantproReloaded (Joecker
et al., 2010), which was a redesigned software application based on the ideas
of Quantpro. In addition to the .gpr-files, Quantpro and QuantproReloaded
required a slidedescription and a captureantibody file. The slidedescription
file contained the information on the subarrays, for example the specification
of the sample, namely calibrator or measurement. Additionally, the dilution
factor, the name, and the time point of each sample or the amount of standard
protein had to be specified. The captureantibody file contained a list of all
capture antibodies printed on the array and the name of the corresponding
target protein.
In order to determine the accuracy of a new capture/detection antibody pair
using Quantpro, the calibrator measurements were used in a crossvalidation
procedure. A linear regression was fitted to 60% of the calibrator measure-
ments and the remaining calibrator measurements were treated as samples of
unknown concentration. The absolute deviation from the theoretical concentra-
tion was recorded. This was repeated 100 times, and the average deviation was
determined.
QuantproReloaded consists of two independent parts. First, the performance
analysis employed a cross-validation approach on calibrator data points. The
accuracy of the calibrator curve was given for each concentration separately.
Different linear and non-linear functions could be chosen to fit the calibrator
curve. The example of a calibrator curve and the corresponding performance
plot is shown in figure 2.4. After evaluation of the performance plots, the mea-
surement analysis was carried out using the function which had shown the best
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Figure 2.4: Analysis performed using QuantproReloaded
Calibrator plot of pSTAT3 capture antibody BD612653 (A) and the corresponding
performance plot (B). The accuracy is calculated for each protein concentration
of the serial dilution separately.
performance. Here, the calibrator curve was applied to estimate the concentra-
tion of the target analyte in the sample.
2.2.7 Reverse Phase Protein Arrays
Spotting of RPPAs
As the first step with respect to the sample normalisation, the lysates were
adjusted to a fixed protein concentration with lysis buffer. Outliers with a low
protein concentration were not adjusted. The number of outliers should not
exceed 5%. As described before, Tween® 20 was added to a final concentration
of 0.05%. Lysates were transferred to a 384-well plate and centrifuged at 700 x g
for 1min. Depending on the number of samples, two or three subarrays were
printed per slide. For printing, a print head configuration with 4.5µm pin
spacing was used, equipped with 4 x 4 pins for three subarrays and 4 x 6 pins for
two subarrays.
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Incubation of RPPAs with antibody solutions
Incubation of the spotted slides with different antibodies was performed in cus-
tomised incubation chambers. Comparable with the MIA incubation, frames for
two or three subarrays were used. The antibody incubation was performed either
manually or automated using antibody mediated signal amplification (AMSA)
(Brase et al., 2010).
Manual incubation was performed comparable to the procedure described
for Western blots. First, slides were blocked over night in blocking buffer at 4◦C
on a rocking platform. Primary antibody dilutions (1:300) were incubated for
2 h at room temperature on a rocking platform. Afterwards, slides were washed
4 x 8min in PBST. Next, the slides were incubated with secondary antibody
dilution (1:8,000) for 1 h and subsequently washed as described before. After
washing the slides in ddH2O, they were dried vertically in a slide chamber on
paper tissue for 30min.
AMSA detection was performed using the 96-channel head robot Biomek FX
to increase the throughput and to minimise experimental variation. Blocking
and incubation with primary antibody was performed as described before. Di-
lutions prepared from anti-rabbit Alexa Flour®680-labeled from goat and anti-
goat Alexa Flour®680-labeled antibodies from rabbit (1:8,000) were filled in
96-deep-well plates and incubated alternating for a total of four cycles. For
the detection of primary mouse antibodies, anti-mouse Alexa Flour®680 raised
in goat was added to the anti-rabbit antibody. Each secondary antibody was
incubated for 30min and slides were washed 4 x 5min between the incubation
steps with washing buffer (PBS + 0.02% SDS (w/v) + 0.02% NP-40). After the
last incubated step, slides were washed in ddH2O and dried as described before.
RPPA image analysis
RPPA slides were scanned using the Odyssey with a laser excitation of 685 nm
and a resolution of 21 µm. The images were analysed using the GenePix Pro5.0
software and rawdata was saved as gpr-files. These were used for the further
analysis of the data.
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RPPA data analysis
In close collaboration with the bioinformatics subgroup of the division and the
division Medical Statistics at the University Medical Center Göttingen, an ana-
lysis routine was developed tailored towards the requirements of analysing dy-
namic RPPA data. The scripts needed for the analysis were written in the
programming language R (R Development Core Team, 2010) by members of
the bioinformatics group. In addition to the gpr-files, two annotation files were
needed. The description file contained the specification of every sample sorted
by the spot ID as defined by the gal-file. This was used to annotate each spot on
each array. The second file, the antibody list, contained the information of anti-
bodies incubated on each subarray. The workflow of the analysis is described in
detail in section 3.2. In addition, the R-package “RPPanalyzer” was developed
in the division (Mannsperger et al., 2010) and certain features of this package
for quality control of the data were used.
Quality control of RPPA data
In order to estimate the quality of the antibodies, dilution series of lysates ob-
tained from stimulated, unstimulated, and starved cells were spotted. First,
the raw signal intensities of the dilution series were plotted versus the protein
concentration of the lysates and the mean of the technical replicates was cal-
culated. Second, a constant model was fitted to the dilution data, as well as
linear models. For the linear models, the first, second, and so on dilution step
was left out and a linear model fit for each set of dilutions was calculated. The
linear models were compared to the constant fit using ANOVA. The one with
the smallest p-value was considered as optimal. Furthermore, a 75% confidence
intervall (CI) was calculated. This means that with a confidence of 75% the
signal intensity of a protein lysate concentration of the dilution series differs
significantly from the signal intensity of the next lower protein concentration.
The better the antibody, the less data points were excluded from the 75% CI. A
second aspect of the quality control was the comparison of the signal intensities
of each antibody to the blank signal. The blank corresponded to signal inten-
sities after incubation with secondary antibody without the primary antibody.
Antibodies, which revealed the same signal intensities as the blank were omitted
from the further analysis. This analysis included the dilution series as well as
the samples.
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Normalisation of RPPA data
The total protein concentration may differ between the spots due to pipetting
and spotting errors. Thus, the antibody signals had to be normalised for the
total protein amount per spot as described by Loebke et al. (2007). One slide
per spotting run was incubated with the protein dye Fast Green FCF (FCF).
This dye can be detected using the Odyssey. The slide was wetted with PBS
and incubated in FCF staining solution for 1 h at room temperature on a ro-
cking platform. For destaining, the slide was immersed twice in FCF destaining
solution for 30min each. The slides were scanned at 800 nm and analysed using
the GenePix Pro5.0 software as described before. The raw signal intensity (RSI)
of each spot was normalised using the signal intensity of FCF readout of each
spot (FSI) and the mean of all FCF values (FSI) resulting in the normalised
signal intensities (NSI) using the following equation.
NSI = log2
(
RSI
FSI FSI
)
= log2(RSI)− log2(FSI) + log2(FSI)
Analysis of time-resolved measurements
To smooth the signals and estimate a response over the time, the R-package
“gam” (Hastie, 2010) was used to fit smoothing splines (Chambers, 1991) on
the time-resolved data. Smoothing splines model the signal over time in a
nonparametric way. The output are fits describing the estimated dynamics of the
phosphoprotein measurement changes. To calculate if a particular condition had
a significant effect, smoothing splines with increasing degrees of freedom were
fitted over the median of all biological replicates as explained in section 3.2.3.
Afterwards, each model was compared to the constant model fit via analysis of
variance (ANOVA). The model with the lowest p-value was chosen as best fit.
To find significant differences between two time series experiments, a two-sided
two-sample t-test for each time point was performed, using a significance level
of alpha=0.05.
2.2.8 Cell culture
The cells were grown in media described in section 2.1.13. Depending on the
particular cell size, cells were seeded in differing densities as listed in table 2.9.
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Table 2.9: Overview of seeded cell density
Cell lines Cell density
T75 T175 6-well 6 cm 10 cm 14.5 cm
BT474 2 x 106 4 x 106 5 x 105 1.4 x 106 4 x 106 8 x 106
HCC1954 8 x 105 1.8 x 106 2 x 105 5 x 105 2 x 106 4 x 106
MCF7 1 x 106 2.3 x 106 4 x 105 1 x 106 3 x 106 7 x 106
SKBR3 1.2 x 106 2.8 x 106 4 x 105 1.8 x 106 3 x 106 6 x 106
Subculturing of cells
To keep the cells constantly in the exponential growth phase, cells were pas-
saged every two to three (HCC1954) or three to four days (SKBR3, BT474,
and MCF7). The medium was completely removed and cells were washed with
DPBS. Subsequently, cells were incubated with 2ml (T75) or 4ml (T175) of
0.25% trypsin for two (MCF7) to four (HCC1954, SKBR3, and BT474) minutes
at 37◦C until they detached from the surface. Trypsin was deactivated by ad-
dition of 8ml growth medium, and cells were gently resuspended and counted.
Then, the number of cells listed in table 2.9 were transferred into new culture
flasks and incubated at 37◦C in an atmosphere of 5% CO2 and 95% humidity.
Freezing and thawing cells
To prepare frozen stocks of the cell lines, actively growing cells were trypsinised,
counted and centrifuged at 1,200 rpm for 5min to remove the medium. After-
wards, cells were resuspended in freezing medium to a quantity of 1.5–2 x 106/ml
and 1ml was pipetted into each cryo vial. Vials were put into a freezing contai-
ner to provide the -1◦C/min cooling rate and placed into -80◦C. For long term
storage, cells were transferred to liquid nitrogen.
Cells were thawed in a 37◦C waterbath for approximately 2min and immediately
resuspended in prewarmed growth medium. Afterwards, cells were centrifuged
for 5min at 1,200 rpm to remove the freezing medium containing DMSO. The
cell pellet was gently resuspended in growth medium, transferred into the culture
flask and incubated at 37◦C in an atmosphere of 5% CO2 and 95% humidity.
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2.2.9 Growth factor stimulation experiments
High throughput stimulation experiments were carried out in 6-well plates. For
Western blot analysis or to gain more lysate, all formates between 6 cm and
14.5 cm plates were used. Cells were seeded according to table 2.9. Cells were
cultivated for 24 h and serum-starved in phenol-red free medium for additional
24 h. The stimulation experiments in 6-well plates were carried out using two
different protocols.
Automated cell culture experiments were performed using an automated liquid
handling system with an integrated incubator (Biomek FX) to ensure consis-
tency between the biological replicates. The inhibitors and ligands for each
experiment were provided in 96-well plates. 50 µl of inhibitor and ligand dilu-
tion were added to the cells. For preincubation with inhibitors, the plates were
transferred by the system into the incubator for 1 h. For stimulation experi-
ments, the first two time points were left on the deck of the Biomek FX while
the further time points were again transferred by the system into the incubator.
After the indicated time points (0, 4, 8, 12, 16, 20, 30, 40, 50, 60min), me-
dium was replaced by ice-cold PBS and plates were placed on ice. Afterwards,
PBS was aspirated off and cells were harvested by manual scraping in 40µl lysis
buffer. Lysate were collected on dry ice and stored at -80◦C.
Manual stimulation in 6-well plates was carried out with a Liquidator96, a
manual 96 channel pipette. Therewith, the solutions were applied to each well
comparable to the automated system. The plates and the Liquidator96 were
put on a 37◦C preheated pet surgery table. The solution was pipetted using
five tips per wells and afterwards the plates were put either to the incubator or
were left on the 37◦C table, depending on the time of incubation.
Stimulation experiments using other formats than 6-well plates were carried out
on the pet surgery table. This was preheated to 37◦C. Plates were put on the
table and ligands were added using a Multipette. After each time point, medium
was discarded, cells were washed with ice-cold PBS and plates were placed on
ice. PBS was aspirated off and cells were lysed as described before.
Impact of targeted therapeutics on ERBB signalling
Stimulation experiments were performed in triplicate applying three inhibitors
trastuzumab, pertuzumab, and erlotinib at concentrations listed in table 2.1
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and two ligands EGF and HRG at a concentration of 5 nM in all possible com-
binations. Including a control, 0.000008% Tween®20, this resulted in eight ex-
periments per ligand or ligand combination. The layout of the experiments is
shown in figure 2.5. Experiments 1–4 were carried out separately for each ligand,
exp. 1 exp. 2 exp. 3
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A A A
B X T P B T P + E T + P + E B E T + P H + E
C C C
D D D
E E E
F E T + P H + E F X P E F P + E T + P + E
G G G X
H H H
exp. 4 exp. 5 EFG HRG EGF+HRG
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
A A control
B X H + E P + E B X X X trastuzumab
C C pertuzumab
D D erlotinib
E E trastuzmab + pertuzumab
F T + P P F T + P + E T + P + E T + P + E trastuzumab + erlotinib
G T G pertuzumab + trastuzumab
H H tras. + pert. + erl.
Figure 2.5: Design of stimulation in 6-well format
Layout of inhibitor conditions prepared in 96-well plate for automatical transfer
into 6-well plates with growing cells conducted by the Biomek FX. Exp. 1-4 were
incubated separately with all the ligand combination. Exp. 5 was accomplished
once.
experiment 5 combined three ligand combinations in a single experiment. Alto-
gether, the setup resulted in 13 single experiments performed in 6-well format
per cell line. This layout comprised three replicates for all inhibitor conditions
and five replicates for the uninhibited controls. Additionally, the impact of the
drugs were analysed without addition of a ligand.
2.2.10 siRNA-mediated receptor knockdown
siRNA transfection was performed in the 6-well format. Per well, 2.5 µl Lipofec-
tamine 2000 was added to 147.5µl OptiMEM, mixed, and incubated for 10min
at room temperature. Afterwards, 300 µl OptiMEM was added. The siRNA
stock (20µM) was diluted 1:100 in sterile, nuclease free H2O. 150µl of diluted
siRNA was pipetted into each well and 450 µl Lipofectamine 2000/OptiMEM
mix was added, mixed, and incubated for 20min at room temperature. For the
mock control, 150µl sterile, nuclease free H2O was used instead of siRNA dilu-
tion. Meanwhile, cells were trypsinated and counted. 3 x 105 cells were added in
900µl growth medium to the siRNA/Lipofectamine mixture. Growth medium
was renewed 6 h after transfection. After transfection, cells were incubated for
48 h and serum-starved for additional 24 h prior to stimulation.
45
2 Materials and methods
2.2.11 Preparation of protein extracts
The frozen lysates were thawed on ice and lysis was performed on an end-over-
end shaker for 20min at 4◦C. Afterwards, lysates were cleared by centrifugation
for 10min at 16,000 x g. The supernatant was transferred to a fresh, prechilled
reaction tube and stored at -20◦C and for long term storage at -80◦C.
Determination of protein concentration
Total protein concentration was determined using the BCA assay. The micro-
plate procedure was carried out according to protocol whereas only 5 µl instead
of 25µl of each sample of unknown concentration were used (Korf et al., 2008a).
2.2.12 RNA isolation
RNA was isolated using the RNeasy®Kit. Cells were detached by trypsinisation,
counted, and pelleted by centrifugation at 1,200 rpm for 5min. 5 x 105 cells were
washed once in PBS and resuspended in 350 µl RLT buffer. 350 µl 70% ethanol
was added and the solution was pipetted onto RNeasy®spin columns. Isolation
of RNA was performed according to the manufacturers protocol. Elution of
RNA was carried out twice by adding 50µl nuclease-free H2O. The isolated
RNA was stored at -80◦C.
Determination of RNA concentration
Total RNA concentration was determined using the NanoDrop ND-1000
UV/VIS spectrophotometer. The absorption of the nucleic acid solution was
measured between 230 nm and 280 nm and the concentration was calculated
automatically by the software. The absorption maximum of nucleic acids is
260 nm whereas proteins show the maximum absorption at 280 nm. In addition
to the concentration, the purity was determined by calculating the ratio of the
extinction values at 260 nm/280 nm and 260 nm/230 nm.
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2.2.13 First strand synthesis of complementary DNA (cDNA
synthesis)
First strand synthesis of complementary DNA (cDNA) was performed applying
the ReverdAid™H-Minus First Strand cDNA Synthesis Kit. 400 ng extracted
total RNA was mixed with 1 µl oligo(dT)18-primer and incubated for 5min at
70◦C in a PCR cycler and subsequently cooled at 4◦C. After addition of 8 µl
reaction master mix (4 µl 5 x reaction buffer, 2 µl 10mM dNTPs, 30 units prime
RNAse inhibitor and RevertAid™H Minus M-MuLV Reverse Transcriptase), the
reaction mix was first heated to 37◦C and first strand synthesis was performed
for 60min at 42◦C and stopped for 10min at 70◦C. The resulting cDNA solution
was directly used for quantitative real-time-PCR.
2.2.14 Quantitative real-time-PCR (TaqMan)
Quantitative real-time-PCR allows the detection of the relative expression of
genes with high sensitivity. The probes used for quantification consist of a
fluorophore covalently linked to the 5’-end of the oligonucleotide probe and a
quencher molecule at the 3’-end. As long as the quencher and the fluorophore
are in proximity, the quencher erases the fluorescence emitted by the fluorophore
despite exitation. The DNA polymerase exhibits 5’-3’ exonuclease activity and
degrades the probe which annealed to the template. Degradation of the probes
releases the fluorophore and therefore relieves the quenching effect. Thus, fluo-
rescence can be detected by the real-time PCR thermal cycler. Only probes
bound to DNA are degraded by the DNA polymerase and therefore the fluo-
rescence detected is directly proportional to the amount of DNA template in
the PCR. The increasing fluorescence signal is detected and plotted against the
number of PCR cycles.
To perform the Taqman experiment, 20 ng cDNA dissolved in 5µl H2O were
transferred into a 384-well plate and 6 µl master mix consisting of 5.5µl 2x
PCR buffer and 0.5µl TaqMan Assay for the probe of interest was added to the
well. Each assay reaction was set up in triplicate. The qRT-PCR reaction was
executed in the 7900HT Fast Real-Time PCR System. The assay was preheated
for 2min at 50◦C and 15min at 95◦C. The reaction cycle of 15 sec 95◦C and
1min 60◦C was repeated 40 times.
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Quantification of relative gene expression (∆∆Ct method)
The Ct values were determined by the SDS-software. The analysis was per-
formed applying the R-package “ddCt” (Biczok et al., 2010). In a first step,
the median of the GAPDH Ct values (CtH,j) were calculated for each sample
triplicate. This value was subtracted from the median Ct values (Cti,j) of each
gene (∆Ct).
∆Cti,j = Cti,j −CtH,j
In a second step, the normalised expression values of a control was subtracted
from the normalised expression values (∆Cti,j). The “ddCt” package was de-
signed mainly to analyse knockdown experiments. However, this package was
applied to analyse the relative amount of gene expression for the four cell lines.
As control, the mean expression value of the EGFR for the four cell lines was
used as control (∆Cti,R). This resulted in ∆∆Ct-values.
∆∆Cti,j = ∆Cti,j − ∆Cti,R
The relative gene expression level of one gene compared to the mean EGFR
expression within the four cell lines, normalised to the expression of GAPDH
was given by the following equation:
expression leveli,j = 2−∆∆Ct
2.2.15 Cell cycle analysis applying 7AAD
Cell cycle analysis was performed in 6-well format. 2.5 x 105 cells were seeded in
2ml medium per well and incubated for 24 h. Medium was replaced by 1.2ml
fresh medium and a 1:10 dilution of the therapeutics were added to a final
concentration as listed in table 2.1. Cells were incubated for 24 h at 37◦C in an
atmosphere of 5% CO2 and 95% humidity. After treatment for 24 h, cells were
taken out of the incubated and washed with PBS. To detach the cells, 500µl
trypsin was added and cells were incubated for 3–4min at 37◦C and 5% CO2.
500µl medium was added and cells were separated by gently pipetting up and
down. Cells were transferred to a 96-well 1.2ml deep-well-plate and centrifu-
ged at 1450 x g for 5min at RT. The following steps were performed using the
Liquidator96. For fixation and permeabilisation, 1ml icecold 90% methanol was
added and carefully resuspended. Afterwards, cells were incubated for 30min on
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ice. Meanwhile, 7AAD solution was prepared by adding 7.5 µl 7AAD to 300 µl
PBS per well. Cells were again centrifuged at 1450 x g for 5min at RT. Superna-
tant was removed and 300µl 7AAD staining solution was pipetted per well and
cells were resuspended. Plate was covered with foil and left at 4◦C for 90min.
DNA content was determind by flow cytometric analysis (FACS Calibur). Ana-
lysis of the rawdata to determine the proportion of cells in a specific cell cycle
phase was accomplished using the R-package “flowDeconvolutor” (Zhang et al.,
2010).
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3.1 Microspot Immunoassay
The microspot immunoassay (MIA) technology was established for the exact
quantification of pERK1/2 in human samples as part of my diploma thesis
(Henjes, 2006). To generate an experimental platform suitable for the analysis
of ERBB signalling, the assay was extended to the quantification of the phos-
phoproteins pAKT (S473), pAKT (T308) and pSTAT3 (S727). The readout
of the assay was calculated in ng phosphoprotein per µg total protein lysate
(ng/µg).
In general, two options exist to detect the phosphorylation status of a protein.
Phosphoproteins can be captured either with a phosphoprotein specific antibody
and detected with a protein specific antibody or vice versa. Using phosphospe-
cific antibodies in the capture step has major advantages. First, total protein
and phosphoprotein concentration can, in principle, be detected within one as-
say, when a specific antibody for total protein is printed in parallel. This is not
possible if a phosphospecific antibody is used in the detection step. Second, the
detection with the phosphospecific antibody requires that the phosphoepitope
of interest is accessible for the detection antibody. This is critical as protein
binding to immobilised antibodies cannot ensure even exposure of all proteins.
In addition, polyclonal antibodies can bind to different epitopes on the surface
of the captured proteins, which might increase signal intensity. Although phos-
phoproteins were quantified with high reproducibility using the MIA approach,
the corresponding measurements of the total target protein amount were highly
variable.
3.1.1 Development of a Microspot Immunoassay
The antibody validation routine comprised several steps to ensure high speci-
ficity as well as low cross reactivity among antibodies used in the multiplexed
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Figure 3.1: Antibody validation by Western blot
Western blot of four capture antibodies A: 05-669 (AKT S473; 60 kDa), B:
BD558316, C: CST5106 (pAKT T308; 60 kDa) and D: BD612543 (pSTAT3;
92 kDa) probed on starved and EGF- or HRG-stimulated HCC1954 (H), SKBR3
(S), and MCF7 cells (M). The arrow points to the specific signal.
format. The steps required for assay development are explained in the following
section.
Assessment of antibody specificity
As a first step in the development of a new assay, all antibodies were tested
by Western blot for their specificities. Phosphospecific antibodies were probed
on starved and stimulated breast cancer cell lysates to control if the antibo-
dies detected only the phosphorylated protein present in the stimulated sample
(Fig. 3.1). All antibodies caused a stronger signal in the stimulated samples
confirming phosphospecificity. To keep the assay format similar to the success-
fully established pERK1/2 assay, only monoclonal mouse antibodies were used
as capture antibodies. The development of the assay for AKT (T308) will be ex-
plained in detail. Assays for pAKT (S473) and pSTAT3 (S727) were established
accordingly.
Determination of antibody reactivity
Two phosphospecific antibodies against the new target of interest were spotted
along with other capture antibodies already established for microspot immuno-
assays. Next, a serial dilution of recombinant phosphoprotein was incubated
on the mounted slide as described in section 2.2.6. Several detection antibodies
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were tested, alone and in combination with already established detection anti-
bodies. In general, the signal intensities of the capture antibody had to show
a linear correlation with the protein concentration. The quality of an antibody
pair was evaluated as described in section 2.2.6.
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Figure 3.2: Performance plot
Analysis of reactivity between the capture antibodies for AKT-S473 (05-669),
AKT-T308 (BD558316, CST5106) and STAT3 (BD612543) with recombinant
pAKT and the AKT detection antibodies sc-1619-r and CST9272. The higher
the accuracy, the broader the box of the antibody pair. A broad, red box indica-
ted a reliable combination of capture and detection antibody, a small, grey box
indicates low accuracy and a small dynamic range, and no box indicated that the
antibody pair did not detect the phosphoprotein.
In the initial experiment, the slide was divided into two equal parts comprising
eight pads each. Six subarrays were incubated with a five-step two-fold serial
dilution of recombinant pAKT and assay buffer as a negative control. Two ad-
ditional subarrays were incubated with MCF7 cell lysates, HRG-stimulated and
unstimulated. The first part of the slide was then incubated with sc-1619-r as
detection antibody, and the second part with CST9272. Figure 3.2 shows the
resulting performance plots generated by Quantpro. First of all, the perfor-
mance plots revealed that the pSTAT3 capture antibody did neither cross react
with recombinant pAKT nor with the AKT detection antibodies. This was an
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Table 3.1: Antibody combinations tested to newly establish a AKT (T308) assay
capture antibodies detection antibodies
AKT STAT3
sc-1619-r CST9272 CST9132
BD558316 AKT (T308) good good no signal
CST5106 AKT (T308) background background no signal
05-669 AKT (S473) good not working no signal
BD612543 STAT3 (S727) no signal no signal good
important requirement for the combination of both phosphoproteins within a
single assay. Second, the three pAKT capture antibodies showed a good perfor-
mance with the detection antibody sc-1619-r, but the capture antibody 05-669
did not work well in combination with CST9272. For both detection antibodies,
CST5106 revealed a high background signal, however, since the correlation bet-
ween protein concentration and signal intensity was linear, a good performance
plot was obtained for both detection antibodies. According to these results, the
AKT detection antibody sc-1619-r was used for the further development of the
assay, as it showed good performance with all capture antibodies. Then, a serial
dilution of both recombinant phosphoproteins, pAKT and pSTAT3, were incu-
bated in parallel and a mixture of the detection antibodies CST9132 (STAT3)
and sc-1619-r (AKT) was applied. In this experiment, the pSTAT3 capture
antibody showed a good performance plot as a linear correlation between signal
intensity and the protein concentration was also obtained for pSTAT3 (data not
shown).
As second validation step, the potential crossreactivity between recombinant
pSTAT3 and the AKT capture and detection antibodies was assessed. A serial
dilution of recombinant pSTAT3 and two protein lysates, as described before,
were applied to each half of the slide. In the first setup, sc-1619-r as AKT detec-
tion antibody was incubated and in the second part, both detection antibodies
were mixed. The performance plot indicated no correlation between pSTAT3
and the AKT antibodies, whereas the pAKT capture antibody CST5106 resul-
ted in a very high signal intensity, even for the negative control. For this reason,
CST5106 was not suitable for the MIA platform and was discarded from the
assay and BD558316 was used to capture AKT (T308). On the other hand, the
high specificity of the pSTAT3 detection was confirmed since no crossreactivity
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with the pAKT capture antibodies was observed. Table 3.1 summarises the
identification of suitable pAKT (T308) antibody pairs to integrate the quantifi-
cation of pAKT (T308) into the existing assay for pAKT (S473) and pSTAT3.
As a final validation experiment, selected antibody pairs were examined using
biological samples obtained from dynamic measurements of MCF7 cells stimula-
ted with HRG. Taking into account the highly different abundance of the phos-
phoprotein of interest, two separate MIAs were established in which different
dilutions of the lysates are applied. The first MIA quantifies pERK1/2 and
pAKT (S473) and the second assay the less abundant phosphoproteins pAKT
(S473), pAKT (T308) and pSTAT3 (S727) (table 3.2).
Table 3.2: Antibody combinations used for the two microspot immunoassays
capture detection antibodies
antibodies ERK1/2 AKT STAT3
Assay 1: sc-94 / 06-182 sc-1619-r
M9692 pERK1/2
CST9106 pERK1/2
05-669 pAKT S473
Assay 2: sc-1619-r 9132
05-669 pAKT S473
BD558361 pAKT T308
BD612543 pSTAT3 S727
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3.2 Reverse Phase Protein Arrays
Reverse phase protein arrays (RPPA) are a tool for quantitative measurements
of protein abundance and activation. Specificities and sensitivities of the anti-
bodies were examined thoroughly, since protein quantification relies on a single
antibody. RPPAs were used to analyse signalling networks on the protein level.
Before analysing the time-resolved measurements, the quality of the experimen-
tal data had to be validated carefully. During the advancement of the RPPA
technology, additional steps of quality control were introduced which were re-
quired to analyse the generated high amount of data.
3.2.1 Antibody validation
For the reliability of RPPA analysis, it was crucial, that all antibodies were
very specific. Therefore, the first step of the antibody validation routine was
screening new antibodies for specificity towards the respective target proteins
using the Western blot technique. Figure 3.3 shows the Western blots of two
antibodies specific against pPKCα. The antibody 06-822 showed a single specific
Figure 3.3: Antibody validation by Western blot
Two antibodies against pPKCα (S657) (82 kDa) 06-822 (A) and ab23513 pPKCα
(S657/Y658) (B) probed on EGF or HRG stimulated and unstimulated cell lysates
from HCC1954 (H), SKBR3 (S), A431 (A), and MCF7 (M) cells. The arrow points
at the specific signal.
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band and was positively validated for RPPA. In contrast, ab23513 revealed in
addition a prominent unspecific band and high background and therefore this
antibody was not used for RPPA analysis.
To establish antibodies suitable for the quantification of downstream targets
of ERBB signalling, all antibodies validated as specific on Western blot were
analysed on RPPA. To achieve this, dilution series prepared from lysates of
HCC1954, SKBR3, and BT474 cells under steady-state and stimulated condi-
tions were spotted, and 45 antibodies against different proteins and phosphosites
from the ERBB signalling network were applied (table 3.3). Before lysis, cells
were serum-starved for 24 h and stimulated with EGF or HRG for 10min to
induce protein phosphorylation.
Table 3.3: Antibody qualities evaluated based on dilution series
target phosphosite company catalog number quality
AKT T308 CST 4056 high
AKT S473 CST 4058 high
AKT S473 CST 9271 high
AKT T308 CST 9275 high
EGFR Santa Cruz sc-03 high
EGFR CST 2646 high
EGFR Y1068 CST 2236 moderate
EGFR Y1173 CST 4407 high
EGFR Y845 CST 2231 high
EGFR Y992 CST 2235 moderate
EGFR Y1045 CST 2237 low
EGFR Y1148 CST 4404 moderate
EGFR Y1086 CST 2220 moderate
ERBB2 Neomarkers AB-17 high
ERBB2 CST 2165 high
ERBB2 Y1139 abcam ab53290 moderate
ERBB3 Neomarkers AB-2 high
ERBB3 Y1197 CST 4561 high
ERBB3 Y1222 CST 4784 moderate
ERK1/2 T202/Y204 CST 9106 high
GAB1 CST 3232 high
GAB1 Y307 CST 3234 high
MEK BD 610122 high
MEK1/2 S217/221 Sigma M7683 high
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Table 3.3: Antibody qualities evaluated based on dilution series
target phosphosite company catalog number quality
MET CST 3127 low
MET Y1003 CST 3135 low
MET Y1234/35 CST 3077 low
NFkB Santa Cruz sc-109 high
NFkB S536 CST 3033 high
p90RSK S380 CST 9341 high
p90RSK T359S363 CST 9344 high
PDK1 CST 3062 high
PDK1 S241 CST 3061 high
PKC abcam ab32376 high
PKC S657/Y658 abcam ab23513 high
PLCγ abcam ab41433 high
PLCγ S1248 CST 4510 high
PTEN T366/S370 Epitomics 2195-1 high
RSK CST 9355 high
SDHA Santa Cruz sc-59687 high
SRC Y416 CST 2101 high
SRC CST 2123 high
STAT3 Y705 CST 9131 moderate
STAT3 S727 CST 9134 high
STAT3 Santa Cruz sc-482 high
34 of the 45 antibodies tested revealed a linear correlation between lysate concen-
tration and signal intensity and a high dynamic range. Phosphospecific anti-
bodies also showed different signal intensities between the dilution series with
stimulated and unstimulated lysates, indicating the phospho-specificity of the
antibodies. However, a few antibodies showed a linear correlation but the in-
tensity range was very low. A linear correlation but low signal intensity might
be due to the fact that the target protein is of low concentration as observed for
the phospho-EGFR antibodies. Those antibodies were used with caution and
quality was validated on each new sample set. Besides showing a linear corre-
lation and a high dynamic range, the resulting data had to reflect the actual
protein expression or activation status of the samples. This was not possible
for the MET and pMET and the corresponding antibodies were excluded from
further RPPA experiments.
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In summary, the experiments showed that most antibodies tested by Western
blot analysis worked well on RPPAs. Several phosphospecific ERBB receptor
antibodies had to be validated carefully for each single experiment but only
the MET specific antibodies failed. However, the quality of each antibody was
assessed for each RPPA experiment as explained in the following sections.
3.2.2 Quality control of RPPA data
Three antibodies, anti-pERK1/2 CST4370, anti-pAKT (S473) CST9271, and
anti-pp70S6K (T421/S424) 1135-1, were chosen to exemplify the antibody qua-
lity control (Fig. 3.4).
Figure 3.4: Determination of antibody specificity by Western blot
Lysates from starved and EGF-stimulated HCC1954 (H), SKBR3 (S), and MCF7
(M) cells were probed with antibodies against pERK1/2 (A), pAKT (S473)
(B), and pp70S6K (T421/S424) (C). Red arrows indicate the specific signals (C:
p70S6K and p85S6K).
Each slide contained dilution series of the corresponding cell lines in addition to
the measurement samples to serve as basis for antibody quality control. Only
antibodies showing a linear correlation between signal intensity and protein
concentration were considered for further data analysis. Figure 3.5 shows the
dilution curve of the antibodies specific for pERK1/2 (A), pAKT (S473) (B), and
pp70S6K (T421/S424) (C). The corresponding Fast Green FCF protein stain of
the serial dilution of the protein lysate is shown in figure D. The analysis of the
dilution series was performed as described in section 2.2.7. In case of pERK1/2
and pAKT (S473), no point was excluded from the linear fit, indicating a perfect
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Figure 3.5: Serial dilution curve
The diagrams show the dilution curve of an EGF stimulated lysate immobilised
on RPPA and incubated with the pERK1/2 antibody CST4370 (A), the pAKT
(S473) antibody CST9271 (B), the pp70S6K (T421/S424) antibody 1135-1 (C)
and the protein dye Fast Green FCF (D). The grey crosses represent the single
technical replicates, the black circle the median of the replicates. The light blue
line represents the linear fit of the dilution series with the lowest p-value. The
light dashed lines represent the fits with higher p-values. The vertical blue line
shows the cutoff of the 75% CI.
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fit of the antibody. Regarding the detection of pp70S6K (T421/S424), only the
lowest protein concentration was excluded from the linear correlation, where the
antibody signal was not above the background signal.
A B C
Figure 3.6: Exemplary RPPA slide images
Images of slides from the HCC1954 data set incubated with pERK1/2 antibody
(A) pAKT (S473) (B) and pp70S6K (T421/S424) (C) scanned with the same
intensity setting of the Odyssey scanner.
RPPA experiments normally comprised a number between 400 and up to more
than 1000 samples. Antibody quality was therefore not only evaluated for the
control dilution series, printed with every sample set, but for all immobilised
samples. The visual inspection of RPPA slide images gave a first impression of
the quality and consistency of the antibody incubation (Fig. 3.6). The pERK1/2
and the pAKT (S473) antibody resulted in images with very strong signals while
the image of the pp70S6K (T421/S424) antibody showed much weaker signal
intensities. For all three phosphospecific antibodies, differences in the signal in-
tensities between the samples were observed indicating a different concentration
of the phosphoproteins. Furthermore, the images of all three antibodies revea-
led an uniform background indicating an even antibody incubation process. To
evaluate the quality of the antibody signal, the signal intensity of each antibody
was compared with the corresponding blank signal of the secondary antibody.
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In order to do this, the measurement signal of each spot was plotted against the
corresponding blank signal (Fig. 3.7). In all cases, the specific signal of the anti-
body was stronger than the blank signal, although the pERK1/2 and the pAKT
antibodies revealed much stronger signals than the pp70S6K (T421/S424) anti-
body, suggesting a careful evaluation of the pp70S6K (T421/S424) time series
data.
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Figure 3.7: Signal versus blank
The figure shows all measurement signals plotted against the corresponding blank
signal of HCC1954 cells. (A) pERK1/2 antibody plot, (B) pAKT (S473) antibody
plot, and (C) pp70S6K (T421/S424) antibody plot.
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3.2.3 Data analysis of time-resolved measurements
After quality control, the first step in RPPA data analysis was the normalisation
of the raw signal intensities of each antibody using the signal intensities of the
total protein stain FCF as described in section 2.2.7. Figure 3.8 shows the effect
of normalisation of the pERK1/2 signal for dynamic measurements performed in
HCC1954 cells. The five biological replicates are represented by lines of different
colours. The antibody signal intensities of the light and the dark blue lines were
weaker compared to the others (A). The same was true for the FCF signals
of the corresponding lysates indicating a lower amount of protein in these two
time series (B). After FCF-based normalisation of the antibody signals, the five
biological replicates approximated (C).
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Figure 3.8: Signal normalisation using FCF and centering of the data.
Raw signal intensity of pERK1/2 antibody (A), FCF signal (B), normalised anti-
body signal intensities (C), and centered signal intensities (D). The coloured line
represent the five biological replicates.
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To facilitate comparability of biological replicates, a centering around zero was
tested (D). The centering was performed on the level of technical replicates:
xˆi = xi − x 1 ≤ i ≤ 10
where xi is the signal of a technical replicate at a given time point i and x
the mean of this replicate over all time points. This approach was used for
the analysis of the BT474 cells described by Szabó (2009). Yet, this method
resulted in masking inhibitory effects. Figure 3.9 shows the comparison of the
same biological conditions centered around zero (A) and uncentered (B). In the
centered data, effects were displayed according to the time dependent dynamics,
but information on the absolute signal intensity was lost. Additionally, different
time-dependent model fits were calculated for centered and uncentered data
(Fig. 3.9: blue line). The differences were explained with the high distance
between the signal intensities of the biological replicates at single time points.
The comparison between the two methods pointed out that centering signal
intensities did not reflect the biology behind the data. Therefore, dynamic
signalling data were analysed uncentered.
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Figure 3.9: Centered and uncentered data
pERK1/2 signal after stimulation with EGF without inhibition (red) and prior
inhibition with trastuzumab (green), pertuzumab (orange) and erlotinib (blue).
A: Data centered around zero. B: Uncentered data.
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To cope with the given variability of biological data, a novel strategy of fit-
ting the smoothing splines was applied to determine time-dependent effects.
In figure 3.10, two strategies were compared showing one of the most drastic
examples to illustrate the differences in the outcome of the two methods. The
biological replicate represented by the blue line did not result in a comparable
activation of pERK1/2 as the other two replicate measurements shown in red
and light blue. In the first approach, the technical replicates were combined for
each time point using the median as a robust estimator. Fitting a spline on the
median of each biological replicate resulted in artifactual data due to experi-
mental outliers represented by the blue line (Fig. 3.10 A). In order to account
for biological variability and experimental outliers, an algorithm was developed
to differently weight biological replicates by fitting the spline over the median of
the biological replicates. This resulted in a more robust fit and thus was more
suitable to reveal time-dependent effects (Fig. 3.10 B). For experiments without
biological outliers, the two methods revealed no difference (data not shown).
Therefore, the strategy of fitting the smoothing splines on the median of the
biological replicates was chosen for the analysis of time series data.
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Figure 3.10: Comparison of two different spline fit models
The diagram shows the pERK1/2 signal of simultaneous stimulation with EGF
and HRG after erlotinib inhibition. The coloured lines represent three biological
replicates. The splines are shown in dark red. The spline fit over the median of
the technical replicates is shown in figure A, the spline fit over the median of all
technical and biological replicates is shown in figure B.
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3.3 Characterisation of breast cancer cell lines
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Figure 3.11: Receptor expression in breast cancer cell lines
Expression of the four ERBB receptors and the MET receptor in HCC1954
(black), SKBR3 (red), BT474 (green), and MCF7 (yellow) cells via qRT-PCR
(A) and Western blot analysis (B). The expression level of the qRT-PCR results
are normalised to the mean expression of EGFR.
For the analysis of the ERBB receptor signalling network in breast cancer, four
well established breast cell lines were selected, BT474, HCC1954, MCF7, and
SKBR3. First, the expression of the receptors in the different cell lines was
characterised on the mRNA level via qRT-PCR and on the protein level by
Western blot analysis (Fig. 3.11). ERBB2 was highly expressed in HCC1954,
SKBR3, and BT474 but low in MCF7 cells. Additionally, EGFR was highly
expressed in HCC1954 and SKBR3 cells. This was detected on the mRNA as
well as on the protein level. Transcripts for ERBB3 were of slightly higher
abundance in SKBR3 cells and expressed in nearly equal amounts in the other
three cell lines. On the protein level, ERBB3 was only detected in SKBR3 cells.
According to the transcript data, the ERBB4 receptor was expressed at a very
low level in BT474 and MCF7 cells, and not expressed in HCC1954 and SKBR3
cells. However, ERBB4 was not detectable on protein level in any of the cell
lines. The MET receptor was mainly expressed in HCC1954 cells in comparison
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to the other three cell lines when assessed by qRT-PCR, but was not detectable
by Western blot.
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Figure 3.12: Kinase expression and activation in breast cancer cell lines
The Western blots show the expression (A) and the phosphorylation status (B)
of ERK1/2, AKT, p38 and p70S6K in steady-state (+) and 24 h serum-starved
(-) HCC1954 (H), SKBR3 (S), BT474 (B) and MCF7 (M) cells.
The abundance and the phosphorylation status of ERK1/2, AKT, p38, and
p70S6K in steady-state and in cells serum-starved for 24 h was determined by
Western blot (Fig. 3.12). ERK1 and ERK2 were equally expressed in HCC1954,
SKBR3, and BT474 cells, while ERK1 was higher expressed than ERK2 in
MCF7 cells. AKT expression was low in HCC1954 and higher in BT474 and
MCF7 cells compared to SKBR3 cells. HCC1954 cells revealed higher p38 ex-
pression compared to the other three cell lines. Overall, differences in protein
expression were not so strong for ERK1/2, AKT, and p38 as those observed for
p70S6K which was highly expressed in BT474 and in MCF7 cells. p70S6K and
p85S6K are two isoforms of the same kinase. p85S6K is identical to p70S6K
except for additional 23 amino acids at the N-terminus which encode a nuclear
translocation motif. Antibodies specific for p70S6K also detect p85S6K which is
also true for phosphospecific antibodies, as the phosphosites are identical. The-
refore, it was not possible to distinguish between these two kinases using RPPA.
Both isoform were reported to be equally regulated and are therefore referred
to as p70S6K. In Western blot analysis, separation of the proteins depending
on the size allowed the differentiation of the isoforms.
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Regarding the phosphorylation status of these proteins, differences between the
cell lines were revealed. For example, HCC1954 and SKBR3 cells showed a high
baseline level of ERK1/2 phosphorylation, which was reduced after starvation
in HCC1954 cells but not in SKBR3 cells. In contrast, starvation resulted in an
increase of AKT phosphorylation in HCC1954 and BT474 cells. Phosphoryla-
tion of p38 was reduced by starvation in all four cell lines while p70S6K phos-
phorylation was increased after starvation in MCF7 cells. Notably, HCC1954
and SKBR3 cells revealed a higher phosphorylation of p85S6K compared to the
p70S6K isoform, although total protein expression indicated a higher abundance
of the p70S6K isoform.
Figure 3.13: Protein expression in breast cancer cell lines
Western blot analysis of expression of p27, cyclinD1, SRC, PTEN, and the PI3K
subunits in HCC1954 (H), SKBR3 (S), BT474 (B), and MCF7 (M) cells.
Further analysis of the cell lines revealed that there was almost no p27 expres-
sion in HCC1954 and only weak in SKBR3 cells whereas cyclin D1 was mainly
expressed in HCC1954 and MCF7 cells (Fig. 3.13). PTEN was most strongly
expressed in BT474 cells while SRC had a high abundance in HCC1954 and
SKBR3 cells. The p110 subunit of the PI3K was expressed equally in the four
cell lines while p85 was slightly stronger expressed in HCC1954 and MCF7 cells.
As HCC1954 cells were reported to be trastuzumab resistant and sensitivity was
correlated with an increase of p27 expression (Sahin et al., 2009), the induction
of p27 after treatment with trastuzumab was analysed in the three ERBB2
overexpressing cell lines. Indeed, no increase in p27 expression after addition
of trastuzumab was observed in HCC1954 cells while an induction of p27 was
detected in BT474 and SKBR3 cells as shown in figure 3.14.
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Figure 3.14: Trastuzumab induced p27 expression
Western blot analysis of p27 expression after trastuzumab treatment for 24, 28,
and 72 h in HCC1954, BT474, and SKBR3 cells.
To complete the information about the cell lines, breast cancer li-
terature as well as the Catalogue Of Somatic Mutations In Cancer
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) was screened for known am-
plifications of ERBB2 (Kauraniemi et al., 2001), p70S6K (Barlund et al., 2000,
Couch et al., 1999), and PI3K mutations (Saal et al., 2005). A summary of the
expression and mutation status of key proteins is given in table 3.4.
Table 3.4: Expression and mutation of proteins
protein HCC1954 SKBR3 BT474 MCF7
EGFR high high low low own data
ERBB2 amplified amplified amplified wt literature
PI3K H1047R wt K111N E545K literature
p27 low high high high own data
p70S6K wt wt amplified amplified literature
PTEN low low high low own data
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3.4 Quantitative analysis of ligand-induced ERBB
signalling in MCF7 cells
The breast cancer cell line MCF7 was chosen as model system for the analysis
of ligand-induced ERBB signalling. In this cell line, the four ERBB receptors
were expressed at a low level and in comparable amounts (Fig. 3.11). There-
fore, the unperturbed ERBB signalling was measured without the impact of
alterations due to overexpression of one or several receptors. Three ligands
(epidermal growth factor (EGF), heregulin-β1 (HRG), and betacellulin (BTC)),
representing three different receptor specificity groups (Fig. 1.4), were chosen
for analysis.
3.4.1 Quantitative measurements of ligand-induced signalling
First, the dose-dependent, ligand-induced phosphorylation of downstream
targets within the ERBB receptor signalling network, namely pERK1/2
(T202/Y204), pSTAT3 (S727), pAKT (S473), and pAKT (T308), was studied
applying the MIA approach. Each ligand was applied in a series of different
concentrations ranging between 0.1 and 20 nM.
Cell stimulation with HRG resulted in a strong increase in phosphorylation of all
four phosphoproteins. The time courses for pERK1/2, pAKT, and pSTAT3 of
one biological replicate are shown in figure 3.15. The amount of phosphorylated
ERK1/2 ranged from 235 ng/µg (0.1 nM) over 1880 ng/µg (1 nM) to 4200 ng/µg
(3 nM). The phosphorylation of AKT (S473) increased after addition of HRG
from 10 (0.1 nM) over 200 (1 nM) to 800 ng/µg (3 nM) and of AKT (T308) from
almost zero (0.1 nM) over 100 (1 nM) to 300 ng/µg (3 nM). For STAT3 phospho-
rylation, a further effect was observed. In addition to the quantitative dispa-
rity between stimulation with 1 nM and 3 nM HRG, phosphorylation dynamics
shifted. In detail, for concentrations higher than 3 nM, the phosphorylation im-
mediately increased after stimulation while the baseline phosphorylation level
remained unaffected for 4min at lower concentrations. The phosphorylation
was sustained for all phosphoproteins at a high level. The activation of AKT
and STAT3 remained on the highest activation level for more than 60min while
pERK1/2 level started to decline 30min after treatment.
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Figure 3.15: Dose-dependent stimulation of MCF7 cells with HRG
MCF7 cells were stimulated with HRG in concentrations ranging from 0.1 nM
to 20 nM. Phosphorylation of ERK1/2, STAT3 (S727), AKT (S473), and AKT
(T308) was quantified.
The activation of ERK1/2 and AKT was dose-dependent in response to EGF.
The phosphorylation of ERK1/2 peaked between 12 and 16min for concen-
trations below 1 nM and shifted to a 4min peak for concentrations above 3 nM
(Fig. 3.16). No difference in ERK1/2 activation between 10 and 20 nM EGF was
observed. In contrast to HRG, stimulation with EGF resulted in a sharp peak.
The activation rapidly declined, returned to a low level after 20min and conti-
nued to fade slowly. The phosphorylation of AKT (S473) was very weak after
stimulation with EGF although dose-dependent and reaching a concentration
of 100 ng/µg pAKT (S473) after addition of 20 nM EGF. AKT phosphorylation
dynamics were similar to the pattern described for ERK1/2 phosphorylation.
The peak of activation was reached after 16min for the low and after 4min for
the higher EGF concentrations, and a steady state was reached again 20min
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Figure 3.16: Ligand-induced ERK1/2 phosphorylation in MCF7 cells
MCF7 cells were stimulated with EGF and BTC in concentrations ranging from
1nM to 20 nM and concentration of pERK1/2 was measured over time.
after stimulation. No pronounced phosphorylation of pAKT (T308) was measu-
red after EGF stimulation and also STAT3 was phosphorylated only to a minor
extent (Fig. A.1).
Finally, the activating potential of BTC was analysed. In addition to EGFR,
BTC also binds to ERBB4. The activation was dose-dependent for all four
phosphoproteins. The ERK1/2 and AKT activation kinetics were very similar
compared to EGF (Fig. 3.16). The highest amount of phosphorylated ERK1/2
was measured after 12min for the low concentrations, shifting to 8min for 10
and 20 nM BTC. The activation rapidly declined until 20min after stimulation.
The concentration of pERK1/2 ranged from 40 ng/µg (0.1 nM) to 2150 ng/µg
(20 nM). The phosphorylation of AKT (S473) also showed the same dynamics
as observed for ERK1/2 ranging from 10 to 200 ng/µg (Fig. A.2). AKT (T308)
was weakly phosphorylated with the highest concentration of 60 ng/µg after
addition of 20 nM BTC. The kinetics of STAT3 phosphorylation differed from
the pattern described for pERK1/2 and pAKT as it continously increased for
30min reaching a concentration of 80 ng/µg for 20 nM BTC.
Although the activation of all phosphoproteins was dose-dependent for all biolo-
gical replicates and the relative correlation of the stimulation curves was highly
comparable for the different biological replicates, the absolute amount of phos-
phoprotein varied. The median of phosphoprotein formation 8min after addition
of a certain ligand was calculated from three biological replicates and is listed for
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Figure 3.17: Dose-dependency of ERK1/2 and AKT phosphorylation
MCF7 cells were stimulated with HRG, EGF, and BTC at concentrations ranging
between 0.1 and 20 nM. Bar plots show the amount of phosphoprotein 8min after
stimulation.
the four phosphoproteins in table 3.5. To make the biological replicates more
comparable, the data was scaled for each biological replicate separately. For
each experiment comprising six time series, the maximum value of phosphopro-
tein was set to one, and the data was scaled in relation to this data point. The
correlation between the time series of the scaled data resembled the data of the
single biological measurements (Fig. A.3).
To sum up, the phosphorylation of ERK1/2 and AKT was clearly dose-
dependent for the three ligands but saturation was reached at different concen-
trations (Fig. 3.17). HRG resulted in the strongest increase in phosphorylation,
reaching saturation at a concentration of 3 nM. EGF mediated activation was
saturated at 10 nM for most phosphoproteins while addition of BTC was still
increasing at the highest measured concentration. STAT3 was phosphorylated
only after stimulation with HRG and BTC while addition of EGF resulted in
very weak phosphorylation. For further analysis of ligand-dependent ERBB
signalling in MCF7 cells, a concentration of 1 nM for each ligand was chosen.
This ligand concentration induced strong activation of the target proteins but
the phosphorylation rate was not saturated. This was important for the analysis
of possible additive effects of the ligands.
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3.4.2 Quantitative analysis of signalling in response to ligand
combinations
After analysing the dose-dependency of ligand-mediated signalling in MCF7
cells, combinatorial ligand treatment was studied. The quantitative analysis of
the combinations revealed significant differences between the three biological
replicates. Not only the absolute readout but also the relation between the
ligands differed. To gain a better understanding of the signalling features of the
ligands and the combinations, the data was scaled in relation to the highest value
of each biological replicate which was set to one as already explained before.
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Figure 3.18: Ligand-dependent signalling in MCF7 cells.
Cells were serum-starved for 24 h and subsequently stimulated with 1 nM of each
ligand, alone and in combination. Each biological replicate was scaled to its
maximal value. Phosphorylation of ERK1/2, AKT, and STAT3 is shown.
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Figure 3.18 shows the phosphorylation dynamics of the four phosphoproteins.
The median values are listed in table 3.5.
EGF had the weakest capacity to activate ERK1/2 and AKT, while stimulation
with BTC resulted in a slightly stronger activation of both proteins. The com-
bination of BTC and EGF compared to BTC alone did not result in an increase
of pERK1/2 and was even weaker regarding the AKT activation. BTC+EGF
reached 35% of the maximal phosphorylation of AKT and 80% of maximal
ERK1/2 phosphorylation. HRG stimulation resulted in a more sustained phos-
phorylation of both proteins and contrasted the dynamics observed for the other
two ligands. Compared to BTC, HRG led to the phosphorylation of twice the
amount of AKT which was slightly increased after simultaneous treatment with
EGF or BTC. In contrast, activation of ERK1/2 was slightly stronger upon ad-
ditional EGF or much stronger by BTC and HRG cotreatment. With exception
of EGF, all ligands and combinations resulted in a uniform phosphorylation of
STAT3. EGF only led to a transient activation reaching the highest phospho-
rylation after 20–30min, which was corresponding to almost 70% of maximal
phosphorylation, while the other combination resulted in a sustained phospho-
rylation.
In summary, HRG was the most potent ligand in MCF7 cells and strongly
activated the key signalling pathway proteins downstream of ERBB family re-
ceptors. With regard to activation of ERK1/2, EGF and BTC slightly increased
this pathway due to the simultaneous activation of EGFR and ERBB4. How-
ever, this effect did not result in increasing AKT phosphorylation. This data
will provide a basis to calculate a quantitative model of fast ligand-induced and
dose-dependent signalling via ERBB receptors in a systems biology approach.
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Table 3.5: Median amount of phosphoproteins 8min after stimulation [ng/µg]
HRG pERK1/2 pAKT S473 pAKT T308 pSTAT3 S727
control 6 2 8 20
0.3 nM 676 39 13 19
1 nM 1871 163 68 40
3 nM 3617 555 200 70
10 nM 3150 562 202 63
20 nM 3093 441 173 64
EGF pERK1/2 pAKT S473 pAKT T308 pSTAT3 S727
0.1 nM 174 0 4 31
0.3 nM 389 0 7 24
1 nM 1482 31 13 39
3 nM 1419 37 18 39
10 nM 2318 102 33 55
20 nM 1765 88 34 52
BTC pERK1/2 pAKT S473 pAKT T308 pSTAT3 S727
0.1 nM 179 0 0 20
0.3 nM 406 7 2 20
1 nM 1051 39 16 39
3 nM 1871 84 41 65
10 nM 1897 112 48 61
20 nM 2243 131 58 55
1 nM each pERK1/2 pAKT S473 pAKT T308 pSTAT3 S727
BTC 1986 169 74 50
EGF 1355 88 29 42
HRG 1831 263 140 42
BTC+EGF 1875 154 78 48
BTC+HRG 2171 287 145 48
EGF+HRG 1968 236 117 43
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3.4.3 Ligand-induced ERBB signalling
Having analysed the dose-dependent measurements in a quantitative manner
using the MIA technique, the ligand-induced signalling was examined applying
the RPPA approach. This allowed studying the phosphorylation status of fur-
ther pathway proteins in addition to ERK1/2, AKT, and STAT3. Figure 3.19
shows the phosphorylation of ERK1/2, cRAF, AKT, p70S6K, STAT3, PLCγ,
mTOR, EGFR, ERBB2, and ERBB3 after stimulation with 1 nM EGF, HRG, or
BTC for four biological replicates. The effects of the three ligands were ranked
as weak, moderate, and strong (table 3.6). Proteins, which showed no effect for
any of the ligands were not listed.
Table 3.6: Effects in MCF7 cells after stimulation with ligands
protein phosphosite BTC EGF HRG
AKT S473 weak weak strong
AKT T308 weak no strong
cRAF S289/296/301 moderate weak strong
EGFR Y845 moderate no strong
EGFR Y992 weak no moderate
EGFR Y1173 moderate no strong
ERBB2 Y1139 no no weak
ERBB2 Y1248 no no weak
ERBB3 Y1197 no no strong
ERBB3 Y1289 no no strong
ERK1/2 T202/Y204 moderate weak strong
MEK1/2 S217/221 moderate weak strong
mTOR S2481 no no weak
p38 T180/Y182 no no no
p70S6K T389 weak no strong
p70S6K T421/S424 strong moderate strong
PLCγ S1248 no no weak
SRC Y416 no no weak
STAT3 S727 weak no weak
HRG had by far the strongest impact on the activation of several downstream
pathways. ERBB3 was phosphorylated at Y1197 and Y1289, and the phospho-
rylation of EGFR and ERBB2 was induced by transphosphorylation as HRG
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Figure 3.19: RPPA measurements of ligand-dependent responses in
MCF7 cells.
MCF7 cells were stimulated with 1 nM EGF (blue), HRG (red) or BTC (green).
The plots show the phosphorylation of ERK1/2, cRAF (S289/296/301), STAT3
(S727), AKT (S473, T308), PLCγ (S1248), p70S6K (T389, T421/S424), mTOR
(S2481), EGFR (Y1173), ERBB2 (Y1248), and ERBB3 (Y1197). The thick lines
are the smoothing splines, the dashed lines represent the biological replicates.
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only binds to ERBB3 and induces activation by dimerisation with ERBB2.
Upon receptor phosphorylation, a maximum peak of ERK1/2 phosphorylation
was observed after 12min. The curve declined until 30min after stimulation
but did not return to the baseline level of the starved conditions within 60min.
AKT was also phosphorylated at both phosphorylation sites S473 and T308.
This activation reached its highest level after 12min and was sustained over
a time period of 60min except a weak drop after 20min which was noted for
both phosphorylation sites. A significant activation was observed for p70S6K
also for both phosphorylation sites T389 and T421/S424. However, the dy-
namics of the phosphorylation were different: Addition of HRG resulted in a
continuous increase in phosphorylation of p70S6K (T389) which was compa-
rable to the activation of cRAF and mTOR. In contrast, the phosphorylation
of p70S6K (T421/S424) resembled the dynamics of ERK1/2 activation with a
peak after 12min, although the decline of activation was weaker for p70S6K
than for ERK1/2. PLCγ, SRC, and STAT3 showed a weak increase after addi-
tion of HRG reaching the highest level 12min after stimulation. The pmTOR
signal slowly increased within the 60min. The same behaviour was observed for
cRAF, but to a higher extent. No activation of p38 and PKCα by any of the
ligands was seen in MCF7 cells.
After addition of EGF, no phosphorylation of EGFR, ERBB2, and ERBB3 was
detectable. However, the activation of the MAPK pathway including cRAF,
MEK1/2 and ERK1/2, and p70S6K (T421/S424) points to an activation of
EGFR. AKT phosphorylation after addition of EGF was not detected by RPPA.
For almost all phosphoproteins measured by RPPA, the activating potential of
BTC ranked between that of the other two ligands, EGF and HRG. In contrast
to EGF, BTC was able to induce a weak AKT activation. Phosphorylation
of the EGFR was also stronger after addition of BTC when compared to the
EGF stimulation. However, the time-dependent dynamics of the phosphoprotein
formation were similar between the three ligands.
The results obtained from RPPA analysis confirmed the MIA result that HRG
was the most potent ligand in MCF7 cells. Therefore, further analysis of ERBB
signalling in MCF7 cells was performed using HRG as ligand.
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3.4.4 Ligand-induced ERBB signalling after kinase inhibition
To analyse the pathways in more detail, several kinase inhibitors were applied
and the activation of the proteins described before was studied. Although the
inhibitor experiments were only performed once, they allowed to describe the
interplay of the various proteins and the impact of the inhibitors on signal
transduction. The results are shown in figure 3.20. For this study, the specific
pathway inhibitors PD98059 (inhibiting MEK1/2), LY294002 (inhibiting PI3K),
rapamycin (inhibiting mTORC1) and gefitinib (inhibiting EGFR) were applied.
Inhibitors were added at a concentration of 10 µM (PD98059, LY294002, gefiti-
nib) or 10 nM (rapamycin) corresponding to concentrations used in the litera-
ture.
The preincubation with gefitinib for 1 h resulted in the prevention of ligand-
induced phosphorylation, not only of EGFR, but also of the other ERBB recep-
tors. Thus, HRG did not induce phosphorylation of ERBB2 or ERBB3 after
gefitinib treatment. The inactivation of all ERBB receptors was also reflected in
the inhibition of all downstream pathways. MAPK, PI3K, p70S6K, and mTOR
activation was entirely inhibited by gefitinib. Although the activation of PLCγ,
STAT3, and SRC was very weak in response to HRG, gefitinib prevented PLCγ
and STAT3 activation and delayed and reduced the phosphorylation of SRC.
To analyse which downstream targets were activated through the MAPK path-
way or the PI3K pathway, selective inhibitors against MEK1/2, PD98059, and
PI3K, LY294002, were applied. As expected, PD98059 did not affect the phos-
phorylation of the receptors or of cRAF, which is upstream of MEK1/2, and
inhibited only the phosphorylation of MEK1/2 and the downstream kinase
ERK1/2. However, the inhibition of both kinases was not complete. This
might be due an insufficient inhibition caused by a too low concentration of the
inhibitor PD98059. Furthermore, the phosphorylation of p70S6K (T421/S424)
was slightly delayed after preincubation with PD98059, but no inhibition was
observed. No change was observed for p70S6K (T389) activation. Although
the phosphorylation of mTOR after addition of HRG was very weak, PD98059
treatment led to a slight but not significant increase in mTOR phosphorylation.
In contrast, LY294002 had strong effects on HRG signalling. Similar to the
inhibition with PD98059, LY294002 was not able to inhibit or block the acti-
vation and phosphorylation of the receptors, but inhibited the phosphorylation
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Figure 3.20: Inhibitory effects on HRG-mediated signalling in MCF7
cells.
The plots show the effects of gefitinib (blue), PD98059 (green), LY294002
(orange), and rapamycin (violet) on HRG-mediated signalling in comparison to
the uninhibited control (red) in MCF7 cells. The thick lines are the smoothing
splines, the dashed lines represent the biological replicates.
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of AKT at both phosphorylation sites as well as of p70S6K (T389). Additio-
nally, the phosphorylation of mTOR and PLCγ was prevented by LY294002,
but MEK1/2, ERK1/2, and p70S6K (T421/S424) were not affected.
Finally, the mTORC1 inhibitor rapamycin was analysed. As expected, rapa-
mycin inhibited mTOR phosphorylation and displayed the same inhibitory po-
tential on p70S6K (T389) phosphorylation as gefitinib and LY294002, whereas
it slightly increased the phosphorylation of p70S6K (T421/S424). Additionally,
the phosphorylation of ERK1/2 and AKT was also slightly increased. Table 3.7
summarises the effects of the different inhibitors on HRG signalling. As expec-
ted, gefitinib inhibited all downstream pathways and its impact on signalling
proteins is therefore not listed in the table.
Table 3.7: Effects of inhibitors in MCF7 cells on HRG mediated signalling
protein phosphosite PD LY rapamycin
AKT S473 no strong induction
AKT T308 no strong induction
cRAF S289/296/301 no no no
ERK T202/Y204 weak no induction
MEK S217/221 strong no weak
mTOR S2481 induction strong weak
p70S6K T389 no strong strong
p70S6K T421/S424 no no induction
PLCy Y1248 no strong no
SRC Y416 weak no no
STAT3 S727 no no induction
The impact of the different inhibitors was similar after EGF or BTC stimulation
as the described for HRG (data not shown) with a few exceptions. For example,
stimulation with EGF after preincubation with rapamycin resulted in a doubling
of ERK1/2 phosphorylation from 850 ng/µg to 1665 ng/µg, as measured by MIA
(Fig. A.4).
Two signalling modules were identified as major effectors of ERBB signalling
and the key effects are summarised in figure 3.21. First, HRG induced AKT si-
gnalling via ERBB3/ERBB2 and PI3K. This led to the downstream activation
of mTOR and p70S6K (T389) which both revealed a steadily increasing phos-
phorylation. This HRG/PI3K signalling module was LY294002 sensitive. The
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second cascade started with the activation of cRAF, MEK1/2, and ERK1/2 and
resulted in the phosphorylation of p70S6K (T421/S424). Except for cRAF, all
other proteins from this PD98059 sensitive pathway revealed a transient phos-
phorylation. A crosstalk between both pathways was observed as inhibition of
PI3K led so a slight upregulation of the pERK1/2 (Fig. A.4). Additionally, in-
hibition with rapamycin resulted in an upregulation of the PD98059 sensitive
pathway. To analyse this crosstalk in more detail, other selective inhibitors
against all kinases of both pathways would have to be analysed. As the kinase
domains of the receptors are very similar, gefitinib might inhibit other ERBB
receptors in addition to EGFR. Therefore, it is difficult to attribute inhibitory
effects mediated by gefitinib solely to EGFR inhibition.
Figure 3.21: ERBB signalling in MCF7 cells.
Schematic overview of inhibitory effects on HRG mediated signalling in MCF7
cells. Phosphorylation of p70S6K is depicted for T421/S421 (pSpT) and T389
(pT).
3.4.5 Ligand-induced signalling after siRNA-mediated
knockdown of ERBB receptors
To further analyse the impact of ERBB1–4, ligand-induced signalling was analy-
sed after siRNA-mediated knockdown. MCF7 cells were transfected with siRNA
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Figure 3.22: siRNA-mediated knockdown of the four ERBB receptors
in MCF7 cells.
MCF7 cells were transfected with siRNA targeting each of the four ERBB recep-
tors for 48 h and serum-starved for additional 24 h. The plots show the knockdown
of the four ERBB receptors and the mock control detected with antibodies against
EGFR, ERBB2, ERBB3, and ERBB4.
for 48 h and serum-starved for an additional 24 h period prior to stimulation
with 1 nM HRG, EGF, or BTC, respectively. First, antibody quality was ana-
lysed as already described in section 3.2.2. The phosphospecific ERBB receptor
antibodies did not perform well in this experiment as signals were below the
blank signal and thus were not further analysed. However, antibodies recogni-
sing ERBB receptors and several downstream signalling proteins showed good
results and were analysed.
Figure 3.22 shows the validation of the knockdown on the protein level. Ap-
plying total protein antibodies against the receptors, the specific knockdown
of EGFR, ERBB2 and ERBB3 was confirmed. Knockdown was ignificant as
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Figure 3.23: Ligand-induced signalling in MCF7 cells after siRNA-
mediated knockdown of ERBB receptors
MCF7 cells were transfected with siRNA targeting the four ERBB receptors and
subsequently stimulated with 1 nM HRG (A) or EGF (B). The diagrams show the
phosphorylation of ERK1/2, AKT, p70S6K (T421/S424), and p70S6K (T389).
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Table 3.8: Estimated receptor knockdown efficiency [%]
EGFR ERBB2 ERBB3 ERBB4
HRG 52 63 61 10
EGF 78 50 42 19
calculated using Wilcoxon test (p<0.01). Probably due to low protein expres-
sion and insufficient antibody quality, an ERBB4 knockdown was not observed.
Knockdown efficiency for the EGF- and HRG-induced time series was calculated
using the R-package “RPPanalyzer” (table 3.8).
Knockdown of ERBB2 and ERBB3 had the highest impact on HRG induced
signalling (Fig. 3.23 A), and AKT activation was more affected than ERK1/2
signalling. Quantitative analysis applying MIA revealed that ERK1/2 phos-
phorylation was reduced by 50% from 2200 ng/µg to 1370 ng/µg for ERBB3
knockdown and 1090 ng/µg for ERBB2 knockdown, while AKT phosphoryla-
tion was reduced by 80% from 160 ng/µg to 30 ng/µg (Fig. A.5 A). In contrast
to AKT activation, which was equally dependent on both receptors, ERK1/2
and p70S6K activation was stronger affected by ERBB2 than by ERBB3 down-
regulation.
EGFR knockdown had the highest impact on EGF mediated signalling (Fig.
3.23 B). It strongly reduced the phosphorylation of all measured signalling pro-
teins. Applying MIA, a reduction of ERK1/2 phosphorylation from 1990 ng/µg
by 54% down to 930 ng/µg for EGFR knockdown and by 33% down to
1340 ng/µg for ERBB2 knockdown was measured. AKT phosphorylation was
reduced from 62 ng/µg by 63% for EGFR and ERBB2 knockdown (Fig. A.5 B).
As seen for ERK1/2, p70S6K activation was more affected by EGFR than by
ERBB2 knockdown. This might be due to the different knockdown efficiency
of EGFR and ERBB2 (table 3.8). However, the impact on AKT signalling was
similar despite the difference. Knockdown of ERBB3 and ERBB4 did not show
any difference compared to the mock control.
In summary, ERBB3 knockdown reduced HRG induced signalling while EGFR
knockdown decreased EGF mediated signalling (Fig. 3.24). Knockdown of
ERBB2 had a strong impact on both signalling cascades, HRG- and EGF-
induced, but AKT signalling was stronger impaired than ERK1/2 signalling.
Additionally, the ERBB2 knockdown had a stronger impact on HRG than on
EGF signalling.
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Figure 3.24: Effects of ERBB knockdown on ligand-induced signalling
Schematic overview of HRG- (A) and EGF-induced (C) signalling and effects of
siRNA-mediated ERBB knockdown (B, D). Green receptors illustrate activation,
faint colour shows receptor reduction. Thick arrows indicate a strong, thin arrows
a weak activation. Strong phosphorylation is depicted by large phospho-symbols,
weak phosphorylation by small phospho-symbols. Only coloured proteins were
analysed.
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3.5 Impact of targeted therapeutics on
ERBB-mediated signal transduction
The aim of the study was to analyse the impact of single and combinatorial drug
administration of ERBB receptor targeting therapeutics on ligand-induced path-
way activation and to determine the most potent drug combination for treat-
ment of ERBB2 overexpressing breast cancer. To analyse the impact on the
network level as well as for the reconstruction of dynamic protein networks in
ERBB2 overexpressing breast cancer, a time-resolved data set was generated.
Three ERBB2 overexpressing breast cancer cell lines HCC1954, SKBR3, and
BT474 representing different molecular characteristics were chosen. HCC1954
and SKBR3 cells highly express EGFR while BT474 have a low EGFR expres-
sion level, and HCC1954 and BT474 cells additionally harbour different oncoge-
nic PI3K mutations (section 3.3). The three different therapeutics trastuzumab
(10 ng/µl), pertuzumab (10 ng/µl), and erlotinib (1µM) and the two ligands
EGF and HRG (5 nM) were applied in all possible combinations in triplicate
measurements. The results of BT474 cells were already published as master
thesis by Szabó (2009). Each dynamic measurement consisted of 10 time points
and resulted in 1010 data points per cell line. Finally, the phosphorylation sta-
tus of 16 cytoplasmic signalling proteins was measured. These proteins did not
cover only the ERBB signalling network but did also include proteins from other
pathways to analyse the potential crosstalk. Additionally, the phosphorylation
status of the ERBB receptors was measured. To generate such a large data set,
proteins arrays were used.
3.5.1 Ligand-dependent ERBB signalling in HCC1954 and
SKBR3 cells
The first step of ligand-induced signalling was the receptor phosphorylation,
subsequently leading to receptor activation. Unfortunately, a ligand-dependent
phosphorylation of the EGFR was not detectable by RPPA and was only seen
after addition of the antibody therapeutics (see section 3.5.2). For this reason,
the activation of EGFR after stimulation with EGF was analysed by Western
blot in HCC1954 and SKBR3 cells including several EGFR phosphotyrosine
residues (Fig. 3.25). EGFR was phosphorylated at Y1068, Y1086, and Y1173
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Figure 3.25: Western blot analysis of EGFR phosphorylation in
HCC1954 and SKBR3 cells after stimulation with EGF.
Western blot results for EGFR phosphorylation at residues Y1173, Y1086, Y1068,
and Y845 after stimulation with EGF for the indicated time points are shown.
within 4min after stimulation with EGF but not phosphorylated at Y1148 and
Y992. Furthermore, Y845 was already phosphorylated before addition of EGF
and stimulation produced only a slight increase. In summary, the phosphoryla-
tion of the EGFR after addition of EGF was similar in HCC1954 and SKBR3
cells.
As the next step, the activation of the downstream pathways in response to
the ligands EGF, HRG, and the combination of EGF and HRG was analysed
without adding inhibitors. As both cell lines expressed different levels of ERBB
receptors, the responses to the ligands was expected to be different.
ERBB signalling in HCC1954 cells
To gain insight into ERBB signalling in HCC1954 cells, the influence of the
two ligands EGF, HRG, and the combination of both ligands on downstream
pathways was studied without perturbation of inhibitors. Figure 3.26 shows the
phosphorylation of ERK1/2, MEK1/2, p38, AKT, SRC, p70S6K, S6, PLCγ,
STAT3, and STAT5 including different phosphorylation sites of AKT and
p70S6K after stimulation with EGF, HRG, and both ligands in combination
in HCC1954 cells.
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Figure 3.26: Ligand-specific responses in HCC1954 cells
Phosphorylation of ERK1/2, MEK1/2, p38, AKT, SRC, p70S6K, S6, PLCγ,
STAT3, and STAT5 after stimulation with EGF (blue), HRG (red), and the
combination of both ligands (green). The dashed lines represent the biological
replicates, the thick lines show the fit of the smoothing splines.
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3.5 Impact of targeted therapeutics on ERBB signal transduction
First, the impact of EGF on different downstream targets in HCC1954 cells was
analysed (Fig. 3.26, blue lines). EGF strongly activated the MAPK pathway as
indicated by a strong phosphorylation of MEK1/2 and ERK1/2. The activation
reached a peak 12min after stimulation and slightly decreased afterwards. The
basal phosphorylation level was not reached again during the 60min measure-
ment. Another protein which was phosphorylated with comparable kinetics as
the MAPK pathway was p70S6K at T389. The activation reached its peak after
12min and declined afterwards. The activation of a second phosphorylation site
of p70S6K, T421/S424, was weaker compared to T389 but more sustained. The
ribosomal protein S6, a downstream target of p70S6K, showed a continuous in-
crease in phosphorylation and a dynamic behaviour which was different from all
other analysed phosphoproteins. The PI3K pathway was only weakly activated
by EGF. Both phosphorylation sites of AKT, S473 and T308, were determined
and only AKT (S473) showed a weak response to EGF stimulation. In addition,
p38 showed almost no activation after addition of EGF. Four proteins, which
directly bind to the phosphorylated ERBB receptors, SRC, PLCγ, and the two
STAT proteins STAT3 and STAT5, were analysed additionally. SRC showed a
decrease of phosphorylation within the first 10min after EGF stimulation with
a subsequent increase for the next 10min. Afterwards, SRC phosphorylation
remained on the same level. PLCγ showed a weak increase of phosphorylation
with a peak after 10min. STAT3 responded with phosphorylation of S727 to
the addition of EGF, while STAT5 was poorly phosphorylated at Y694/699.
In comparison to EGF, the effect of the ERBB3 ligand HRG resulted in only
weak or no activation of the proteins described before (Fig. 3.26, red lines).
Thus, the MAPK pathway was activated to a minor extent. Regarding the
activation of AKT and SRC, there was no difference between the ligands. Fur-
thermore, the STAT proteins, p70S6K, S6 and PLCγ also showed no response
to a stimulation with HRG. None of the proteins assessed revealed strong HRG-
mediated activation in HCC1954 cells.
Finally, the combination of both ligands, EGF and HRG, was analysed (Fig.
3.26, green lines). The simultaneous stimulation with EGF and HRG led to
different effects, depending on the downstream protein. For ERK1/2, p70S6K
(T389), and S6, the response was slightly weaker than for EGF alone. Although
MEK1/2 is upstream of ERK1/2 and the effects should be similar, the differen-
tiation between EGF and the combination was not so clear in case of MEK1/2.
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Table 3.9: Alteration of protein phosphorylation status in HCC1954 cells after
stimulation with ligands
protein phosphosite EGF HRG EGF+HRG
AKT S473 weak weak weak
AKT T308 no weak weak
β-catenin no no no
ERK T202/Y204 strong weak strong
GSK3αβ Y279/216 no no no
MEK S217/221 strong weak strong
mTOR S2448 no no no
mTOR S2481 no no no
NFκB S536 no no no
p38 T180/Y182 no no no
p70S6K T389 strong no moderate
p70S6K T421/S424 moderate no moderate
PDK1 S241 no no no
PKCα S657Y658 no no no
PLCγ S1248 weak no weak
PRAS T246 no no no
S6 S235/236 strong no moderate
SRC Y416 weak no weak
STAT1 Y701 no no no
STAT3 Y705 no no no
STAT3 S727 moderate no strong
STAT5 Y694/699 weak no no
This is possibly due to the higher dynamic range of the pERK1/2 antibody
which permitted the detection of only small changes of phosphoprotein. For
p70S6K (T421/S424) and PLCγ, no difference between EGF and the combi-
nation of EGF and HRG was detected. However, STAT3 (S727) responded
with an additive effect and the phosphorylation was significantly higher for the
combination compared to the single ligands.
In summary, addition of EGF resulted in the strongest increase of phosphoryla-
tion of signalling proteins while HRG only led to a small increase of signalling
activities in HCC1954 cells. The impact of the combination was slightly weaker
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than for EGF alone except for STAT3 (S727). In this instance, the combination
of both ligands induced the strongest phosphorylation. The signalling dynamics
for each protein were similar for the single ligands and the combination. AKT,
PLCγ, and SRC showed no distinct differences between the different conditions.
Table 3.9 shows the summary of ligand-dependent effects in HCC1954 cells.
ERBB signalling in SKBR3 cells
The same analysis described before was performed in SKBR3 cells. Figure 3.27
shows the phosphorylation of the same proteins ERK1/2, MEK1/2, p38, AKT,
SRC, p70S6K, S6, PLCγ, STAT3, and STAT5 after stimulation with EGF,
HRG, and the combination of both ligands in SKBR3 cells.
EGF led to a strong and sustained activation of ERK1/2 as well as of MEK1/2
(Fig. 3.27, blue lines). The highest phosphorylation level was reached after
12min and remained on this high level for at least 60min. p38 reached the stron-
gest phosphorylation after 16min and declined to the basal level after 40min.
AKT showed a weak activation after addition of EGF at its phosphosite S473
and an even fainter phosphorylation at T308. STAT5 responded weakly to the
addition of EGF. The phosphorylation level of PLCγ even seemed to decline
after addition of the ligand. EGF induced a strong S6 phosphorylation which
reached a plateau 16min after stimulation. SRC, p70S6K, and STAT3 showed
no distinct activation.
Stimulation with HRG resulted in a different outcome in comparison to EGF
(Fig. 3.27, red lines). ERK1/2 and MEK1/2 showed the same activation dyna-
mics as well as amplitude after stimulation with both ligands alone. AKT was
phosphorylated strongly after stimulation with HRG and remained on a high
level for at least 60min. p38 showed only a weak response to HRG compared to
EGF but the dynamics were the same. STAT5 was not phosphorylated at all,
and S6 was activated weakly compared to the stimulation with EGF.
Analysing the impact of the combination of the ligands on cellular signalling,
different responses were observed (Fig. 3.27, green lines). Again, the activa-
tion of ERK1/2 and MEK1/2 after stimulation with the combination showed
no difference compared to the single agents. AKT and S6 activation was the
same as for HRG alone. On the other hand, STAT5 responded stronger to the
combination of EGF and HRG than to both ligands alone. SRC showed a weak
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Figure 3.27: Ligand-specific responses in SKBR3 cells
Phosphorylation of ERK1/2, MEK1/2, p38, AKT, SRC, p70S6K, S6, PLCγ,
STAT3, and STAT5 after stimulation with EGF (blue), HRG (red), and the
combination of both ligands (green).
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activation 12min after addition of the combination whereas both ligands alone
were not able to induce SRC phosphorylation.
Table 3.10: Alteration of protein phosphorylation status in SKBR3 cells after
stimulation with ligands
protein phosphosite EGF HRG EGF+HRG
AKT S473 moderate strong strong
AKT T308 moderate moderate moderate
β-catenin no no no
ERK T202/Y204 strong strong strong
GSK3αβ Y279/216 no no no
MEK S217/221 strong strong strong
mTOR S2448 no no no
mTOR S2481 no no no
NFκB S536 no no no
p38 T180/Y182 strong moderate strong
p70S6K T389 weak weak weak
p70S6K T421/S424 no no no
PDK1 S241 no no no
PKCα S657/Y658 no no no
PLCγ S1248 weak weak weak
PRAS T246 no no no
S6 S235/236 strong weak weak
SRC Y416 weak weak moderate
STAT1 Y701 no no weak
STAT3 Y705 no no weak
STAT3 S727
STAT5 Y694/699 moderate weak strong
To recapitulate, EGF, HRG, and the combination had a similar potential with
respect to activating signalling in SKBR3 cells. AKT was stronger activated by
HRG and the combination than by EGF, while EGF and the combination had
a stronger impact on p38 activation than HRG. For STAT5, the simultaneous
stimulation with both ligands resulted in the strongest increase in phosphory-
lation. Table 3.10 summarises the effects of the ligands in SKBR3 cells.
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In conclusion, the response of downstream pathways differed between the cell
lines. Only ERK1/2 and MEK1/2 were strongly activated in both cell lines.
However, the activation in SKBR3 cells was more sustained. While p70S6K, S6,
and STAT3 were mainly activated in HCC1954 cells, the most distinct effects
were observed for p38 and STAT5 in SKBR3 cells. In both cell lines, activation
kinetics were comparable for the single ligands and the combination. In contrast,
the differences between EGF and HRG were much stronger in HCC1954 than in
SKBR3 cells. Furthermore, the biological replicates revealed that the signalling
in SKBR3 cells was of higher biological variability compared to HCC1954 cells.
3.5.2 Immediate effects of targeted therapeutics
First of all, the immediate effect of the therapeutics within the first hour of
preincubation was analysed. This was additionally measured for BT474 cells,
as this experiment was not included by Szabó (2009). Adding the antibody
therapeutics trastuzumab and pertuzumab had already activating potential and
resulted in the phosphorylation of receptors, not only of ERBB2, but also of
EGFR and ERBB3. Table 3.11 summarises if a specific phosphosite of a receptor
was phosphorylated (yes) or not (no). If a phosphorylation site was activated in
a particular cell line, it responded comparably to both antibody therapeutics.
Table 3.11: Phosphorylation status of ERBB receptors after addition of
trastuzumab or pertuzumab
target phosphosite HCC1954 SKBR3 BT474
EGFR Y992 yes no yes
EGFR Y1068 yes yes yes
EGFR Y1086 yes no yes
EGFR Y1173 no yes no
ERBB2 Y877 NA yes yes
ERBB2 Y1112 yes NA no
ERBB2 Y1139 yes yes yes
ERBB2 Y1221/2 yes yes yes
ERBB2 Y1248 yes yes yes
ERBB3 Y1197 no yes no
ERBB3 Y1289 yes no yes
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Figure 3.28: Receptor phosphorylation after drug treatment
The phosphorylation of EGFR (Y1068), ERBB2 (Y1248), and ERBB3 (Y1289)
after treatment with pertuzumab (orange), trastuzumab (green), erlotinib (blue)
and the control (red) is shown for HCC1954 (A) and SKBR3 cells (B) within
60min. The dashed lines represent the biological replicates while the thick lines
show the fit of the smoothing splines.
The phosphorylation dynamics were nearly identical for all phosphorylation
sites. Figure 3.28 shows as example phosphorylation sites of the three receptors,
EGFR (Y1068), ERBB2 (Y1248) and ERBB3 (Y1289). Strikingly, cell line de-
pendent and specific phosphorylation sites were detected for all receptors. For
ERBB3, the phosphorylation of the two tyrosines Y1197 and Y1289 was cell
line specific, position Y1289 was phosphorylated in HCC1954 and BT474 cells,
phosphorylation of Y1197 was exclusively detected in SKBR3 cells. Erlotinib
showed no effect on receptor phosphorylation.
Additionally, cell line specific effects on downstream targets were observed
(Fig. 3.29). In HCC1954 cells, the incubation with trastuzumab and pertu-
zumab resulted in phosphorylation of SRC, STAT5, and STAT3 (Y705). In
SKBR3 cells, the incubation with the antibody drugs resulted in activation of
SRC, STAT5 and PLCγ. Erlotinib on the other hand resulted in a downregu-
lation of pERK1/2 (Fig. A.6).
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Figure 3.29: Immediate effects of the targeted therapeutics
The diagrams show the phosphorylation of SRC, STAT5, and PLCγ in HCC1954
(A) and SKBR3 cells (B) after addition of pertuzumab (orange), trastuzumab
(green), erlotinib (blue) and the control (red). The dashed line represent the
biological replicates while the thick lines show the fit of the smoothing splines.
3.5.3 Impact of therapeutics on ligand-induced signalling
After the analysis of the direct effects of trastuzumab, pertuzumab, and erlotinib
on receptor and effector protein phosphorylation, the inhibitory potential of the
single therapeutics on ligand-induced pathway activation was measured.
Impact of therapeutics on ligand-dependent signalling in HCC1954 cells
In HCC1954 cells, mainly the impact of the inhibitors on EGF signalling was
analysed, as this ligand resulted in the highest activation of downstream path-
ways compared to HRG and to both ligands in combination. Figure 3.30 shows
the impact of the three inhibitors after addition of EGF on the proteins ERK1/2,
AKT, p70S6K, S6, STAT3, PLCγ, and SRC. The inhibitors led to similar ef-
fects on the MAPK pathway, p70S6K, S6, PLCγ, and STAT3. Trastuzumab
and pertuzumab had almost no inhibitory effect on these proteins. However,
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Figure 3.30: Impact of inhibitors after stimulation with EGF in
HCC1954 cells.
The diagrams show the phosphorylation of ERK1/2, AKT, p70S6K, S6, STAT3,
PLCγ, and SRC after preincubation with the control (red), erlotinib (blue), tras-
tuzumab (green), pertuzumab (orange) and subsequent stimulation with EGF.
The dashed line represent the biological replicates while the thick lines show the
fit of the smoothing splines.
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3 Results
the inhibitory effect of pertuzumab was slightly stronger. In contrast, erloti-
nib clearly inhibited the phosphorylation of all these proteins. The addition of
EGF resulted in a further increase of SRC phosphorylation, which was already
induced by the antibody therapeutics alone (Fig. 3.29). The phosphorylation
of STAT5 was decreased within 30min after addition of EGF. The response of
AKT was complex. While the antibody drugs had no effect on AKT phosphory-
lation, erlotinib reduced the basal phosphorylation of AKT, but it was not able
to inhibit the increase of phosphorylation after addition of EGF. Thus, erlotinib
did not inhibit the slope of AKT activation but shifted the activation to a lower
level.
HRG had only very weak activating potential in HCC1954 cells compared to
EGF. However, trastuzumab and pertuzumab did not reduce ERK1/2 phospho-
rylation after HRG stimulation. Erlotinib, in contrast, inhibited the activation
of ERK1/2. The same was true for MEK1/2, p70S6K, S6, and STAT3 (S727)
(Fig. A.7). Regarding the combination of EGF and HRG, the inhibitors had
the same effect as observed for the ligands alone.
In summary, trastuzumab and pertuzumab slightly decreased the activation of
the proteins mainly activated by the ligands but the effects were not significant.
Erlotinib instead was able to inhibit the activation of all proteins.
Impact of therapeutics on ligand-dependent signalling in SKBR3 cells
In SKBR3 cells, the impact of the three inhibitors was similar to HCC1954
cells. Figure 3.31 shows the phosphorylation of 10 proteins after preincubation
with erlotinib, trastuzumab, and pertuzumab and subsequent stimulation with
EGF. While trastuzumab and pertuzumab showed almost no inhibitory effect,
erlotinib inhibited the phosphorylation of all 10 proteins. The preincubation
with pertuzumab and trastuzumab led to an increase in the phosphorylation
of PLCγ, SRC, and STAT5. This phosphorylation was further increased after
addition of EGF. While no inhibitor was able to inhibit AKT signalling in
HCC1954 cells, erlotinib and pertuzumab were both able to downregulate and
diminish phosphorylation of both phosphorylation sites in SKBR3 cells. In two
of three biological replicates, the downregulation of AKT phosphorylation by
pertuzumab was significant. Notably, the activation mode of the third biologi-
cal replicate correlated with the uninhibited control for all measured proteins,
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Figure 3.31: Impact of inhibitors after stimulation with EGF in SKBR3
cells
The diagrams show the phosphorylation of ERK1/2, AKT, p70S6K, S6, STAT3,
PLCγ, and SRC after preincubation with the control (red), erlotinib (blue), tras-
tuzumab (green), pertuzumab (orange) and subsequent stimulation with EGF.
The dashed line represent the biological replicates while the thick lines show the
fit of the smoothing splines.
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where pertuzumab showed an effect for the other two replicates, indicating an
experimental error of this replicate. Although trastuzumab was not able to in-
hibit activation of AKT, the dynamics were altered and resulted in a decrease of
phosphorylation after 20min. For p38, the effects of the inhibitors were very si-
milar. Trastuzumab had no effect, pertuzumab slightly inhibited p38 activation
while erlotinib completely prevented this step.
As observed for HCC1954 cells, trastuzumab and pertuzumab only slightly de-
creased signalling activation, while erlotinib was able to inhibit phosphorylation
of all measured proteins. In contrast, AKT activation was downregulated by
trastuzumab and pertuzumab in SKBR3 cells.
The main difference between EGF- and HRG-induced signalling resided in
an AKT phosphorylation which was much stronger upon addition of HRG in
SKBR3 cells. Activation of AKT was only reduced weakly by erlotinib, while
the antibody drugs showed no inhibitory potential against HRG-initiated si-
gnalling (Fig. 3.32). Preincubation with trastuzumab even seemed to increase
the phosphorylation of AKT after addition of HRG. Stimulation with EGF and
HRG resulted in a strong activation of AKT which was not prevented by er-
lotinib. Regarding the other proteins, the impact of the inhibitors was ligand
independent.
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Figure 3.32: Activation of AKT in SKBR3 cells
Cells were preincubated with trastuzumab (green), pertuzumab (orange), erloti-
nib (blue) and subsequently stimulated with EGF (A), HRG (B), or EGF and
HRG (C). The plots show the phosphorylation of AKT (S473). The dashed lines
represent the biological replicates, the thick lines show the smoothing splines.
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3.5.4 Combinatorial impact of therapeutics on
ligand-induced signalling
In contrast to pertuzumab and erlotinib, trastuzumab is already part of the
clinical routine in the treatment of ERBB2 positive breast cancer. According
to results from single drug treatment, trastuzumab was not able to significantly
inhibit fast signalling downstream of ERBB2. Since one aim of the study was to
analyse the potential benefit of combinatorial treatments, the three therapeu-
tics were applied in all combinations in HCC1954 and SKBR3 cells to identify
additive effects may circumvent de novo resistance mechanisms. The impact
of the combinations of trastuzumab and pertuzumab, trastuzumab and erlo-
tinib, pertuzumab and erlotinib, and all three inhibitors was analysed after
addition of EGF. To cover all major pathways, phosphorylation of ERK1/2
(T202/Y204), AKT (S473), p70S6K (T389), S6 (S235/236), STAT3 (S727),
and p38 (T180/Y182) was measured.
Combinatorial treatment of HCC1954 cells
Figure 3.33 shows the time series of these six proteins preincubated with the
drug combinations after addition of EGF to HCC1954 cells. The combination
of trastuzumab and pertuzumab resulted in a small increase of the inhibitory
potential towards MAPK signalling compared to single drug treatments. All
erlotinib containing combinations nearly abolished the activation of MEK1/2
and ERK1/2, but no significant differences between the combinations were ob-
served. None of the applied drug combinations was able to inhibit activation of
AKT. The downregulation of AKT phosphorylation by the erlotinib containing
combinations resulted in a lower activation level, but the absolute change of
phosphorylated protein remained similar as observed for erlotinib alone. The
inhibitory behaviour of the combinations towards p70S6K was similar to those
observed for ERK1/2. An exception was that trastuzumab and pertuzumab
in combination slightly increased the phoshorylation of T389 instead of leading
to a decrease. Within the first 16min, the combination of trastuzumab and
pertuzumab also caused a stronger increase of S6 phosphorylation in compari-
son to the control. This correlated with the activation peak of p70S6K (T389).
However, after 16min the phosphorylation remained static while the control
steadily increased. All erlotinib containing combinations entirely inhibited S6
phosphorylation in HCC1954 cells.
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Figure 3.33: Combinatorial drug treatment in HCC1954 cells.
Cells were preincubated with drug combinations for 1 h and subsequently stimu-
lated with EGF for the indicated time points. The dashed lines represent the
single biological replicates, the thick shows the fitted smoothing spline.
Combinatorial treatment of SKBR3 cells
Comparable to HCC1954 cells, the erlotinib containing combinations strongly
reduced the activation of ERK1/2 allowing just a small peak after 12min follo-
wed by total downregulation after 20min, as shown in figure 3.34. In contrast,
the combination of trastuzumab and pertuzumab showed no combinatorial be-
nefit and the inhibition was indeed weaker than for pertuzumab alone. In terms
of AKT inhibition, all combinations resulted in a significant inhibition of the
activation peak and subsequent downregulation of the signal to the basal level.
But again, trastuzumab and pertuzumab had only a minimal effect. The same
was true for the p38 phosphorylation. The phosphorylation of S6 was prevented
by all erlotinib containing combinations. In contrast to HCC1954 cells, the com-
bination of trastuzumab and pertuzumab was capable of reducing the activation
of S6 in SKBR3 cells.
Since the HRG induced AKT (S473) activation was not inhibited by single
drug treatment, the impact of combinatorial treatment was analysed (Fig. 3.35).
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Figure 3.34: Combinatorial drug treatment in SKBR3 cells.
SKBR3 cells were preincubated with all possible drug combinations for 1 h and
subsequently stimulated with EGF. The dashed lines represent the single biolo-
gical replicates, the thick shows the fitted smoothing spline.
The dual combinations containing trastuzumab slightly reduced HRG-induced
AKT phosphorylation and to a weaker extent EGF+HRG-induced AKT phos-
phorylation. However, the combinations containing pertuzumab and erlotinib
completely prevented HRG induced AKT activation and significantly inhibited
EGF+HRG-induced AKT phosphorylation.
In summary, the application of an antibody drug together with the small mo-
lecule erlotinib resulted in improved inhibition of the MAPK and the PI3K
pathways represented by ERK1/2 and AKT1. This effect was also observed for
p70S6K and, in the case of SKBR3 cells, also for p38. In contrast, the combina-
torial treatment of trastuzumab and pertuzumab did not result in an enhanced
inhibitory effect in HCC1954 cells. However, in SKBR3 cells this combination
was able to reduce the activation of AKT and S6. The combination of pertuzu-
mab and erlotinib effectively inhibited HRG-induced AKT activation in SKBR3
cells.
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Figure 3.35: Impact of combinatorial drug treatment on AKT activa-
tion in SKBR3 cells.
Cells were preincubated with trastuzumab and pertuzumab (orange), trastuzu-
mab and erlotinib (green), pertuzumab and erlotinib (blue) and the combination
of all three inhibitors (violet) and subsequently stimulated with EGF (A), HRG
(B), or EGF and HRG (C). The plots show the phosphorylation of AKT (S473).
The dashed lines represent the biological replicates, the thick lines show the smoo-
thing splines.
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3.5.5 Long-term inhibition experiments
Erlotinib was the therapeutic agent which had the strongest inhibitory potential
towards all pathways within the 60min time series. To analyse if the inhibitory
effects on MAPK and PI3K pathway had an extended activity, the effects of er-
lotinib and all possible drug combinations in full growth medium was measured
up to 30 h. As one biological replicate lacked the 18 h time point, this value was
set as the mean of the 12 h and the 24 h time point. In addition to HCC1954
and SKBR3 cells, the experiment was also carried out in BT474 cells. Major
signalling proteins measured in short time experiments were also analysed in the
long-term study. Figure 3.36 shows the combinatorial effects on ERK1/2 and
AKT phosphorylation in the three cell lines. Additionally, proteins playing a role
in cell cycle progression were studied. Figure 3.37 displays the phosphorylation
of the ribosomal protein S6 and the retinoblastoma tumour suppressor protein
(RB). Phosphorylation of S6 correlates with increased mRNA transcription in
response to growth factors, an important aspect of sustained cell growth and
proliferation. RB regulates cell proliferation by controlling the restriction point
in G1-phase and phosphorylation of RB is correlated with cell cycle progression.
With respect to ERBB receptor activation, ERBB2 phosphorylation at Y1248
was analysed, as Y1248 is one major autophosphorylation site of ERBB2 cor-
relating well with receptor activation (Fig. 3.38). The results are described in
detail for each cell line separately.
Long-term inhibitory effects in HCC1954 cells
In the control experiment without any inhibitor, ERK1/2 showed a first activa-
tion peak after 2 h with a subsequent decline until 6 h and a second long lasting
activation reaching a maximum after 18 h. The erlotinib containing combina-
tions led to an immediate downregulation of pERK1/2 and no activation was no-
ticed for the following 30 h. In contrast, trastuzumab and pertuzumab resulted
in an activation of ERK1/2 similar to the control, and ERK1/2 phosphorylation
level remained elevated for 24 h and declined afterwards.
As already observed in the short time series, no clear AKT activation profile
was detected in HCC1954 cells. The dual combinations containing erlotinib
resulted in a general downregulation of pAKT compared to the control. The
combination of pertuzumab and trastuzumab and the triple combination were
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Figure 3.36: Phosphorylation of ERK1/2 and AKT after addition of
inhibitors within 30 h
The figure shows the phosphorylation of ERK1/2 and AKT (S473) in response
to the inhibitor combinations and the control within 30 h. The coloured lines
represent the three biological replicates.
108
3.5 Impact of targeted therapeutics on ERBB signal transduction
not different from the control which showed two peaks, the first after 2 h and
the second after 12 h followed by a steadily increased AKT phosphorylation.
The phosphorylation of the RB protein started to decline 8 h after addition of
all erlotinib containing combinations. However, the RB phosphorylation after
addition of the trastuzumab and pertuzumab combinations increased compared
to the control. The same effect was observed for the phosphorylation of S6
within the first 24 h. While pS6 stayed on an elevated level for the control
and the trastuzumab/pertuzumab combination, all other combinations led to a
downregulation of S6 phosphorylation. This effect was observed during the first
24 h but lost afterwards.
To sum up, in HCC1954 cells, the erlotinib containing combinations had indeed
the strongest impact on signalling within 24–30 h. Nevertheless, no difference
was observed between erlotinib alone and the combinations. The combination
of trastuzumab and pertuzumab had no inhibitory effect on signalling and even
resulted in elevated protein phosphorylation.
Long-term inhibitory effects in SKBR3 cells
The long term inhibitory effect on ERK1/2 looked different in SKBR3 cell com-
pared to HCC1954 cells (Fig. 3.36). The phosphorylation level of the control
weakly declined and remained on a low level for 6 h. All combinations, ex-
cept trastuzumab and pertuzumab, weakly decreased ERK1/2 phosphorylation
whereas addition of trastuzumab and pertuzumab immediately resulted in an
increase of phosphorylation which declined within the first 6 h. Similar to the
signalling in HCC1954 cells, SKBR3 cells showed a second activation cycle after
8 h which reached a peak after 18 h and returned to baseline activation after 24 h.
The uninhibited control reached the highest level of ERK1/2 activation. How-
ever, trastuzumab and pertuzumab and also the triple combination were not able
to inhibit the activation of ERK1/2. Erlotinib alone strongly inhibited EKR1/2
phosphorylation followed by trastuzumab/erlotinib and pertuzumab/erlotinib.
The impact of the inhibitors on AKT signalling was different. The pAKT level of
the control remained constant during 6 h, followed by a strong increase peaking
after 18 h. In contrast, all inhibitor combinations resulted in a immediate decline
of pAKT within 1 h. The increase of AKT phosphorylation observed for the
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control after 6 h was inhibited by all combinations whereas trastuzumab and
pertuzumab, independent of addition of erlotinib, showed the strongest effect.
The phosphorylation of S6 resembled the AKT activation dynamics for the
control experiment (Fig. 3.37). Trastuzumab and pertuzumab in combination
induced a strong increase of AKT phosphorylation with a peak after 2 h. The er-
lotinib containing combinations resulted in an immediate dephosphorylation and
kept the phosphorylation on a low level. The second activation peak approxi-
mately after 12–18 h was inhibited by the combination trastuzumab/erlotinib
and the triple combination.
In HCC1954 cells, the pRB signal started to decline already after 8 h follo-
wing treatment, which was also observed in the control experiment. In SKBR3
cells, RB phosphorylation of the control stayed on a high level for almost 24 h.
The combination trastuzumab/erlotinib showed a strong impact in this cell line
and RB phosphorylation decreased persistently within the 30 h measurement.
Erlotinib alone and in combination with pertuzumab also induced RB dephos-
phorylation but to a weaker extent. The combination trastuzumab/pertuzumab
and the triple combination showed the weakest effect in terms of downregulating
the pRB level.
In summary, the combination of trastuzumab and erlotinib had a strong inhibi-
tory effect on ERK1/2, AKT, RB and S6 phosphorylation in SKBR3 cells. This
was in line with the results observed for the 60min measurements. The com-
bination of trastuzumab and pertuzumab only inhibited AKT activation while
no inhibition of ERK1/2, S6, and RB phosphorylation was observed.
Long-term inhibitory effects in BT474 cells
In BT474 cells, a downregulation of ERK1/2 was observed for the control within
the first hour (Fig. 3.36). The dephosphorylation was even stronger for erloti-
nib and erlotinib containing combinations. Trastuzumab and pertuzumab in
combination led to an increase of ERK1/2 phosphorylation within 1 h, as seen
for the other two cell lines. A second peak was observed after 8 h, likewise for
the control. For the other combinations, the phosphorylation remained on the
same level.
For AKT, the highest phosphorylation was observed after 18 h. At this time
point, the control showed the strongest signal while trastuzumab and erlotinib
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Figure 3.37: Phosphorylation of S6 and RB after addition of inhibitory
drugs within 30 h
The figure shows the phosphorylation of S6 (S235/236) and RB (S807/811) after
addition of inhibitor combinations in growth medium and the control within 30 h.
The coloured lines represent the three biological replicates.
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Table 3.12: Therapeutics effect summary
strongest effect weakest effect
HCC1954 erlotinib trastuzumab/pertuzumab
SKBR3 trastuzumab/erlotinib trastuzumab/pertuzumab
BT474 trastuzumab/erlotinib erlotinib
used in combination completely inhibited AKT phosphorylation. The triple
combination also revealed a strong inhibitory potential. Erlotinib alone had the
weakest impact on AKT phosphorylation in BT474 cells.
Regarding S6 phosphorylation, erlotinib also had the weakest impact while tras-
tuzumab and erlotinib and the triple combination had the strongest impact. As
observed for HCC1954 cells, the phosphorylation of RB declined for all condi-
tions analysed and significant differences were only detected after 30 h. However,
S6 dephosphorylation was significantly stronger for trastuzumab and erlotinib.
In summary, trastuzumab and erlotinib in combination had the strongest in-
hibitory effect in BT474 cells, comparable to the effect observed for SKBR3
cells. But while AKT and ERK1/2 signalling was still active in SKBR3 cells,
this was totally diminished in BT474 cells. The reduction of protein phospho-
rylation by erlotinib alone was weaker in BT474 cells compared to SKBR3 and
HCC1954 cells. This could be due to the low expression of EGFR in this cell
line (Fig. 3.11). Table 3.12 gives an overview of the strongest and weakest drug
combinations for all three cell lines. The triple combination did not necessarily
reveal the strongest inhibitory potential.
Noteworthy, a single biological replicate of the triple combination showed the
same results as the trastuzumab/pertuzumab combination while the other two
replicates were strongly inhibited. This was observed for all three cell lines.
This result indicated that erlotinib might not have been present in the third
replicate by mistake.
Impact of combinatorial treatment on ERBB2 receptor phosphorylation
The previous experiment revealed that ERBB2 was phosphorylated upon tras-
tuzumab or pertuzumab treatment (section 3.5.2). The phosphorylation remai-
ned on an elevated level for 60min (Fig. 3.28). To investigate the drug influence
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3.5 Impact of targeted therapeutics on ERBB signal transduction
on receptor phosphorylation for a longer time period, we monitored the phos-
phorylation of ERBB2 at Y1248 for 30 h (Fig. 3.38). The drug combinations
clustered in three groups based on the phosphorylation status. Erlotinib did not
induce receptor phosphorylation and was similar compared to the control. The
dual combinations containing erlotinib and any of the antibody drugs induced
phosphorylation within 1 h which stayed on an elevated level for the remaining
30 h.
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Figure 3.38: ERBB2 phosphorylation at Y1248
The plots show the phosphorylation of ERBB2 at Y1248 in the three cell lines
HCC1954, SKBR3 and BT474. Drug combinations were added in growth medium
and effects were measured for 30 h in comparison to the control. The coloured lines
represent the three biological replicates, the dashed lines represent the splines.
Trastuzumab and pertuzumab in combination, independent of added erlotinib,
caused a very strong increase of ERBB2 phosphorylation at Y1248 within the
first hour. The phosphorylation maintained at a high level for 30 h. Overall,
these findings were similar for the three cell lines. However, in HCC1954 cells,
the biological replicates were highly reproducible and showed a sharp separation
between the three clusters while the separation was not so clear in the two cell
lines SKBR3 and BT474.
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3.6 Cell cycle progression after drug treatment
A 7-amino-actinomycin D (7AAD) assay was performed in HCC1954 and
SKBR3 cells to study the impact of treatment with drug combinations on cell
cycle progression. After treatment with erlotinib alone and in combination with
trastuzumab, the proportion of HCC1954 cells in G1-phase significantly increa-
sed compared to the control (Fig. 3.39). Accordingly, the proportion of cells in
S-phase decreased. These results suggested an inhibition of cell cycle progres-
sion as already indicated by reduced RB phosphorylation in HCC1954 cells. In
SKBR3 cells, the combination of erlotinib and trastuzumab revealed a signifi-
cant decrease of cells on G1-phase as it had been observed for HCC1954 cells. In
contrast, treatment with trastuzumab and pertuzumab in combinations resulted
in a significant increase of cells in G1-phase. In HCC1954 cells, no significant
effect was observed for this combination of both therapeutic antibodies.
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Figure 3.39: Cell cycle analysis after drug treatment
Cells were incubated with the therapeutics trastuzumab (tra), pertuzumab (per),
and erlotinib (erl) in the indicated combinations in growth medium for 24 h and
DNA content was analysed using 7AAD. * = p<0.01
In summary, the analysis of cell cycle progression confirmed the results of the
long-term inhibition experiments whereas erlotinib revealed a significant inhibi-
tory effect in HCC1954 cells and the combination of trastuzumab and erlotinib
significantly inhibited cell cycle progression in both cell lines.
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3.7 Regulation of p70S6K activation
The protein kinase p70S6K was reported to be phosphorylated by kinases of
both major signalling pathways, MAPK and PI3K, as observed for MCF7 cells.
Because no clear phosphorylation of p70S6K was detected in SKBR3 cells, ana-
lysis of BT474 cells was included in the study. In HCC1954 cells, the activation
of p70S6K seemed only to be correlated to ERK1/2 activation. To analyse the
contribution of the two pathways on downstream signal integration, the impact
of the PI3K inhibitor LY294002 and the MEK1 inhibitor PD98059 on ligand-
mediated signalling was measured. Therefore, cells were incubated with the
inhibitors for 1 h prior to stimulation with 5 nM EGF. As proof of principle
experiment, the phosphorylation of ERK1/2 and AKT was analysed to ensure
the specificity of the inhibition. For both cell lines, LY294002 resulted in in-
hibition of AKT and PD98059 in inhibition of ERK1/2 as shown for SKBR3
in figure 3.40. Analysis of downstream targets revealed cell line specific effects
which are presented below.
p70S6K regulation in SKBR3 cells
Phosphorylation of p70S6K was hardly detectable in SKBR3 cells. However,
the impact of the two inhibitors on EGF-induced activation of ERK1/2, AKT,
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Figure 3.40: Contribution of MAPK and PI3K pathways on S6 phos-
phorylation in SKBR3 cells.
SKBR3 cells were preincubated with PD98059 or LY294002 and subsequently
stimulated with 5 nM EGF. Phosphorylation of ERK1/2, AKT (S473), and S6
(S235/236) was measured. The dashed lines show the biological replicates, the
thick lines represent the smoothing splines.
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and S6 is shown in figure 3.40. LY294002 almost completely inhibited phos-
phorylation of S6 indicating an PI3K dependent phosphorylation. In addition,
PD98059 was also able to inhibit phosphorylation of S6, although its inhibitory
activity was much weaker compared to LY294002. Phosphorylation was only
reduced within the first 10-20min after stimulation and increased afterwards.
p70S6K regulation in HCC1954 cells
Previous results from experiments performed in HCC1954 cells indicated that
p70S6K is under the control of ERK1/2 as both kinases revealed comparable
kinetics. Experiments with PI3K and MEK1 inhibitors confirmed this assump-
tion. PD98059 completely inhibited the phosphorylation of p70S6K at both
phosphorylation sites in this cell line whereas PI3K inhibition had no influence
on p70S6K activation (Fig. 3.41). However, S6 phosphorylation was dependent
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Figure 3.41: Contribution of MAPK and PI3K pathways on S6 phos-
phorylation in HCC1954 and BT474 cells.
Cells were preincubated with PD98059 or LY294002 and subsequently stimulated
with 5 nM EGF. Phosphorylation of p70S6K (T389), p70S6K (T421/S424), and
S6 (S235/236) was measured. The dashed lines show the biological replicates, the
thick lines represent the smoothing splines.
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on both signalling pathways. In contrast to SKBR3 cells, both inhibitors redu-
ced the phosphorylation of S6 (S235/236) to a similar extent.
p70S6K regulation in BT474 cells
Phosphorylation of p70S6K (T389) in BT474 cells was significantly downregula-
ted after preincubation with LY294002 while preincubation with PD98059 resul-
ted in a significant reduction of the p70S6K (T421/S424) activation (Fig. 3.41).
While inhibition of the PI3K pathway resulted in a complete downregulation
and prevention of S6 phosphorylation in this cell line, inhibition of the MAPK
pathway only led to a reduction of S6 phosphorylation.
Analysing the target proteins p70S6K and S6 downstream of ERK1/2 and AKT
revealed differences in the wiring of the signalling networks between the cell
lines. Whereas activation of p70S6K was MAPK dependent in HCC1954 cells,
S6 was dependent on both pathways indicating an additional regulatory me-
chanism in this cell line. In SKBR3 cells, phosphorylation of S6 was mostly
dependent on AKT activation reflecting the canonical PI3K/mTOR dependent
pathway. However, both pathways resulted in the phosphorylation of S6 whereas
inhibition of the ERK1/2 dependent activation was compensated after 30min.
In BT474 cells, p70S6K (T389) and S6 phosphorylation were PI3K pathway
dependent, while inhibition MAPK pathway only reduced phosphorylation of
p70S6K (T421/S424) and S6.
3.7.1 Impact of rapamycin on p70S6K phosphorylation
The phosphorylation of p70S6K at T389 seemed to be MAPK pathway de-
pendent in HCC1954 cells, although this particular phosphorylation site was
reported to be rapamycin sensitive. Therefore, HCC1954 cells were preincuba-
ted with 10 nM rapamycin and subsequently stimulated with EGF. Preliminary
results indicated that both phosphorylation sites of p70S6K were rapamycin
insensitive. As shown in figure 3.42, preincubation with rapamycin led to an
upregulation of p70S6K and ERK1/2 phosphorylation. Western blot analysis
revealed that mainly p85S6K but not p70S6K was phosphorylated upon EGF
treatment (Fig. 3.43). In contrast to p70S6K, the corresponding phosphoryla-
tion site of p85S6K seemed to be rapamycin insensitive and this isoform was
mainly measured on RPPA.
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Figure 3.42: Rapamycin incubation prior to EGF stimulation in
HCC1954 cells.
The plots show the activation of p70S6K and ERK1/2 with (violet) and without
(blue) preincubation with 10 nM rapamycin and subsequent stimulation with 5 nM
EGF.
For comparison, the experiment was repeated in MCF7 cells. In this cell line,
both isoforms were phosphorylated in response to EGF but p70S6K to a higher
degree (Fig. 3.44). In contrast to HCC1954 cells, the phosphorylation of both
isoforms was inhibited by rapamycin. Nevertheless, rapamycin inhibited S6
phosphorylation in a comparable manner in both cell lines.
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Figure 3.43: Isoform specific analysis of p70S6K/p85S6K phosphoryla-
tion in HCC1954 cells
Cells were preincubated with 10 nM rapamycin for 1 h and subsequently stimu-
lated with EGF. Phosphorylation of p70S6K (T389), p70S6K (T421/S424), the
corresponding phosphorylation sites of p85S6K, and S6 (S235/236) are shown.
Figure 3.44: Isoform specific analysis of p70S6K/p85S6K phosphoryla-
tion in MCF7 cells
Cells were preincubated with 10 nM rapamycin for 1 h and subsequently stimu-
lated with EGF. Phosphorylation of p70S6K (T389), p70S6K (T421/S424), the
corresponding phosphorylation sites of p85S6K, and S6 (S235/236) are shown.
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4 Discussion
Breast cancer is the most frequent cancer in women and five molecular subtypes
have been identified so far. The orphan receptor ERBB2 characterises a parti-
cular subtype which is associated with poor prognosis and short overall survival
(Sorlie et al., 2001). To treat ERBB2-positive breast cancer, the humanised
monoclonal antibody trastuzumab, targeting ERBB2, was clinically approved.
However, only one third of the ERBB2-positive patients respond to trastuzumab
(Baselga et al., 1996, Cobleigh et al., 1999, Vogel et al., 2002) and nearly all de-
velop resistance within the first year of treatment (Esteva et al., 2002). Several
molecular factors were discussed as possible cause for de novo therapy resistance.
Constitutive activation of the PI3K pathway due to loss of PTEN or activating
mutations in the catalytical domain of PI3K were associated with trastuzumab
resistance (Berns et al., 2007, Gymnopoulos et al., 2007, Isakoff et al., 2005,
Kataoka et al., 2009). Although many diseases like cancer are associated with
alterations of particular proteins, little is known how these alterations impact
cellular proteomes. Therefore, ERBB receptor mediated signal transduction was
quantitatively assessed in breast cancer cell lines. In a systematic set of experi-
ments, dynamic measurements were carried out in HCC1954 and SKBR3 cells,
which exhibit ERBB2 overexpression. Additionally, MCF7 cells were chosen as
cell line representative for low level ERBB2 expression. Proteome profiling of
dynamic measurements was carried out using protein microarrays.
4.1 Advancement of protein microarray technology
Two approaches were employed for the analysis of signalling networks, micro-
spot immunoassay (MIA) and reverse phase protein array (RPPA). MIA is a
very sensitive tool for the quantitative analysis of protein phosphorylation. A
major bottleneck for the development of new MIA assays is the identification of
suitable antibody pairs. Performing assays on a long-term basis requires access
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to reliable antibody resources. However, lot-specific changes were observed even
for monoclonal antibodies which hampered the assay quality. An example was
the pAKT (S473) specific capture antibody BD558368. This antibody showed
the best results during the development of the assay and was therefore used
for the analysis of biological samples. Nevertheless, a different pAKT specific
antibody, 05-669, was spotted along with other capture antibodies and gave
comparable results to BD558368. A new lot of this antibody caused poor re-
sults. The fit of the calibrator revealed very low signal intensities and almost no
signal was detected in biological samples. Therefore, the measurements differed
significantly from those obtained for 05-669. As testing further lots of BD558368
did not improve the assay outcome, this antibody was omitted and antibody
05-669 was used as capture antibody for the analysis of AKT signalling. Being
aware of these challenges, data quality was assessed very carefully in all protein
microarray experiments. Whenever possible, each newly established assay was
based on two different capture antibodies detecting a certain phosphosite to
reduce the risk of measurement artefacts.
The quality of nitrocellulose coated slides used for antibody immobilisation also
presented an additional challenge. Initially, slides with 16 single pads were used.
Robust measurements were possible as long as antibody pairs of high dynamic
range were used. However, measurements of low abundant proteins, like pAKT
and pSTAT3, resulted in low dynamic range measurements and exposed incon-
sistencies between different pads on the same slide so that a quantitative analysis
was not possible. Further analysis revealed that inhomogeneous nitrocellulose
coating of the slides resulted in immobilisation of differing amounts of capture
antibodies this way causing a high variation of signals. The technical problem
was solved by using slides with an overall nitrocellulose coating.
Antibody specificity is also the most important factor for RPPA analysis. Each
project started with the Western blot validation of antibodies using a suitable
set of samples. However, not all antibodies resulting in specific bands on Wes-
tern blot performed well on RPPA and for this reason serial dilutions of control
samples were spotted to assess the linear correlation between signal intensity and
target protein concentration. The major difference between both techniques is
that the Western blot is denaturating while the proteins on RPPAs are almost
native. Therefore, an epitope might not be exposed properly in the native state.
Good results were obtained with antibodies certified to work for immunoprecipi-
tations by the supplier. In this case, the antibody has to bind the native protein
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and is likely to work also on RPPA. For both protein microarray approaches, it
was observed that phosphospecific antibodies showed a higher specificity than
total-protein antibodies. In general, data from measurements with total-protein
antibodies were highly variable and were therefore not applied for the norma-
lisation of phosphoprotein signals. An additional observation was that certain
total-protein antibodies, detecting STAT5, AKT, and ERBB2, preferably bound
to the phosphorylated protein (data not shown).
Biological samples from cells incubated with antibody therapeutics revealed
cross-reactivity with the secondary anti-rabbit antibody on RPPA although this
cross-reactivity was not detected by Western blots. For this reason, only an-
tibodies showing signal intensities clearly higher than those of the blank were
considered as valid.
The microspot immunoassay was successfully established for the absolute quan-
tification of three phosphoproteins: pAKT (S473), pAKT (T308), and pSTAT3
(S727). This new assay and the previously developed pERK1/2 assay were ap-
plied to generate quantitative data on ligand- and dose-dependent signalling
in MCF7 cells. RPPAs were efficiently adapted to the requirements of high
throughput analysis of signal transduction networks for more than 40 phos-
phoproteins. Using phosphospecific antibodies, RPPA enabled the reproducible
generation of quantitative data and the analysis of more than 1,000 biological
samples in parallel. The high sensitivity and the robust technology of this ap-
proach allowed the detection of small changes in the dynamic network of protein
phosphorylation. To sum up, protein microarrays were established for the ge-
neration of large high quality data sets suitable for systems biology approaches.
ERBB receptor signalling in MCF7 cells was analysed quantitatively using the
microspot immunoassay. Additionally, RPPAs were performed on the MCF7
samples to analyse additional phosphoproteins known to be involved in signal-
ling downstream of ERBB receptors. In ERBB2 overexpressing cell lines, the
influence of the ERBB receptors targeting therapeutics trastuzumab, pertuzu-
mab, and erlotinib on ligand induced signalling was analysed using reverse phase
protein arrays.
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4.2 Statistical analysis of time-resolved data
The statistical analysis of time series experiments was a challenging task. The
question of how to identify significant differences in the time-dependent expres-
sion or activation of markers under different conditions has to be solved. Tai
and Speed (2009) discussed this problem for microarray data comprising seve-
ral thousand genes and suggested to rank the features instead of testing for
significance. This method is not applicable to the analysis of time-dependent
changes in the phosphorylation status of proteins since here the number of dif-
ferent features is much lower, e.g. limited to 40 different antibodies. Moreover,
the kinetics of protein phosphorylation differ immensely from that of gene ex-
pression due to rapid dephosphorylation events induced by feedback loops. In
most cases, the effects of external stimuli on the phosphorylation status is visible
only for a very limited timeframe whereas differences in gene expression tend
to be evident for a larger time period. Here, a t-test for each time point was
used, decoupling the multivariate problem into single test problems. However,
analysing the significance of changes in the phosphorylation status of proteins
over time remains a challenge. To further analyse the data, dynamic model-
ling approaches and signalling network reconstruction were performed (Bender
et al., 2010).
4.3 Quantitative analysis of ERBB receptor
signalling in breast cancer cell lines
The human breast cancer cell line MCF7 was used to analyse ERBB signalling
without the dominant impact of an overexpressed receptor. Comparing the acti-
vation potential of the three ligands EGF, BTC, and HRG at a concentration of
1 nM revealed that HRG had the strongest impact on ERBB receptor signalling
in MCF7 cells. It strongly induced receptor phosphorylation and a higher and
more sustained activation of targets of the MAPK and the PI3K pathway, like
ERK1/2 and AKT, compared to both other ligands (Fig. 3.19). Analysing the
simultaneous stimulation with two different ligands revealed that HRG was the
dominant ligand as the HRG-containing combinations resembled downstream
signalling mediated by HRG alone (Fig. 3.18). In a systems biology approach,
a similar observation was made for increasing EGF and HRG concentrations
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in MCF7 cells (Birtwistle et al., 2007). HRG binds to ERBB3, which has a
non-functional kinase domain and therefore depends on transphosphorylation
by other receptors, mainly ERBB2. However, it has been reported that ERBB3
exhibits very weak kinase activity and can only weakly phosphorylate its di-
merisation partner (Shi et al., 2010). On the other hand, the ERBB2/ERBB3
dimer, which is activated by HRG, is the dimer with the strongest oncogenic
potential (Citri et al., 2003). RPPA data revealed that HRG induced not only
phosphorylation of ERBB2 but also of EGFR in MCF7 cells. Riese et al. (1995)
showed that HRG can indeed regulate EGFR signalling in the mouse pro-B-
lymphocyte cell line Ba/F3 transfected with exogenous ERBB receptors. The
same effect was reported for Tamoxifen resistant MCF7 (Hutcheson et al., 2007)
and for melanoma cells (Ueno et al., 2008) and in ERBB2-positive pancreatic
cells, only EGFR/ERBB3 dimers were formed upon EGF or HRG treatment
(Frolov et al., 2007). The reports demonstrated that EGFR/ERBB3 dimers
exist in cells which are not overexpressing ERBB2. However, other studies des-
cribed that these dimers are relatively weak (Wehrman et al., 2006) and that
their transphosphorylation activity is limited (Tzahar et al., 1996). A second
mechanism of HRG-induced EGFR activation is the formation of secondary
dimers, as reported to occur in PC12 cells by Gamett et al. (1997). After
HRG-mediated activation, the transiently formed ERBB3/ERBB2 dimers dis-
sociate and the phosphorylated ERBB2 monomers interact with unphospho-
rylated receptors to form secondary ERBB2/EGFR dimers. Additionally, an
EGF-induced formation of ERBB2/ERBB3 dimers was observed in SKBR3 cells
(Graus-Porta et al., 1997). To determine the influence of the single ERBB re-
ceptors on downstream kinase activation, ligand induced signalling was analysed
after knockdown of the single receptors EGFR, ERBB2, ERBB3, and ERBB4
in MCF7 cells. The knockdown of ERBB2 and ERBB3 caused an equal reduc-
tion of HRG-induced MAPK and PI3K pathway activation, namely MEK1/2,
ERK1/2, AKT, p70S6K (Fig. 3.23), and S6 (data not shown), confirming the
co-dependency on both receptors. Signalling via EGFR was not able to com-
pensate for the loss of ERBB2. Instead, knockdown of EGFR slightly enhanced
HRG-mediated activation of the MAPK and PI3K pathways. In contrast, ad-
dition of gefitinib, an EGFR inhibitor, resulted in inhibition of EGFR, ERBB2,
and ERBB3 phosphorylation and prevented downstream pathway activation.
This has also been shown by Yang et al. (2006) and was interpreted as an essen-
tial role of EGFR in HRG signalling. However, the knockdown of EGFR did not
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support a role of EGFR in HRG signalling since knockdown of EGFR did not
reduce HRG-mediated pathway activation in MCF7 cells. The different effects
obtained from gefitinib-mediated EGFR inhibition and siRNA-mediated EGFR
knockdown could result from sequestration of ERBB receptors by formation of
inactive dimers with the inhibited EGFR acting as a dominant negative recep-
tor (Moulder et al., 2001). In the presence of EGFR, this receptor is involved
in HRG-induced receptor dimerisation and signalling. If inhibited, EGFR still
forms dimers as described before, but downstream signalling is not possible.
However, the lack of EGFR steers the increased formation of ERBB2/ERBB3
dimers, which results in enhanced pathway activation. The knockdown of EGFR
and ERBB2 had the strongest impact on EGF mediated signalling. AKT and
STAT3 phosphorylation was reduced equally after knockdown of both recep-
tors, whereas ERK1/2 activation was stronger influenced by EGFR than by
ERBB2 knockdown (Fig. 3.23). In cell lines expressing several different ERBB
receptors, EGF mainly induces EGFR/ERBB2 heterodimer formation (Lenfe-
rink et al., 1998), leading to the activation of both pathways, MAPK and PI3K.
Knockdown of ERBB2 forced the formation of EGFR homodimers which mainly
induced ERK1/2 activation. Additionally, homodimers produce weaker signals
than heterodimers, they are less mitogenic and transforming (Kokai et al., 1989,
Pinkas-Kramarski et al., 1996). In summary, AKT signalling in response to EGF
is dependent on ERBB2 activation while EGFR homodimers are still able to
induce ERK1/2 phosphorylation although to a lesser extent. It is well known,
that ERBB2, as the preferred dimerisation partner of ERBB receptors, enhances
and prolongs signalling. However, the dynamics of ligand induced protein phos-
phorylation in MCF7 cells did not change after the ERBB2 knockdown. It
solely reduced the absolute amount of phosphorylated proteins. In conclusion,
in MCF7 cells, ERBB2 indeed enhanced the amplitude of downstream signal-
ling but did not prolong the pathway activation and the signal-amplifying role
of ERBB2 was ligand-independent.
In SKBR3 cells, no ligand-dependent differences were observed with respect
to the activation of ERK1/2, indicating a saturated response. HRG and the
combination of EGF+HRG induced a stronger AKT phosphorylation compared
to EGF alone, as seen also in MCF7 cells. In HCC1954 cells, EGF induced
strong MAPK signalling in contrast to HRG. Both ligands did not induce AKT
phosphorylation in HCC1954 cells but starvation resulted in an upregulation of
baseline pAKT (Fig. 3.12). This has also been reported by Chakrabarty et al.
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(2010) and was correlated with oncogenic PI3K mutations leading to increa-
sed HRG expression. Consequently, secretion of HRG resulted in an autocrine
loop activating ERBB3 and subsequently AKT. Interestingly, the combination
of both ligands in HCC1954 cells decreased the phosphorylation of ERK1/2 and
p70S6K compared to stimulation with EGF alone. These observations can so-
lely be explained by the expression pattern of ERBB receptors in the two cell
lines. SKBR3 cells express high levels of EGFR and ERBB3 and therefore EGF-
and HRG-induced signalling resulted in a strong ERK1/2 activation, probably
reaching saturation as no additive effect was caused by the addition of both
ligands in parallel. In contrast, HCC1954 cells barely expressed ERBB3 but
instead high amounts of EGFR. Therefore, EGF was the predominant ligand in
HCC1954 cells and simultaneous stimulation with EGF and HRG even resulted
in a reduction of ERK1/2 activation compared to EGF alone, as HRG leads to
the formation of ERBB3 containing dimers not contributing to the activation of
the MAPK pathway. To sum up, the differential expression of the ERBB recep-
tors resulted in different ligand-induced activation of the two major downstream
pathways, MAPK and PI3K, in the three breast cancer cell lines.
4.4 Impact of targeted therapeutics on ERBB
mediated signal transduction
Therapeutic antibodies exhibit high target specificity, whereas ATP-competitive
small molecule inhibitors often possess off-site effects, as the ATP binding po-
ckets of related kinases are very similar (Karaman et al., 2008). Therefore, it
cannot be ruled out that the clinical benefit is indeed at least partly caused by
unspecific effects (Jimeno and Hidalgo, 2006). Recently, Kriegs et al. (2010) pos-
tulated that the different effects of cetuximab, a chimeric monoclonal antibody
against EGFR, and erlotinib, a small molecule drug inhibiting EGFR, on DNA
repair might be due to the low specificity of the small molecule inhibitor erloti-
nib. The impact of three targeted therapeutics, trastuzumab, pertuzumab, and
erlotinib on ligand induced signalling was analysed in two ERBB2 overexpressing
cell lines, SKBR3 and HCC1954. The aim was to delineate whether a combina-
torial use of the drugs would yield any evidence to suggest also a possible clinical
beneficial which could then be addressed in clinical studies. HCC1954 cells are
resistant to trastuzumab (O’Brien et al., 2010, Sahin et al., 2009), which was of-
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ten correlated with activating mutations of the PI3K pathway. While HCC1954
as well as SKBR3 cells express wt-PTEN in a comparable amount (Fig. 3.13),
the cell line HCC1954 harbours a H1047R mutation in the kinase domain of
catalytical subunit p110α of PI3K. Additionally, very low levels of p27 were
present and not upregulated upon trastuzumab treatment in HCC1954 cells,
in contrast to the other ERBB2 overexpressing cell lines SKBR3 and BT474
(Fig. 3.14). In trastuzumab sensitive cells, treatment leads to an upregulation
of p27 and a downregulation of cyclinD1 and therefore low p27 abundance has
been associated with trastuzumab resistance (Nahta et al., 2004).
4.4.1 Protein phosphorylation upon drug treatment
Amino acid Y1248 is one of the major autophosphorylation sites of the ERBB2
receptor and was correlated with ERBB2 activation (Akiyama et al., 1991).
After ligand binding, proliferation is induced by recruiting SHC, thus activating
the MAPK pathway. Phosphorylation of ERBB2 at Y1248 has already been
associated with poor clinical prognosis (Cicenas et al., 2006, Thor et al., 2000).
However, a high phosphorylation of ERBB2 indicates a strong signalling activity
and growth dependency of the tumour on this signalling pathway. Therefore,
response rates to trastuzumab tend to be higher in patients with tumours exhi-
biting phosphorylated ERBB2 (Hudelist et al., 2003). Additionally, activation
of EGFR in tumours enhances the significance of the predictive role of pERBB2
(Hudelist et al., 2006). This is in line with in vitro experiments as studies in a
set of breast cancer cell lines revealed that not only overexpression of ERBB2
but also the phosphorylation status of the ERBB2 receptor is an important
factor for trastuzumab sensitivity (Ginestier et al., 2007).
A controversy still exists if antibody drugs exhibit activating potential on the
targeted receptor or not. Nagata et al. (2004) reported no change of ERBB2
phosphorylation within 1 h of trastuzumab treatment in BT474 and SKBR3
cells. Lane et al. (2000) reported that ERBB2 was rapidly dephosphorylated
after addition of 4D5, the murine precursor of trastuzumab. In contrast, Sa-
rup et al. (1991) showed that 4D5 acts as partial agonist and rapidly induced
receptor phosphorylation in SKBR3 cells. Additionally, Scott et al. (1991) re-
ported that PI3K was activated after addition of 4D5. Moreover, Diermeier
et al. (2005) reported that treatment of SKBR3 cells with trastuzumab led to
an increase in ERBB2 phosphorylation. However, despite the controversy on
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ERBB2 activation, an inhibition of cell proliferation in SKBR3 cells was seen in
all these studies. The reports of receptor phosphorylation and subsequent inhi-
bition of cell proliferation are in line with the observed results that addition of
both antibody agents trastuzumab and pertuzumab resulted in a strong increase
of receptor phosphorylation in BT474, SKBR3, and HCC1954 cells, which was
even stronger than after addition of a ligand. Despite the phosphorylation of
ERBB2 at Y1248, the cell cycle regulator RB and the ribosomal protein S6
were dephosphorylated after treatment with trastuzumab or pertuzumab if the
antibody therapeutics applied were in combination with erlotinib. A possible
explanation for reduced cell cycle progression in the context of sustained re-
ceptor phosphorylation is supported by the report that sustained activation of
ERBB2 can result in apoptosis instead of proliferation (Tikhomirov and Car-
penter, 2004). In contrast, addition of EGF leads only to transient receptor
phosphorylation, subsequent receptor internalisation and induction of prolife-
ration. Therefore, the cellular response to receptor phosphorylation might be
dependent on the strength and duration of receptor phosphorylation.
Although the main focus of this study was the analysis of the MAPK and PI3K
signalling pathway activation downstream of ERBB receptors, further proteins
were monitored as well. For example, the ERBB effectors SRC, PLCγ, and
STAT5, which directly bind to the receptors via their SH2 domains (Rotin
et al., 1992, Schulze et al., 2005) were strongly phosphorylated after exposure
to therapeutic antibodies.
Phosphorylated PLCγ catalyses the hydrolysis of phosphatidylinositol-
trisphosphate (PIP3) to inositol triphosphates (IP3). Sarup et al. (1991) repor-
ted increased levels of IP3 5min after addition of 4D5 to SKBR3 cells which is
in line with the observed phosphorylation of PLCγ in response to both antibody
drugs. Furthermore, a different monoclonal antibody against ERBB2 (ID5) ac-
tivated PLCγ in SKBR3 cells but this activation had no impact on ID5 induced
G1 arrest (Le et al., 2000). Therefore, the role of PLCγ in trastuzumab media-
ted cell cycle arrest remains unclear. Activation of PLCγ has been associated
with migration, and phosphorylation of ERBB2 at Y1248 was proposed to ini-
tiate this signalling cascade (Dittmar et al., 2002). However, transient rather
than sustained PLCγ activation attributed to migration.
SRC plays a role in development, progression, and metastasis of breast can-
cer (Biscardi et al., 2000, Di Cosimo and Baselga, 2008). In addition, it has
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been described that metastasis of ERBB2 overexpressing cells is correlated with
increased SRC activity in vivo and this was confirmed by cell invasion assays
in vitro (Tan et al., 2005). However, it has also been reported that inhibition
of SRC activation has no effect on ERBB2-mediated oncogenesis in transgenic
mice, and that SRC expression rather than activation is important (Kaminski
et al., 2006). Results observed for SRC phosphorylation in this study are in
contrast to those reported by Nagata et al. (2004). In that case a dephospho-
rylation of SRC after trastuzumab treatment but also no increase of ERBB2
phosphorylation was observed. Therefore, the role of SRC in response targeted
therapy remains to be elucidated.
STAT proteins are involved in cellular differentiation, proliferation, and survival
and play a role in the differentiation of the breast epithelium (Liu et al., 1996).
Nevalainen et al. (2004) reported that STAT5 phosphorylation is a marker of
favourable prognosis in breast cancer. However, involvement of STAT5 in breast
cancer progression is still unclear.
To sum up, a role of signalling proteins such as SRC, STAT5, and PLCγ in
mediating the functionality of the drugs has to be addressed by further studies.
4.4.2 Impact of drug treatment on ligand-induced signalling
The two major pathways downstream of the ERBB receptor family are the
MAPK and the PI3K pathway. Both contribute to cancer growth as described in
detail in section 1.4. Regarding single drug treatments, results obtained in this
thesis suggest that both antibody drugs had only minimal effects on ERK1/2
activation. This was observed for both cell lines, HCC1954 and SKBR3. Erlo-
tinib, on the other hand, was able to inhibit the EGF mediated activation of all
measured proteins. The AKT phosphorylation dynamics were very different in
both cell lines. In HCC1954 cells, no inhibition of AKT was evident (Fig. 3.30).
Preincubation with antibody therapeutics revealed no influence while erlotinib
was able to downregulate, but not to inhibit, phosphorylation of AKT at posi-
tion S473. AKT phosphorylation at T308 seemed to be unaffected in this cell
line. PI3K mutations, as reported for HCC1954 cells, decouple the activation of
AKT from the receptor level. Therefore, the inhibition of ERBB2 had no inhibi-
tory potential towards the activation of AKT in this cell line. This is in line with
the previously reported trastuzumab resistance of HCC1954 cells. However, er-
lotinib alone was able to reduce cell cycle progression in this cell line (Fig. 3.39).
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In SKBR3 cells, all three drugs resulted in a downregulation of EGF mediated
AKT activation but with different impact on the phosphorylation dynamics.
For example, trastuzumab did not reduce the amount of phosphorylated pro-
tein formed at the activation peak after 12min, but it was able to subsequently
downregulate pAKT so that the steady state level was reached again after 20min
while the control showed a sustained AKT activation for at least 60min. Fur-
thermore, pertuzumab significantly reduced the activation of AKT and resulted
in a downregulation of AKT phosphorylation after 20min (Fig. 3.31). Thus,
the data reflect previously reported mechanisms of both drugs. Pertuzumab is
known to prevent dimerisation of ERBB2 with other receptors, for example the
formation of EGFR/ERBB2 dimers in response to EGF stimulation. As ERBB2
is more potent in activating AKT than EGFR, lower AKT activation was due
to a shift from EGFR/ERBB2 heterodimer to EGFR homodimer formation
which was already shown in pertuzumab-treated SKBR3 cells (Hughes et al.,
2009). Junttila et al. (2009) reported that trastuzumab was not able to prevent
a ligand-induced dimerisation but instead disrupted ligand-independent dimers.
The activation peak at 12min after stimulation with EGF observed in the time-
resolved data matched to the single time point analysed in the study performed
by Junttila et al. (2009). After 12min, no difference between trastuzumab and
the uninhibited control was observed with respect to AKT phosphorylation,
confirming that trastuzumab had no effect on the initial receptor heterodimer
formation. Measuring the effects of the inhibitors in a time-resolved manner
revealed the differences between both therapeutic antibodies. Although tras-
tuzumab did not prevent the ligand-induced activation, it downregulated AKT
phosphorylation probably by inducing a disruption of ERBB2 heterodimers and
prevented a sustained activation. The effects of the inhibitors are illustrated in
figure 4.1. The impact of inhibitors on S6 phosphorylation resembled the effects
observed for the upstream proteins pAKT, pERK1/2, and p70S6K. While er-
lotinib was able to entirely inhibit S6 phosphorylation in both cell lines, both
antibody drugs downregulated the phosphorylation of S6 in SKBR3 (Fig. 3.31),
but not in HCC1954 cells (Fig. 3.30).
While both antibody drugs altered EGF-mediated AKT signalling, HRG-
induced AKT activation was not influenced. On the contrary, trastuzumab
pretreatment resulted in a slight upregulation of AKT activation. The fact,
that trastuzumab had only a weak impact on fast signalling is in line with re-
ports that it inhibits the interaction of EGFR and ERBB2 but not of ERBB2
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Figure 4.1: Impact of targeted therapeutics on EGF signalling
Schematic overview of inhibitory effects of trastuzumab, pertuzumab, and erloti-
nib on EGF induced signalling.
and ERBB3 (Wehrman et al., 2006). It was reported, that HRG is able to
compensate the inhibitory effect of trastuzumab on cell proliferation (Diermeier
et al., 2005). The main feature of pertuzumab, however, is to prevent ERBB2 re-
ceptor dimerisation with any other receptor. It has been reported several times,
that pertuzumab is able to inhibit HRG-induced signalling in breast, prostate,
(Agus et al., 2002), and colon carcinoma cells (Jackson et al., 2004). However, in
this study, pertuzumab did not prevent HRG-induced ERBB2 dimerisation as
it did not inhibit HRG mediated AKT signalling in SKBR3 cells (Fig. 3.32). In
contrast to previous reports, Cai et al. (2008) demonstrated, that pertuzumab
prevented a dimerisation of ERBB2 with EGFR, but that it only reduced the
extent of HRG-induced ERBB2/ERBB3 dimer formation in SKBR3 cells. This
is in line with the observation made in this thesis that pertuzumab decreased
EGF- but not HRG induced AKT signalling. It was anticipated that simulta-
neous stimulation with EGF and HRG will additionally induce EGFR/ERBB3
heterodimers if ERBB2 is excluded from dimerisation after preincubation with
pertuzumab or trastuzumab. The combination of both ligands resulted in a
slightly stronger AKT phosphorylation compared to HRG alone and the impact
of the inhibitors was even weaker. Both ligands when applied in combination
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can induce activation of dimers involving EGFR, ERBB2, ERBB3 and thereby
circumvent the inhibition of single receptors.
Franklin et al. (2004) have shown that pertuzumab binds to the dimerisation arm
of ERBB2. However, this study was carried out with the extracellular domain
of ERBB2 and not with the membrane-spanning full-length receptor. Although
the extracellular domain is responsible for homodimerisation, other regions of
the receptor, like the transmembrane domain or the intracellular domain, play
a crucial role for the formation of heterodimers as reviewed by Lemmon (2009).
For example, Duneau et al. (2007) showed that transmembrane domains of the
ERBB receptors governed a hierarchy of receptor interactions which reflected
the dimerisation preferences of the full length receptors in the cellular context.
Certainly, dimers can form due to multiple mechanisms which influence the
particular binding preferences of the individual receptors. ERBB3 does not
form homodimers while ERBB2 only forms homodimers when it is overexpressed
(Tzahar et al., 1996, Yarden and Sliwkowski, 2001). On the contrary, both
receptors form the strongest heterodimers in response to ERBB3 stimulation
(Ferguson et al., 2000), an effect mediated by other domains apart from the
dimerisation loop. Domain IV plays a role in receptor heterodimerisation of
ERBB2 with EGFR. Therefore, binding of trastuzumab to domain IV of ERBB2
leads to disruption of heterodimers. Hence, the binding of pertuzumab to the
dimerisation domain of ERBB2 did not categorically prevent ligand-induced
heterodimerisation, as suggested by the data generated in this study.
4.4.3 Effects of combinatorial drug treatment
Drug resistance can be due to an upregulation of non-targeted receptor tyrosine
kinases, for example MET (Shattuck et al., 2008), VEGFR (Bianco et al., 2008),
and IGFR (Lu et al., 2001, Nahta et al., 2005). Therefore, targeting more than a
single receptor is a promising strategy. Several inhibitors are already clinically
approved (lapatinib: targeting EGFR and ERBB2) or are in clinical studies
(vandetanib: targeting EGFR, VEGFR, and RET (Alferez et al., 2008, Pennell
and Lynch, 2009, Ryan and Wedge, 2005)). Another promising approach is
the development of dual PI3K and mTOR inhibitors (Maira et al., 2008), since
inhibition of mTOR results in upregulation of AKT signalling due to a feedback
loop including p70S6K (Yang and Guan, 2007). Therefore, the dual inhibition
of mTOR and PI3K was demonstrated to disable this feedback loop and induce
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apoptosis in vitro (Brachmann et al., 2009) and inhibit tumour growth in vivo
(Mallon et al., 2010).
In in vivo models and clinical trials, the combination of the two therapeutical
antibodies trastuzumab and pertuzumab promised to be beneficial for trastu-
zumab resistant patients (Baselga et al., 2010, Scheuer et al., 2009). However,
according to data on signalling dynamics in ERBB2 overexpressing breast can-
cer cell lines obtained in this thesis, this drug combination did not improve the
efficiency of the single agents. The combination of trastuzumab and pertuzumab
reduced the fast ligand-induced activation of ERK1/2 and S6 in both cell lines
and also of AKT in SKBR3 cells (Fig. 3.33, 3.34). However, in a long-term
experiment applying both antibody drugs in full growth medium, the combi-
nation of trastuzumab and pertuzumab seemed to be rather activating as it
increased receptor phosphorylation and resulted in the activation of RB and S6
compared to the control. Furthermore, this combination significantly induced
cell cycle progression in SKBR3 cells (Fig. 3.39). In cell culture experiments,
no increased antibody-dependent cellular cytotoxicity (ADCC) was observed for
the combination trastuzumab/pertuzumab (Scheuer et al., 2009). However, in
vitro studies certainly miss the impact of the tumour microenvironment. Thus,
the clinical benefit observed for the combination of trastuzumab and pertu-
zumab might therefore result from a combination of impact on signalling and
ADCC which can only be approached in vivo. In contrast, the combination
trastuzumab/erlotinib or pertuzumab/erlotinib showed a strong inhibition of
signalling in both short and long term experiments. Cell cycle analysis revea-
led that the combination of trastuzumab and erlotinib significantly reduced cell
cycle progression in both cell lines. With respect to the fact, that pertuzu-
mab and also trastuzumab shift the dimer equilibrium from ERBB2 containing
heterodimers towards formation of EGFR homodimers (Hughes et al., 2009),
the addition of erlotinib to inhibit specifically EGFR signalling prevents the cell
from taking an alternative route to activate downstream signalling (Fig. 4.1).
This was shown for EGF as well as HRG induced AKT (S473) phosphorylation
in SKBR3 cells (Fig. 3.35) which was significantly inhibited by pertuzumab
and erlotinib applied in combination. As ADCC is important for the clinical
outcome, combinatorial therapies combining a small molecule inhibitor and a
monoclonal antibody might be superior compared to dual small molecule inhi-
bitors, like lapatinib, targeting EGFR and ERBB2 in parallel. The combination
of trastuzumab and erlotinib is already in clinical trials in phase II studies as
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therapy of breast cancer (NCT00033514). Another study was closed before mee-
ting its accrual goal due to the introduction of other combinatorial therapies,
for example of trastuzumab with bevacizumab, a VEGFR specific antibody, or
the dual specific inhibitor lapatinib (Britten et al., 2009). The combination of
pertuzumab and erlotinib was superior when compared to monotherapy with
either substance alone in human tumour xenografts of breast and lung cancer
cells (Friess et al., 2005).
The results obtained in this study implied that HCC1954 cells were dependent
on ERK1/2 signalling, but not on AKT signalling, and were therefore responsive
to erlotinib treatment. Breast tumour are very heterogenous and in tumours
with PI3K mutations or loss of PTEN, which are resistant to trastuzumab, the
addition of erlotinib in combination with trastuzumab or pertuzumab might not
be sufficient to inhibit tumour growth. In these tumours, combinations with
PI3K/mTOR inhibitors might be more promising. However, the combination
of trastuzumab and erlotinib revealed downregulation of signalling and of cell
cycle progression in both cell lines, trastuzumab sensitive and resistant cells,
and should therefore be addressed by further clinical studies.
4.5 Regulation of p70S6K activation in breast
cancer cell lines
ERK1/2 and AKT are key intermediates upon EGF and HRG stimulation.
However, the activation or inhibition of these two proteins can not always be
correlated with the clinical outcome. Therefore, phosphoproteins further down-
stream integrating signals from different pathways were investigated to identify
targets of clinical relevance. Klos et al. (2006) reported that breast cancer pa-
tients with increased p70S6K phosphorylation revealed worse disease-free survi-
val and increased metastasis. Recently, it was shown that growth inhibition is
more closely correlated with p70S6K than with AKT phosphorylation (Kataoka
et al., 2009). Therefore, mechanisms for the activation of p70S6K signalling were
analysed in more detail. In general, activation of p70S6K is a complex process.
Phosphorylation of p70S6K at the dual site T421/S424, which is located in
the autoinhibitory pseudosubstrate segment in the noncatalytic tail of p70S6K,
is the first step of activation as it releases autoinhibition. Phosphorylation of
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p70S6K at position T389 is the last step and leads to full kinase activity (Weng
et al., 1998).
The four cell lines MCF7, HCC1954, SKBR3, and BT474 showed different ef-
fects regarding the regulation of p70S6K phosphorylation. Preincubation with
different inhibitors targeting ERK1/2 and AKT signalling, revealed that indeed
both pathways were involved in the phosphorylation of p70S6K at the two dis-
tinct phosphorylation sites. In MCF7 cells, the phosphorylation of p70S6K at
position T389 was dependent on PI3K/mTOR signalling, while the p70S6K dual
phosphorylation site T421/S424 was ERK1/2 dependent, as revealed by the spe-
cific inhibition with LY292004 (PI3K inhibitor) and PD98059 (MEK1 inhibitor),
respectively (Fig. 3.21). This is in line with the reported crosstalk of the MAPK
and the PI3K pathways merging in p70S6K activation. For example, Ahmed and
Kundu (2010) recently reported that p70S6K is phosphorylated at T421/S424
via the MAPK pathway upon osteopontin stimulation in MCF7 cells, while the
main phosphorylation site of p70S6K, T389, remained unaffected. Additionally,
it has been reported that in neutrophils, p70S6K is phosphorylated at position
T421/S424 via a MAPK dependent pathway while phosphorylation of p70S6K
at T389 is rapamycin sensitive (Lehman et al., 2003). As shown here, the rapa-
mycin sensitive phosphorylation site T389 was indeed not phosphorylated after
rapamycin treatment of MCF7 cells. However, rapamycin also increased phos-
phorylation rate of AKT, ERK1/2, and p70S6K (T421/S424). This is in line
with the observation that inhibition of mTORC1 by rapamycin can lead to PI3K
pathway activation due to inhibition of a p70S6K dependent negative feedback
loop (O’Reilly et al., 2006). Furthermore, activation of ERK1/2 signalling after
addition of rapamycin has also been shown. For example, treatment of breast
tumours with RAD001, a rapamycin analog, resulted in increased ERK1/2 phos-
phorylation so that a p70S6K dependent feedback loop activating ERK1/2 via a
RAS dependent pathway was postulated (Carracedo et al., 2008). Furthermore,
Kinkade et al. (2008) showed that a combinatorial inhibition of mTOR and
MAPK pathways synergistically prevented prostate cancer cell growth, both, in
vitro and in vivo.
In SKBR3 cells, p70S6K phosphorylation was not detected by RPPA. How-
ever, the downstream target S6 was strongly affected by AKT inhibition while
ERK1/2 inhibition had only minor inhibitory effects. Inhibition of MEK1/2
delayed only the initial activation of S6 within the first 10-20min and full S6
phosphorylation was reached after 30min. Roux et al. (2007) reported that
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both pathways can result in phosphorylation of S6 (S235/236) via p70S6K and
p90RSK in HEK293E and HeLa cells. Furthermore, inhibition of the MAPK
pathway resulted in a strong decrease of S6 phosphorylation during the first
10min which corresponded to the activation peak of ERK1/2 and p90RSK.
In conclusion, in SKBR3 cells, the MAPK pathway seemed to be involved in
the initial S6 phosphorylation, however, the PI3K pathway is mandatory and
sufficient for the sustained activation of S6. In BT474 cells, p70S6K phospho-
rylation was AKT dependent at T389 and MAPK dependent at T421/S424, as
observed for MCF7 cells. S6 phosphorylation was significantly downregulated
upon PI3K inhibition and ligand-induced activation was entirely prevented. In
contrast, MEK1 inhibition had only a temporary impact on S6 phosphorylation
as observed for SKBR3 cells.
In HCC1954 cell, RPPA data suggested that both phosphorylation sites of
p70S6K were dependent on ERK1/2 activation, since MEK1 inhibition by
PD98059 inhibited phosphorylation at both phosphorylation sites. In contrast,
the PI3K inhibitor LY292004 was not able to inhibit p70S6K phosphorylation
at all (Fig. 3.41). In contrast, the phosphorylation of S6 (S235/236) was equally
dependent on AKT and ERK1/2 activation as both inhibitors, LY292004 and
PD98059, inhibited the phosphorylation to a comparable extent. Preliminary
results of an additional experiment applying rapamycin in HCC1954 cells sho-
wed that both phosphorylation sites of p70S6K were indeed rapamycin insen-
sitive (Fig. 3.42). In contrast, the phosphorylation of ERK1/2 and p70S6K
increased after preincubation with rapamycin. Western blot analysis revealed
that the p85S6K isoform was predominantly activated in HCC1954 and that
only phosphorylation of p70S6K but not p85S6K was inhibited by rapamycin
treatment (Fig. 3.43). Thus, p85S6K phosphorylation was MAPK pathway de-
pendent while p70S6K was PI3K pathway dependent. Although p85S6K was
prominently activated in HCC1954 cells, S6 seemed to be phosphorylated by
both isoforms, as inhibition of the both pathways resulted in a reduced of S6
phosphorylation. Except for the nuclear localisation, little is known about the
function of p85S6K. S6 has been shown to reside and to be phosphorylated in the
nucleus as well as in the cytoplasm (Franco and Rosenfeld, 1990). Additionally,
it has been reported that p85S6K is required for S-phase entry (Reinhard et al.,
1994). However, it was suggested that both S6K isoforms lie on the same path-
way and that p85S6K parallels p70S6K regulation (Dennis et al., 1998, Ming
et al., 1994). This is in contrast to the results obtained in this study, which
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indicated a differential regulation of both S6K isoforms at least in HCC1954
cells.
Cells overexpressing ERBB2 or harbouring an oncogenic PI3K mutation like
HCC1954 cells are selectively dependent on PI3K signalling (She et al., 2008). It
has been reported that trastuzumab or lapatinib resistance are due to PI3K mu-
tations and that resistance can be reversed by PI3K or mTOR inhibition (Berns
et al., 2007, Eichhorn et al., 2008, Serra et al., 2008). Therefore, it was surprising
that the p70S6K phosphorylation seemed to be ERK1/2 and not PI3K/mTOR
dependent in HCC1954 cells while S6 phosphorylation was dependent on both
pathways. However, the co-dependency on two survival pathways may present
a benefit for cancer cells and insures that lethal interruption of one pathway can
be overcome. The results on p70S6K regulation indicated that the crosstalk bet-
ween these two major pathways to activate downstream targets differs between
the cell lines. Apart from the data shown here, there is further evidence that the
MAPK and the PI3K pathway converge on S6 phosphorylation and the inhibi-
tion of one pathway might not be sufficient. For example, Faber et al. (2009)
reported that ERBB2 amplified breast cancer cell lines are sensitive to treat-
ment with NVP-BEZ235, a dual PI3K/mTOR inhibitor. The ERBB2 amplified
cell lines used were SKBR3 and BT474 cells. In contrast, EGFR mutant lung
cancer cell lines additionally required MEK inhibition as they were dependent
on both pathways. This is in line with the results, that both cell lines, SKBR3
and BT474, revealed AKT dependency for S6 phosphorylation. In insensitive
cells, e.g. MDA-MB231 cells which harbour a KRAS mutation, co-treatment
with a MEK inhibitor restored sensitivity (Brachmann et al., 2009). Meaningful
clinical progress for drugs targeting only a single kinase or just one molecular
pathway is limited to a few examples (van der Heijden and Bernards, 2010).
The concept of synthetic lethality, where two pathways are targeted, might be a
promising tool (Hartwell et al., 1997). This has already been shown for KRAS
mutant lung cancer (Brachmann et al., 2009, Engelman et al., 2008). In the
latter report, insensitivity was associated with residual S6 phosphorylation as
a result of ERK1/2 pathway activation. Therefore, the ribosomal protein S6
seems to be an appropriate readout for the efficacy of targeted therapeutics.
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A.1 ERBB signalling in MCF7 cells
A.1.1 Dose-dependent signalling
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Figure A.1: Dose-dependent stimulation with EGF in MCF-7 cells.
MCF7 cells were stimulated with EGF in concentrations ranging from 0.1 nM
to 20 nM. Phosphorylation of ERK1/2, STAT3 (S727), AKT (S473), and AKT
(T308) was quantified.
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Figure A.2: Dose-dependent stimulation with BTC in MCF-7 cells
MCF7 cells were stimulated with BTC in concentrations ranging from 0.1 nM
to 20 nM. Phosphorylation of ERK1/2, STAT3 (S727), AKT (S473), and AKT
(T308) was quantified.
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Figure A.3: Scaled data of dose-dependent stimulation of MCF7 cells
with HRG
MCF7 cells were stimulated with HRG in a concentration ranging from 0.1 nM
to 20 nM. Phosphorylation of ERK1/2, STAT3 (S727), AKT (S473), and AKT
(T308) was quantified. The three biological replicates were scaled to the maxi-
mum value of each replicate. A cross marks the median of the replicates.
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A.1.2 Impact of inhibitors on ligand-induced signalling
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Figure A.4: Impact of inhibitors on ligand-mediated signalling in MCF7
cells
Cells were preincubated with the inhibitors PD98059, LY294002, gefitinib, or
rapamycin for 1 h and subsequently stimulated with BTC, EGF, or HRG. The
phosphorylation of ERK1/2 and AKT (S473) is shown.
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A.1.3 Ligand-induced signalling after receptor knockdown
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Figure A.5: Stimulation in MCF7 cells after siRNA-mediated knock-
down of ERBB receptors
MCF7 cells were transfected with siRNA targeting the four ERBB receptors and
subsequently stimulated with 1 nM HRG (A) or EGF (B). The diagrams show
the phosphorylation of ERK1/2, STAT3, AKT (S73), and AKT (T308).
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A.2 Effects of targeted therapeutics
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Figure A.6: Immediate ERK1/2 phosphorylation after drug treatment
HCC1954 and SKBR3 cells were incubated with the therapeutics for the indicated
time points. The dashed lines represent the biological replicates while the thick
lines show the fit of the smoothing splines.
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Figure A.7: Impact of targeted therapeutics on HRG-induced signal-
ling in HCC1954 cells
HCC1954 cells were preincubated with the therapeutics and subsequently stimu-
mation with HRG. The dashed lines represent the biological replicates while the
thick lines show the fit of the smoothing splines.
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Glossary
AKT (v-akt murine thymoma viral oncogene)
key modulator of PI3K-AKT-mTOR pathway, three isoforms,
phosphorylated by mTORC2 (S473) and PDK1 (T308)
regulates cell survival, insulin signalling, angiogenesis, tumour formation
eIF4B (eukaryotic translation initiation factor 4B)
required for the binding of mRNA to ribosomes
ERBB (erythroblastic leukemia viral oncogene) receptor family
family of receptor tyrosine kinases (EGF receptor family)
frequently deregulated in cancer
ERK1/2 (extracellular regulated kinase 1/2) (MAPK3/1)
key modulator of MAPK pathway, translocates to the nucleus,
regulates proliferation, differentiation, transcription and development
MEK1/2 (mitogen-activated protein kinase kinase 1/2)
dual specific protein kinase family, essential component of MAPK signal
transduction pathway, phosphorylates ERK1/2
mTOR (mammalian target of rapamycin)
kinase subunit of mTORC1 and mTORC2,
regulates cell growth and survival in response to growth factors and
nutrients, phosphorylates p70S6K at T389
p27 (cyclin-dependent kinase inhibitor p27)
binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4
complexes, controls cell cycle progression at G1,
regulated by phosphorylation and degradation
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Glossary
p70S6K (p70 S6 kinase)
phosphorylates ribosomal protein S6, isoform p85S6K
p90RSK (p90 S6 kinase)
directly activated by ERK1/2, downstream effector of MAPK pathway,
phosphorylates numerous cytosolic and nuclear targets
PDK1 (3-phosphoinositide-dependent protein kinase-1)
phosphorylates and activates AKT, phosphorylates p70S6K at T229
PI3K (phosphoinositide 3-kinase)
lipid kinase consisting of regulatory p85 and catalytical p110 subunit,
phosphorylates PIP2
PLCγ (phospholipase C gamma)
catalyses hydrolysis of PIP3 to IP3, a second messenger molecule
PRAS40 (40 kDa proline-rich AKT substate)
inhibitory component of mTORC1, phosphorylation by AKT relieves in-
hibition
PTEN (phosphatase and tensin homolog)
dephosphorylates PIP3, negative regulator of PI3K pathway, tumour sup-
pressor
RAF (v-raf murine sarcoma viral oncogene homolog)
plays role in regulating the MAPK/ERK signalling pathway
RAS (rat sarcoma viral oncogene homolog)
monomeric G-protein, GTPase activity, attached to the cell membrane,
mutated in 20–30% of cancers
RB (retinoblastoma tumor suppressor protein)
hypophosphorylated form binds transcription factor E2F1 and leads to
cell cycle arrest, phosphorylation by cyclinD1/CDK4/CDK6 and cy-
clinE/CDK2 inactivates RB and initiates S-phase entry
S6 (ribosomal protein S6)
component of the 40S ribosomal subunit, major substrate of kinases in
ribosomes contributing to control of cell growth and proliferation
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Glossary
SOS (son of sevenless homolog)
guanine nucleotide exchange factor for RAS proteins
SRC (v-src sarcoma viral oncogene homolog)
non-receptor tyrosin kinase, interact with the intracellular domains of
growth factor/cytokine receptors, GPCRs and integrins, key upstream me-
diators of both the PI3K and MAPK signalling pathways, play important
role in cell proliferation, migration and survival
TSC2 (tuberous sclerosis 2)
negatively regulates mTORC1 signalling, implicated as tumour surpressor
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Abbreviations
◦C . . . . . . . . . . . . . . . . degree celsius
µ . . . . . . . . . . . . . . . . . micro
7AAD . . . . . . . . . . . . 7-amino-actinomycin D
ADCC . . . . . . . . . . . . antibody-dependent cellular cytotoxicity
AMSA . . . . . . . . . . . . antibody mediated signal amplification
ANOVA . . . . . . . . . . analysis of variance
BD . . . . . . . . . . . . . . . Becton Dickinson
BSA . . . . . . . . . . . . . . bovine serum albumine
BTC . . . . . . . . . . . . . betacellulin
CST . . . . . . . . . . . . . . Cell Signaling Technology
DMEM . . . . . . . . . . . Dulbecco’s modified eagle medium
DMSO . . . . . . . . . . . dimethylsulfoxid
DTT . . . . . . . . . . . . . 1,4-Bis(sulfanyl)butan-2,3-diol
DTT . . . . . . . . . . . . . dithiothreitol
EDTA . . . . . . . . . . . . ethylendiamintetraacetat
EGF . . . . . . . . . . . . . . epidermal growth factor
EGFR . . . . . . . . . . . . EGF receptor
ELISA . . . . . . . . . . . . enzyme-linked immunosorbent assay
ER . . . . . . . . . . . . . . . oestrogen receptor
FBS . . . . . . . . . . . . . . fetal bovine serum
fig . . . . . . . . . . . . . . . . figure
g . . . . . . . . . . . . . . . . . gramm; acceleration of gravity
GDP . . . . . . . . . . . . . guanosine diphosphate
GTP . . . . . . . . . . . . . guanosine triphosphate
h . . . . . . . . . . . . . . . . . hours
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Abbreviations
HRG . . . . . . . . . . . . . heregulin-β1
IGFR . . . . . . . . . . . . . insulin-like growth factor receptor
IP3 . . . . . . . . . . . . . . . inositol-1,4,5-triphosphates
IPTG . . . . . . . . . . . . . isopropyl β-D-1-thiogalactopyranoside
kDa . . . . . . . . . . . . . . kilo Dalton
l . . . . . . . . . . . . . . . . . . liter
LB . . . . . . . . . . . . . . . lysogeny broth
M . . . . . . . . . . . . . . . . Mol, molar
m . . . . . . . . . . . . . . . . milli
MET . . . . . . . . . . . . . met proto-oncogene (hepatocyte growth factor receptor)
MIA . . . . . . . . . . . . . . microspot immunoassay
min . . . . . . . . . . . . . . . minute
miRNA . . . . . . . . . . . micro RNA
mRNA . . . . . . . . . . . messenger RNA
n . . . . . . . . . . . . . . . . . nano
NEAA . . . . . . . . . . . . non essential amino acids
NP-40 . . . . . . . . . . . . nonident P-40
OD . . . . . . . . . . . . . . . optical density
PBS . . . . . . . . . . . . . . phosphate buffered saline
PCR . . . . . . . . . . . . . polymerase chain reaction
PIP2 . . . . . . . . . . . . . Phosphatidylinositol-4,5-bisphosphate
PIP3 . . . . . . . . . . . . . phosphatidylinositol-3,4,5-trisphosphate
PMSF . . . . . . . . . . . . phenylmethanesulfonylfluoride
qRT-PCR . . . . . . . . quantitative realtime PCR
RET . . . . . . . . . . . . . ret proto-oncogene
RNA . . . . . . . . . . . . . ribonucleic acid
RPMI 1640 . . . . . . . Roswell Park Memorial Institute 1640
RPPA . . . . . . . . . . . . reverse phase protein array
RT . . . . . . . . . . . . . . . room temperature
RTK . . . . . . . . . . . . . receptor tyrosin kinase
SDS . . . . . . . . . . . . . . sodium sodecylsulfatae
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Abbreviations
sec . . . . . . . . . . . . . . . second
SERM . . . . . . . . . . . . selective estrogen receptor modulator
SH2 . . . . . . . . . . . . . . SRC-homology 2
siRNA . . . . . . . . . . . . small interfering RNA
TBS . . . . . . . . . . . . . . tris buffered saline
TBST . . . . . . . . . . . . tris buffered saline with 0.1% Tween®20
U . . . . . . . . . . . . . . . . . unit
v/v . . . . . . . . . . . . . . . volume per volume
VEGFR . . . . . . . . . . vascular endothelial growth factor
w/v . . . . . . . . . . . . . . weight per volume
wt . . . . . . . . . . . . . . . . wild-type
151

References
Adams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKee-
ver, K., and Sliwkowski, M. X. (2006). Humanization of a recombinant monoclonal
antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Can-
cer Immunol Immunother, 55(6):717–27.
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I.,
Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., and Sliwkowski,
M. X. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and pros-
tate tumor growth. Cancer Cell, 2(2):127–37.
Ahmed, M. and Kundu, G. C. (2010). Osteopontin selectively regulates
p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated
ICAM-1 expression in breast cancer cells. Mol Cancer, 9:101.
Akiyama, T., Matsuda, S., Namba, Y., Saito, T., Toyoshima, K., and Yamamoto,
T. (1991). The transforming potential of the c-erbB-2 protein is regulated by its
autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol, 11(2):833–42.
Alferez, D., Wilkinson, R. W., Watkins, J., Poulsom, R., Mandir, N., Wedge, S. R.,
Pyrah, I. T., Smith, N. R., Jackson, L., Ryan, A. J., and Goodlad, R. A. (2008).
Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of
intestinal adenomas in Apc(Min/+) mice. Mol Cancer Ther, 7(3):590–8.
Alley, S. C., Okeley, N. M., and Senter, P. D. (2010). Antibody-drug conjugates:
targeted drug delivery for cancer. Curr Opin Chem Biol.
Arap, W., Haedicke, W., Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby,
H. M., Bredesen, D. E., Pasqualini, R., and Ruoslahti, E. (2002). Targeting the
prostate for destruction through a vascular address. Proc Natl Acad Sci U S A,
99(3):1527–31.
Austin, C. D., De Maziere, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C.,
Sliwkowski, M. X., Klumperman, J., and Scheller, R. H. (2004). Endocytosis and
sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and
geldanamycin. Mol Biol Cell, 15(12):5268–82.
153
References
Bader, A. G., Kang, S., and Vogt, P. K. (2006). Cancer-specific mutations in PIK3CA
are oncogenic in vivo. Proc Natl Acad Sci U S A, 103(5):1475–9.
Barlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y., Bittner, M. L.,
Torhorst, J., Haas, P., Bucher, C., Sauter, G., Kallioniemi, O. P., and Kallioniemi,
A. (2000). Detecting activation of ribosomal protein S6 kinase by complementary
DNA and tissue microarray analysis. J Natl Cancer Inst, 92(15):1252–9.
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi,
G., Cortes, J., McNally, V. A., Ross, G. A., Fumoleau, P., and Gianni, L. (2010).
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal
growth factor receptor 2-positive metastatic breast cancer that progressed during
prior trastuzumab therapy. J Clin Oncol, 28(7):1138–44.
Baselga, J. and Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and
discovering ERBB3. Nat Rev Cancer, 9(7):463–75.
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L.,
Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell,
T., Henderson, I. C., and Norton, L. (1996). Phase II study of weekly intrave-
nous recombinant humanized anti-p185HER2 monoclonal antibody in patients with
HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol, 14(3):737–44.
Bender, C., Henjes, F., Fröhlich, H., Wiemann, S., Korf, U., and Beißbarth, T. (2010).
Dynamic deterministic effects propagation networks: learning signalling pathways
from longitudinal protein array data. Bioinformatics, 26(18):i596–i602.
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen,
K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., Bei-
jersbergen, R. L., Mills, G. B., van de Vijver, M. J., and Bernards, R. (2007). A
functional genetic approach identifies the PI3K pathway as a major determinant of
trastuzumab resistance in breast cancer. Cancer Cell, 12(4):395–402.
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo,
V., De Falco, S., Melisi, D., Benelli, R., Albini, A., Ryan, A., Ciardiello, F., and
Tortora, G. (2008). Vascular endothelial growth factor receptor-1 contributes to
resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
Clin Cancer Res, 14(16):5069–80.
Biczok, R., Ruschhaupt, M., and Zhang, J. D. (2010). ddCt: The ddCt Algorithm for
the Analysis of Quantitative Real-Time PCR (qRT-PCR). R package version 1.2.0.
Birtwistle, M. R., Hatakeyama, M., Yumoto, N., Ogunnaike, B. A., Hoek, J. B.,
and Kholodenko, B. N. (2007). Ligand-dependent responses of the ErbB signaling
network: experimental and modeling analyses. Mol Syst Biol, 3:144.
154
References
Biscardi, J. S., Ishizawar, R. C., Silva, C. M., and Parsons, S. J. (2000). Tyrosine
kinase signalling in breast cancer: epidermal growth factor receptor and c-Src in-
teractions in breast cancer. Breast Cancer Res, 2(3):203–10.
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F.,
Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N.,
Schooley, K. A., Gerhart, M., Davis, R., Fitzner, J. N., Johnson, R. S., Paxton,
R. J., March, C. J., and Cerretti, D. P. (1997). A metalloproteinase disintegrin
that releases tumour-necrosis factor-alpha from cells. Nature, 385(6618):729–33.
Blume-Jensen, P. and Hunter, T. (2001). Oncogenic kinase signalling. Nature,
411(6835):355–65.
Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., Wang,
S., Garcia-Echeverria, C., and Maira, S. M. (2009). Specific apoptosis induction
by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA
mutant breast cancer cells. Proc Natl Acad Sci U S A, 106(52):22299–304.
Brase, J. C., Mannsperger, H., Frohlich, H., Gade, S., Schmidt, C., Wiemann, S.,
Beissbarth, T., Schlomm, T., Sultmann, H., and Korf, U. (2010). Increasing the
sensitivity of reverse phase protein arrays by antibody-mediated signal amplifica-
tion. Proteome Sci, 8(1):36.
Britten, C. D., Finn, R. S., Bosserman, L. D., Wong, S. G., Press, M. F., Malik,
M., Lum, B. L., and Slamon, D. J. (2009). A phase I/II trial of trastuzumab
plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted
approach. Clin Breast Cancer, 9(1):16–22.
Cai, Z., Zhang, G., Zhou, Z., Bembas, K., Drebin, J. A., Greene, M. I., and Zhang,
H. (2008). Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-
p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene, 27(27):3870–4.
Carracedo, A., Baselga, J., and Pandolfi, P. P. (2008). Deconstructing feedback-
signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell
Cycle, 7(24):3805–9.
Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., and
Arteaga, C. L. (2010). H1047R phosphatidylinositol 3-kinase mutant enhances
HER2-mediated transformation by heregulin production and activation of HER3.
Oncogene.
Chambers, J. M. (1991). Statistical Models in S. CRC Press, Inc., Boca Raton, FL,
USA.
155
References
Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W.,
J., and Leahy, D. J. (2003). Structure of the extracellular region of HER2 alone
and in complex with the Herceptin Fab. Nature, 421(6924):756–60.
Christianson, T. A., Doherty, J. K., Lin, Y. J., Ramsey, E. E., Holmes, R., Keenan,
E. J., and Clinton, G. M. (1998). NH2-terminally truncated HER-2/neu protein:
relationship with shedding of the extracellular domain and with prognostic factors
in breast cancer. Cancer Res, 58(22):5123–9.
Cicenas, J., Urban, P., Kung, W., Vuaroqueaux, V., Labuhn, M., Wight, E., Eppen-
berger, U., and Eppenberger-Castori, S. (2006). Phosphorylation of tyrosine 1248-
ERBB2 measured by chemiluminescence-linked immunoassay is an independent
predictor of poor prognosis in primary breast cancer patients. Eur J Cancer,
42(5):636–45.
Citri, A., Skaria, K. B., and Yarden, Y. (2003). The deaf and the dumb: the biology
of ErbB-2 and ErbB-3. Exp Cell Res, 284(1):54–65.
Citri, A. and Yarden, Y. (2006). EGF-ERBB signalling: towards the systems level.
Nat Rev Mol Cell Biol, 7(7):505–16.
Clynes, R. A., Towers, T. L., Presta, L. G., and Ravetch, J. V. (2000). Inhibitory Fc
receptors modulate in vivo cytoxicity against tumor targets. Nat Med, 6(4):443–6.
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher,
L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. (1999).
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal
antibody in women who have HER2-overexpressing metastatic breast cancer that
has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17(9):2639–
48.
Cooley, S., Burns, L. J., Repka, T., and Miller, J. S. (1999). Natural killer cell
cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of
antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp He-
matol, 27(10):1533–41.
Couch, F. J., Wang, X. Y., Wu, G. J., Qian, J., Jenkins, R. B., and James, C. D.
(1999). Localization of PS6K to chromosomal region 17q23 and determination of
its amplification in breast cancer. Cancer Res, 59(7):1408–11.
Dennis, P. B., Pullen, N., Pearson, R. B., Kozma, S. C., and Thomas, G. (1998). Phos-
phorylation sites in the autoinhibitory domain participate in p70(s6k) activation
loop phosphorylation. J Biol Chem, 273(24):14845–52.
156
References
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A.,
Lickley, L. A., Rawlinson, E., Sun, P., and Narod, S. A. (2007). Triple-negative
breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13(15
Pt 1):4429–34.
Depowski, P. L., Rosenthal, S. I., and Ross, J. S. (2001). Loss of expression of the
PTEN gene protein product is associated with poor outcome in breast cancer. Mod
Pathol, 14(7):672–6.
Dhillon, A. S., Hagan, S., Rath, O., and Kolch, W. (2007). MAP kinase signalling
pathways in cancer. Oncogene, 26(22):3279–90.
Di Cosimo, S. and Baselga, J. (2008). Targeted therapies in breast cancer: where are
we now? Eur J Cancer, 44(18):2781–90.
Dickler, M. N., Cobleigh, M. A., Miller, K. D., Klein, P. M., and Winer, E. P. (2009).
Efficacy and safety of erlotinib in patients with locally advanced or metastatic
breast cancer. Breast Cancer Res Treat, 115(1):115–21.
Diermeier, S., Horvath, G., Knuechel-Clarke, R., Hofstaedter, F., Szollosi, J., and
Brockhoff, G. (2005). Epidermal growth factor receptor coexpression modulates
susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via spe-
cific erbB-receptor interaction and activation. Exp Cell Res, 304(2):604–19.
Dittmar, T., Husemann, A., Schewe, Y., Nofer, J. R., Niggemann, B., Zanker, K. S.,
and Brandt, B. H. (2002). Induction of cancer cell migration by epidermal growth
factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor
via EGFR. FASEB J, 16(13):1823–5.
Duneau, J. P., Vegh, A. P., and Sturgis, J. N. (2007). A dimerization hierarchy in the
transmembrane domains of the HER receptor family. Biochemistry, 46(7):2010–9.
Eckstein, N., Servan, K., Girard, L., Cai, D., von Jonquieres, G., Jaehde, U., Kassack,
M. U., Gazdar, A. F., Minna, J. D., and Royer, H. D. (2008). Epidermal growth
factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin
resistance of human breast cancer cells. J Biol Chem, 283(2):739–50.
Eichhorn, P. J., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Bei-
jersbergen, R. L., Valero, V., Seoane, J., Bernards, R., and Baselga, J. (2008).
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that
is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Cancer Res, 68(22):9221–30.
157
References
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R.,
Maira, M., McNamara, K., Perera, S. A., Song, Y., Chirieac, L. R., Kaur, R., Light-
bown, A., Simendinger, J., Li, T., Padera, R. F., Garcia-Echeverria, C., Weissleder,
R., Mahmood, U., Cantley, L. C., and Wong, K. K. (2008). Effective use of PI3K
and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung
cancers. Nat Med, 14(12):1351–6.
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O.,
Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J.,
Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., and
Janne, P. A. (2007). MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science, 316(5827):1039–43.
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L.,
Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., Sneige, N., Smith, T. L.,
and Hortobagyi, G. N. (2002). Phase II study of weekly docetaxel and trastuzumab
for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol,
20(7):1800–8.
Faber, A. C., Li, D., Song, Y., Liang, M. C., Yeap, B. Y., Bronson, R. T., Lifshits, E.,
Chen, Z., Maira, S. M., Garcia-Echeverria, C., Wong, K. K., and Engelman, J. A.
(2009). Differential induction of apoptosis in HER2 and EGFR addicted cancers
following PI3K inhibition. Proc Natl Acad Sci U S A, 106(46):19503–8.
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H. S., Leahy, D. J., and
Lemmon, M. A. (2003). EGF activates its receptor by removing interactions that
autoinhibit ectodomain dimerization. Mol Cell, 11(2):507–17.
Ferguson, K. M., Darling, P. J., Mohan, M. J., Macatee, T. L., and Lemmon, M. A.
(2000). Extracellular domains drive homo- but not hetero-dimerization of erbB
receptors. EMBO J, 19(17):4632–43.
Franco, R. and Rosenfeld, M. G. (1990). Hormonally inducible phosphorylation of a
nuclear pool of ribosomal protein S6. J Biol Chem, 265(8):4321–5.
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., and
Sliwkowski, M. X. (2004). Insights into ErbB signaling from the structure of the
ErbB2-pertuzumab complex. Cancer Cell, 5(4):317–28.
Friess, T., Scheuer, W., and Hasmann, M. (2005). Combination treatment with erlo-
tinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Clin Cancer Res, 11(14):5300–9.
158
References
Frolov, A., Schuller, K., Tzeng, C. W., Cannon, E. E., Ku, B. C., Howard, J. H.,
Vickers, S. M., Heslin, M. J., Buchsbaum, D. J., and Arnoletti, J. P. (2007). ErbB3
expression and dimerization with EGFR influence pancreatic cancer cell sensitivity
to erlotinib. Cancer Biol Ther, 6(4):548–54.
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman,
N., and Stratton, M. R. (2004). A census of human cancer genes. Nat Rev Cancer,
4(3):177–83.
Gamett, D. C., Pearson, G., Cerione, R. A., and Friedberg, I. (1997). Secondary
dimerization between members of the epidermal growth factor receptor family. J
Biol Chem, 272(18):12052–6.
Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz,
G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., and Ward, C. W.
(2003). The crystal structure of a truncated ErbB2 ectodomain reveals an active
conformation, poised to interact with other ErbB receptors. Mol Cell, 11(2):495–
505.
Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O.,
Zhu, H. J., Walker, F., Frenkel, M. J., Hoyne, P. A., Jorissen, R. N., Nice, E. C.,
Burgess, A. W., andWard, C. W. (2002). Crystal structure of a truncated epidermal
growth factor receptor extracellular domain bound to transforming growth factor
alpha. Cell, 110(6):763–73.
Ginestier, C., Adelaide, J., Goncalves, A., Repellini, L., Sircoulomb, F., Letessier, A.,
Finetti, P., Geneix, J., Charafe-Jauffret, E., Bertucci, F., Jacquemier, J., Viens, P.,
and Birnbaum, D. (2007). ERBB2 phosphorylation and trastuzumab sensitivity of
breast cancer cell lines. Oncogene, 26(50):7163–9.
Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. (1997). ErbB-2, the
preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral
signaling. EMBO J, 16(7):1647–55.
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G.,
Davies, H., Teague, J., Butler, A., Stevens, C., Edkins, S., O’Meara, S., Vastrik,
I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., Buck, G., Choudhury,
B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison,
R., Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T.,
Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Tofts, C., Varian, J.,
Webb, T., West, S., Widaa, S., Yates, A., Cahill, D. P., Louis, D. N., Goldstraw,
P., Nicholson, A. G., Brasseur, F., Looijenga, L., Weber, B. L., Chiew, Y. E.,
DeFazio, A., Greaves, M. F., Green, A. R., Campbell, P., Birney, E., Easton, D. F.,
159
References
Chenevix-Trench, G., Tan, M. H., Khoo, S. K., Teh, B. T., Yuen, S. T., Leung,
S. Y., Wooster, R., Futreal, P. A., and Stratton, M. R. (2007). Patterns of somatic
mutation in human cancer genomes. Nature, 446(7132):153–8.
Grubb, R. L., Calvert, V. S., Wulkuhle, J. D., Paweletz, C. P., Linehan, W. M.,
Phillips, J. L., Chuaqui, R., Valasco, A., Gillespie, J., Emmert-Buck, M., Liotta,
L. A., and Petricoin, E. F. (2003). Signal pathway profiling of prostate cancer using
reverse phase protein arrays. Proteomics, 3(11):2142–6.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., and Carraway, K. L.,
r. (1994). Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase
activity. Proc Natl Acad Sci U S A, 91(17):8132–6.
Gymnopoulos, M., Elsliger, M. A., and Vogt, P. K. (2007). Rare cancer-specific muta-
tions in PIK3CA show gain of function. Proc Natl Acad Sci U S A, 104(13):5569–74.
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., and
King, M. C. (1990). Linkage of early-onset familial breast cancer to chromosome
17q21. Science, 250(4988):1684–9.
Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1):57–70.
Harris, R. C., Chung, E., and Coffey, R. J. (2003). EGF receptor ligands. Exp Cell
Res, 284(1):2–13.
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., and Friend, S. H. (1997).
Integrating genetic approaches into the discovery of anticancer drugs. Science,
278(5340):1064–8.
Hastie, T. (2010). gam: Generalized Additive Models. R package version 1.03.
Henjes, F. (2006). Quantifizierung der MAPK (Mitogen-aktivierte Proteinkinase) in
humanen Brustkrebszelllinien mit Hilfe von miniaturisierten Immunoassays. Di-
ploma thesis, University Bielefeld.
Holbro, T., Civenni, G., and Hynes, N. E. (2003). The ErbB receptors and their role
in cancer progression. Exp Cell Res, 284(1):99–110.
Hommelgaard, A. M., Lerdrup, M., and van Deurs, B. (2004). Association with
membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol
Cell, 15(4):1557–67.
Hudelist, G., Kostler, W. J., Attems, J., Czerwenka, K., Muller, R., Manavi, M.,
Steger, G. G., Kubista, E., Zielinski, C. C., and Singer, C. F. (2003). Her-
2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-
independent activation mechanisms and impact upon the efficacy of trastuzumab-
based treatment. Br J Cancer, 89(6):983–91.
160
References
Hudelist, G., Kostler, W. J., Czerwenka, K., Kubista, E., Attems, J., Muller, R.,
Gschwantler-Kaulich, D., Manavi, M., Huber, I., Hoschutzky, H., Zielinski, C. C.,
and Singer, C. F. (2006). Her-2/neu and EGFR tyrosine kinase activation predict
the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Int J Cancer, 118(5):1126–34.
Hughes, J. B., Berger, C., Rodland, M. S., Hasmann, M., Stang, E., and Mad-
shus, I. H. (2009). Pertuzumab increases epidermal growth factor receptor down-
regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimeri-
zation. Mol Cancer Ther, 8(7):1885–92.
Hutcheson, I. R., Knowlden, J. M., Hiscox, S. E., Barrow, D., Gee, J. M., Robertson,
J. F., Ellis, I. O., and Nicholson, R. I. (2007). Heregulin beta1 drives gefitinib-
resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Breast Cancer Res, 9(4):R50.
Hynes, N. E. and Lane, H. A. (2005). ERBB receptors and cancer: the complexity of
targeted inhibitors. Nat Rev Cancer, 5(5):341–54.
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline,
R. V., Cantley, L. C., and Brugge, J. S. (2005). Breast cancer-associated PIK3CA
mutations are oncogenic in mammary epithelial cells. Cancer Res, 65(23):10992–
1000.
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., and Jain, R. K. (2002). Tumour
biology: herceptin acts as an anti-angiogenic cocktail. Nature, 416(6878):279–80.
Jackson, J. G., St Clair, P., Sliwkowski, M. X., and Brattain, M. G. (2004). Blockade
of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-
ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth
effects. Cancer Res, 64(7):2601–9.
Jimeno, A. and Hidalgo, M. (2006). Multitargeted therapy: can promiscuity be
praised in an era of political correctness? Crit Rev Oncol Hematol, 59(2):150–
8.
Joecker, A., Sonntag, J., Henjes, F., Goetschel, F., Tresch, A., Beissbarth, T., Wie-
mann, S., and Korf, U. (2010). QuantProReloaded: Quantitative Analysis of Micro-
spot Immunoassays. Bioinformatics.
Jones, R. B., Gordus, A., Krall, J. A., and MacBeath, G. (2006). A quantitative pro-
tein interaction network for the ErbB receptors using protein microarrays. Nature,
439(7073):168–74.
161
References
Junttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D., Fried-
man, L. S., Sampath, D., and Sliwkowski, M. X. (2009). Ligand-independent
HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibi-
ted by the PI3K inhibitor GDC-0941. Cancer Cell, 15(5):429–40.
Kaminski, R., Zagozdzon, R., Fu, Y., Mroz, P., Fu, W., Seng, S., Avraham, S.,
and Avraham, H. K. (2006). Role of SRC kinases in Neu-induced tumorigenesis:
challenging the paradigm using Csk homologous kinase transgenic mice. Cancer
Res, 66(11):5757–62.
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Camp-
bell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd,
M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G.,
Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008). A quan-
titative analysis of kinase inhibitor selectivity. Nat Biotechnol, 26(1):127–32.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J.,
Seger, R., Hynes, N. E., and Yarden, Y. (1996). ErbB-2 is a common auxiliary
subunit of NDF and EGF receptors: implications for breast cancer. EMBO J,
15(2):254–64.
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., and Minami, H.
(2009). Association between gain-of-function mutations in PIK3CA and resistance
to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol,
21(2):255–62.
Kauraniemi, P., Barlund, M., Monni, O., and Kallioniemi, A. (2001). New amplified
and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by
cDNA microarrays. Cancer Res, 61(22):8235–40.
Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H.,
Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., and Abate-Shen, C. (2008).
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory
prostate cancer in a preclinical mouse model. J Clin Invest, 118(9):3051–64.
Klos, K. S., Wyszomierski, S. L., Sun, M., Tan, M., Zhou, X., Li, P., Yang, W.,
Yin, G., Hittelman, W. N., and Yu, D. (2006). ErbB2 increases vascular endo-
thelial growth factor protein synthesis via activation of mammalian target of ra-
pamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of
human breast cancer cells. Cancer Res, 66(4):2028–37.
Kokai, Y., Myers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi,
K., and Greene, M. I. (1989). Synergistic interaction of p185c-neu and the EGF
receptor leads to transformation of rodent fibroblasts. Cell, 58(2):287–92.
162
References
Korf, U., Derdak, S., Tresch, A., Henjes, F., Schumacher, S., Schmidt, C., Hahn,
B., Lehmann, W. D., Poustka, A., Beissbarth, T., and Klingmuller, U. (2008a).
Quantitative protein microarrays for time-resolved measurements of protein phos-
phorylation. Proteomics, 8(21):4603–12.
Korf, U., Henjes, F., Schmidt, C., Tresch, A., Mannsperger, H., Lobke, C., Beissbarth,
T., and Poustka, A. (2008b). Antibody microarrays as an experimental platform
for the analysis of signal transduction networks. Adv Biochem Eng Biotechnol,
110:153–75.
Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. (1989).
Isolation and characterization of ERBB3, a third member of the ERBB/epidermal
growth factor receptor family: evidence for overexpression in a subset of human
mammary tumors. Proc Natl Acad Sci U S A, 86(23):9193–7.
Kriegs, M., Kasten-Pisula, U., Rieckmann, T., Holst, K., Saker, J., Dahm-Daphi, J.,
and Dikomey, E. (2010). The epidermal growth factor receptor modulates DNA
double-strand break repair by regulating non-homologous end-joining. DNA Repair
(Amst).
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish,
S., Tibbitts, J., Yi, J. H., Sliwkowski, M. X., Jacobson, F., Lutzker, S. G., and
Burris, H. A. (2010). Phase I study of trastuzumab-DM1, an HER2 antibody-drug
conjugate, given every 3 weeks to patients with HER2-positive metastatic breast
cancer. J Clin Oncol, 28(16):2698–704.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature, 227(5259):680–5.
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., and Hynes,
N. E. (2000). ErbB2 potentiates breast tumor proliferation through modulation of
p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine
growth dependency. Mol Cell Biol, 20(9):3210–23.
Le, X. F., Vadlamudi, R., McWatters, A., Bae, D. S., Mills, G. B., Kumar, R., and
Bast, R. C., J. (2000). Differential signaling by an anti-p185(HER2) antibody and
heregulin. Cancer Res, 60(13):3522–31.
Leary, A. F., Hanna, W. M., van de Vijver, M. J., Penault-Llorca, F., Ruschoff, J.,
Osamura, R. Y., Bilous, M., and Dowsett, M. (2009). Value and limitations of
measuring HER-2 extracellular domain in the serum of breast cancer patients. J
Clin Oncol, 27(10):1694–705.
163
References
Lehman, J. A., Calvo, V., and Gomez-Cambronero, J. (2003). Mechanism of ribo-
somal p70S6 kinase activation by granulocyte macrophage colony-stimulating fac-
tor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a
rapamycin-sensitive, m-TOR-related THR389 kinase. J Biol Chem, 278(30):28130–
8.
Lemmon, M. A. (2009). Ligand-induced ErbB receptor dimerization. Exp Cell Res,
315(4):638–48.
Lenferink, A. E., Pinkas-Kramarski, R., van de Poll, M. L., van Vugt, M. J., Klapper,
L. N., Tzahar, E., Waterman, H., Sela, M., van Zoelen, E. J., and Yarden, Y. (1998).
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases
confers signaling superiority to receptor heterodimers. EMBO J, 17(12):3385–97.
Liu, W., Zhou, Y., Reske, S. N., and Shen, C. (2008). PTEN mutation: many birds
with one stone in tumorigenesis. Anticancer Res, 28(6A):3613–9.
Liu, X., Robinson, G. W., and Hennighausen, L. (1996). Activation of Stat5a and
Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentia-
tion. Mol Endocrinol, 10(12):1496–506.
Loebke, C., Sueltmann, H., Schmidt, C., Henjes, F., Wiemann, S., Poustka, A., and
Korf, U. (2007). Infrared-based protein detection arrays for quantitative proteomics.
Proteomics, 7(4):558–64.
Longva, K. E., Pedersen, N. M., Haslekas, C., Stang, E., and Madshus, I. H. (2005).
Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation
of Akt but not endocytic down-regulation of ErbB2. Int J Cancer, 116(3):359–67.
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., and Pollak, M. (2001). Insulin-like growth
factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer
Inst, 93(24):1852–7.
Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann,
S., Chene, P., De Pover, A., Schoemaker, K., Fabbro, D., Gabriel, D., Simonen,
M., Murphy, L., Finan, P., Sellers, W., and Garcia-Echeverria, C. (2008). Iden-
tification and characterization of NVP-BEZ235, a new orally available dual phos-
phatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in
vivo antitumor activity. Mol Cancer Ther, 7(7):1851–63.
Mallon, R., Hollander, I., Feldberg, L., Lucas, J., Soloveva, V., Venkatesan, A., Dehn-
hardt, C., Delos Santos, E., Chen, Z., Dos Santos, O., Ayral-Kaloustian, S., and
Gibbons, J. (2010). Antitumor efficacy profile of PKI-402, a dual phosphatidy-
linositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther,
9(4):976–84.
164
References
Mannsperger, H. A., Gade, S., Henjes, F., Beissbarth, T., and Korf, U. (2010).
RPPanalyzer: Analysis of reverse-phase protein array data. Bioinformatics,
26(17):2202–3.
Ming, X. F., Burgering, B. M., Wennstrom, S., Claesson-Welsh, L., Heldin, C. H.,
Bos, J. L., Kozma, S. C., and Thomas, G. (1994). Activation of p70/p85 S6 kinase
by a pathway independent of p21ras. Nature, 371(6496):426–9.
Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga,
J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal
antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer
cells. Cancer Res, 61(12):4744–9.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and
Arteaga, C. L. (2001). Epidermal growth factor receptor (HER1) tyrosine kinase
inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer
cells in vitro and in vivo. Cancer Res, 61(24):8887–95.
Mullen, P., Cameron, D. A., Hasmann, M., Smyth, J. F., and Langdon, S. P. (2007).
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen
receptor signaling. Mol Cancer Ther, 6(1):93–100.
Nagata, Y., Lan, K. H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S.,
Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M. C., and Yu, D.
(2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6(2):117–27.
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M. C., and Esteva, F. J. (2004).
P27(kip1) down-regulation is associated with trastuzumab resistance in breast can-
cer cells. Cancer Res, 64(11):3981–6.
Nahta, R., Yuan, L. X., Zhang, B., Kobayashi, R., and Esteva, F. J. (2005). Insulin-
like growth factor-I receptor/human epidermal growth factor receptor 2 heterodi-
merization contributes to trastuzumab resistance of breast cancer cells. Cancer
Res, 65(23):11118–28.
Nevalainen, M. T., Xie, J., Torhorst, J., Bubendorf, L., Haas, P., Kononen, J., Sauter,
G., and Rui, H. (2004). Signal transducer and activator of transcription-5 activation
and breast cancer prognosis. J Clin Oncol, 22(11):2053–60.
O’Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J.,
Duffy, M. J., Crown, J., O’Donovan, N., and Slamon, D. J. (2010). Activated
Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but
not Lapatinib. Mol Cancer Ther, 9(6):1489–502.
165
References
O’Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G. B., Smith, D., Lane, H.,
Hofmann, F., Hicklin, D. J., Ludwig, D. L., Baselga, J., and Rosen, N. (2006).
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates
Akt. Cancer Res, 66(3):1500–8.
Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie,
J. W., Emmert-Buck, M. R., Roth, M. J., Petricoin, I. E., and Liotta, L. A. (2001).
Reverse phase protein microarrays which capture disease progression show activa-
tion of pro-survival pathways at the cancer invasion front. Oncogene, 20(16):1981–9.
Pennell, N. A. and Lynch, T. J., J. (2009). Combined inhibition of the VEGFR and
EGFR signaling pathways in the treatment of NSCLC. Oncologist, 14(4):399–411.
Perez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjold, B.,
Rutqvist, L. E., Skoog, L., and Stal, O. (2007). PIK3CA mutations and PTEN loss
correlate with similar prognostic factors and are not mutually exclusive in breast
cancer. Clin Cancer Res, 13(12):3577–84.
Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A.,
Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov,
A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O.,
and Botstein, D. (2000). Molecular portraits of human breast tumours. Nature,
406(6797):747–52.
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper,
L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., and Yarden, Y. (1996). Diver-
sification of Neu differentiation factor and epidermal growth factor signaling by
combinatorial receptor interactions. EMBO J, 15(10):2452–67.
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J.,
Greenman, C. D., Varela, I., Lin, M. L., Ordonez, G. R., Bignell, G. R., Ye, K.,
Alipaz, J., Bauer, M. J., Beare, D., Butler, A., Carter, R. J., Chen, L., Cox, A. J.,
Edkins, S., Kokko-Gonzales, P. I., Gormley, N. A., Grocock, R. J., Haudenschild,
C. D., Hims, M. M., James, T., Jia, M., Kingsbury, Z., Leroy, C., Marshall, J.,
Menzies, A., Mudie, L. J., Ning, Z., Royce, T., Schulz-Trieglaff, O. B., Spiridou,
A., Stebbings, L. A., Szajkowski, L., Teague, J., Williamson, D., Chin, L., Ross,
M. T., Campbell, P. J., Bentley, D. R., Futreal, P. A., and Stratton, M. R. (2010).
A comprehensive catalogue of somatic mutations from a human cancer genome.
Nature, 463(7278):191–6.
Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W.,
Foy, L., Neubauer, M. G., and Shoyab, M. (1993). Ligand-specific activation of
HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.
Proc Natl Acad Sci U S A, 90(5):1746–50.
166
References
Plowman, G. D., Whitney, G. S., Neubauer, M. G., Green, J. M., McDonald, V. L.,
Todaro, G. J., and Shoyab, M. (1990). Molecular cloning and expression of an
additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S
A, 87(13):4905–9.
Pohl, M., Stricker, I., Schoeneck, A., Schulmann, K., Klein-Scory, S., Schwarte-
Waldhoff, I., Hasmann, M., Tannapfel, A., Schmiegel, W., and Reinacher-Schick, A.
(2009). Antitumor activity of the HER2 dimerization inhibitor pertuzumab on hu-
man colon cancer cells in vitro and in vivo. J Cancer Res Clin Oncol, 135(10):1377–
86.
R Development Core Team (2010). R: A Language and Environment for Statistical
Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-
900051-07-0.
Reinhard, C., Fernandez, A., Lamb, N. J., and Thomas, G. (1994). Nuclear lo-
calization of p85s6k: functional requirement for entry into S phase. EMBO J,
13(7):1557–65.
Riese, D. J., n., van Raaij, T. M., Plowman, G. D., Andrews, G. C., and Stern, D. F.
(1995). The cellular response to neuregulins is governed by complex interactions of
the erbB receptor family. Mol Cell Biol, 15(10):5770–6.
Rotin, D., Margolis, B., Mohammadi, M., Daly, R. J., Daum, G., Li, N., Fischer,
E. H., Burgess, W. H., Ullrich, A., and Schlessinger, J. (1992). SH2 domains
prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992
as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO
J, 11(2):559–67.
Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J., Sonen-
berg, N., and Blenis, J. (2007). RAS/ERK signaling promotes site-specific riboso-
mal protein S6 phosphorylation via RSK and stimulates cap-dependent translation.
J Biol Chem, 282(19):14056–64.
Ryan, A. J. and Wedge, S. R. (2005). ZD6474–a novel inhibitor of VEGFR and EGFR
tyrosine kinase activity. Br J Cancer, 92 Suppl 1:S6–13.
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malm-
strom, P. O., Mansukhani, M., Enoksson, J., Hibshoosh, H., Borg, A., and Parsons,
R. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis,
and ERBB2, and are mutually exclusive with PTEN loss in human breast carci-
noma. Cancer Res, 65(7):2554–9.
167
References
Sahin, O., Frohlich, H., Lobke, C., Korf, U., Burmester, S., Majety, M., Mattern, J.,
Schupp, I., Chaouiya, C., Thieffry, D., Poustka, A., Wiemann, S., Beissbarth, T.,
and Arlt, D. (2009). Modeling ERBB receptor-regulated G1/S transition to find
novel targets for de novo trastuzumab resistance. BMC Syst Biol, 3:1.
Sakai, K., Yokote, H., Murakami-Murofushi, K., Tamura, T., Saijo, N., and Nishio,
K. (2007). Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth
of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci,
98(9):1498–503.
Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M. H., and
Yue, W. (2002). The role of mitogen-activated protein (MAP) kinase in breast
cancer. J Steroid Biochem Mol Biol, 80(2):239–56.
Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005). Phos-
phorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science,
307(5712):1098–101.
Sarup, J. C., Johnson, R. M., King, K. L., Fendly, B. M., Lipari, M. T., Napier, M. A.,
Ullrich, A., and Shepard, H. M. (1991). Characterization of an anti-p185HER2 mo-
noclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Growth Regul, 1(2):72–82.
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., and Hasmann,
M. (2009). Strongly enhanced antitumor activity of trastuzumab and pertuzumab
combination treatment on HER2-positive human xenograft tumor models. Cancer
Res, 69(24):9330–6.
Schulze, W. X., Deng, L., and Mann, M. (2005). Phosphotyrosine interactome of the
ErbB-receptor kinase family. Mol Syst Biol, 1:2005 0008.
Scott, G. K., Dodson, J. M., Montgomery, P. A., Johnson, R. M., Sarup, J. C., Wong,
W. L., Ullrich, A., Shepard, H. M., and Benz, C. C. (1991). p185HER2 signal
transduction in breast cancer cells. J Biol Chem, 266(22):14300–5.
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., and
Moasser, M. M. (2007). Escape from HER-family tyrosine kinase inhibitor therapy
by the kinase-inactive HER3. Nature, 445(7126):437–41.
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., Bo-
tero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., Maira, M., Garcia-Echeverria, C.,
Parra, J. L., Arribas, J., and Baselga, J. (2008). NVP-BEZ235, a dual PI3K/mTOR
inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with ac-
tivating PI3K mutations. Cancer Res, 68(19):8022–30.
168
References
Shattuck, D. L., Miller, J. K., Carraway, K. L., r., and Sweeney, C. (2008). Met
receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer
cells. Cancer Res, 68(5):1471–7.
She, Q. B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R.,
DeFeo-Jones, D., Huber, H. E., and Rosen, N. (2008). Breast tumor cells with
PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
PLoS One, 3(8):e3065.
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., and Lemmon, M. A. (2010).
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze auto-
phosphorylation. Proc Natl Acad Sci U S A, 107(17):7692–7.
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire,
W. L. (1987). Human breast cancer: correlation of relapse and survival with am-
plification of the HER-2/neu oncogene. Science, 235(4785):177–82.
Sorlie, T. (2004). Molecular portraits of breast cancer: tumour subtypes as distinct
disease entities. Eur J Cancer, 40(18):2667–75.
Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T.,
Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C.,
Brown, P. O., Botstein, D., Eystein Lonning, P., and Borresen-Dale, A. L. (2001).
Gene expression patterns of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U S A, 98(19):10869–74.
Stein, R. A. and Staros, J. V. (2000). Evolutionary analysis of the ErbB receptor and
ligand families. J Mol Evol, 50(5):397–412.
Stratton, M. R., Campbell, P. J., and Futreal, P. A. (2009). The cancer genome.
Nature, 458(7239):719–24.
Szabó, V. (2009). Impact of targeted therapeutics on ERBB receptor network activa-
tion in the human breast cancer cell line BT474 applying quantitative microarrays.
Master’s thesis, Ruprecht-Karls-Universität Heidelberg.
Tai, Y. C. and Speed, T. P. (2009). On gene ranking using replicated microarray time
course data. Biometrics, 65(1):40–51.
Takai, N., Jain, A., Kawamata, N., Popoviciu, L. M., Said, J. W., Whittaker, S.,
Miyakawa, I., Agus, D. B., and Koeﬄer, H. P. (2005). 2C4, a monoclonal antibody
against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian
carcinoma cell growth. Cancer, 104(12):2701–8.
169
References
Tan, M., Li, P., Klos, K. S., Lu, J., Lan, K. H., Nagata, Y., Fang, D., Jing, T., and
Yu, D. (2005). ErbB2 promotes Src synthesis and stability: novel mechanisms of
Src activation that confer breast cancer metastasis. Cancer Res, 65(5):1858–67.
Thor, A. D., Liu, S., Edgerton, S., Moore, D., n., Kasowitz, K. M., Benz, C. C.,
Stern, D. F., and DiGiovanna, M. P. (2000). Activation (tyrosine phosphorylation)
of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in
breast cancer. J Clin Oncol, 18(18):3230–9.
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., and Kornblau,
S. M. (2006). Reverse phase protein array: validation of a novel proteomic tech-
nology and utility for analysis of primary leukemia specimens and hematopoietic
stem cells. Mol Cancer Ther, 5(10):2512–21.
Tikhomirov, O. and Carpenter, G. (2004). Ligand-induced, p38-dependent apoptosis
in cells expressing high levels of epidermal growth factor receptor and ErbB-2. J
Biol Chem, 279(13):12988–96.
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S.,
Ratzkin, B. J., and Yarden, Y. (1996). A hierarchical network of interreceptor
interactions determines signal transduction by Neu differentiation factor/neuregulin
and epidermal growth factor. Mol Cell Biol, 16(10):5276–87.
Ueno, Y., Sakurai, H., Tsunoda, S., Choo, M. K., Matsuo, M., Koizumi, K., and
Saiki, I. (2008). Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase
activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer,
123(2):340–7.
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee,
J., Yarden, Y., Libermann, T. A., Schlessinger, J., and et al. (1984). Human
epidermal growth factor receptor cDNA sequence and aberrant expression of the
amplified gene in A431 epidermoid carcinoma cells. Nature, 309(5967):418–25.
Valabrega, G., Montemurro, F., Sarotto, I., Petrelli, A., Rubini, P., Tacchetti, C.,
Aglietta, M., Comoglio, P. M., and Giordano, S. (2005). TGFalpha expression
impairs Trastuzumab-induced HER2 downregulation. Oncogene, 24(18):3002–10.
van der Heijden, M. S. and Bernards, R. (2010). Inhibition of the PI3K pathway:
hope we can believe in? Clin Cancer Res, 16(12):3094–9.
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher,
L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart,
S. J., and Press, M. (2002). Efficacy and safety of trastuzumab as a single agent in
first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol,
20(3):719–26.
170
References
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., and Ullrich,
A. (1995). Heregulin-dependent regulation of HER2/neu oncogenic signaling by
heterodimerization with HER3. EMBO J, 14(17):4267–75.
Wang, S. E., Xiang, B., Guix, M., Olivares, M. G., Parker, J., Chung, C. H., Pandiella,
A., and Arteaga, C. L. (2008). Transforming growth factor beta engages TACE
and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing
breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol, 28(18):5605–20.
Wang, Z., Zhang, L., Yeung, T. K., and Chen, X. (1999). Endocytosis deficiency of
epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF
stimulation. Mol Biol Cell, 10(5):1621–36.
Ward, H. W. (1973). Anti-oestrogen therapy for breast cancer: a trial of tamoxifen
at two dose levels. Br Med J, 1(5844):13–4.
Wehrman, T. S., Raab, W. J., Casipit, C. L., Doyonnas, R., Pomerantz, J. H., and
Blau, H. M. (2006). A system for quantifying dynamic protein interactions defines
a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A,
103(50):19063–8.
Weng, Q. P., Kozlowski, M., Belham, C., Zhang, A., Comb, M. J., and Avruch, J.
(1998). Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using
site-specific anti-phosphopeptide antibodies. J Biol Chem, 273(26):16621–9.
Worthylake, R., Opresko, L. K., and Wiley, H. S. (1999). ErbB-2 amplification inhibits
down-regulation and induces constitutive activation of both ErbB-2 and epidermal
growth factor receptors. J Biol Chem, 274(13):8865–74.
Wulfkuhle, J. D., Speer, R., Pierobon, M., Laird, J., Espina, V., Deng, J., Mammano,
E., Yang, S. X., Swain, S. M., Nitti, D., Esserman, L. J., Belluco, C., Liotta, L. A.,
and Petricoin, E. F., r. (2008). Multiplexed cell signaling analysis of human breast
cancer applications for personalized therapy. J Proteome Res, 7(4):1508–17.
Xia, W., Liu, L. H., Ho, P., and Spector, N. L. (2004). Truncated ErbB2 receptor
(p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3
yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. On-
cogene, 23(3):646–53.
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., Seelig, S., and Arteaga,
C. L. (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt
Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Cancer Res, 62(14):4132–41.
171
References
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito,
T., and Toyoshima, K. (1986). Similarity of protein encoded by the human c-erb-
B-2 gene to epidermal growth factor receptor. Nature, 319(6050):230–4.
Yang, C., Liu, Y., Lemmon, M. A., and Kazanietz, M. G. (2006). Essential role for
Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal
growth factor receptor and is independent of ErbB4. Mol Cell Biol, 26(3):831–42.
Yang, Q. and Guan, K. L. (2007). Expanding mTOR signaling. Cell Res, 17(8):666–
81.
Yarden, Y. and Sliwkowski, M. X. (2001). Untangling the ErbB signalling network.
Nat Rev Mol Cell Biol, 2(2):127–37.
Ye, D., Mendelsohn, J., and Fan, Z. (1999). Augmentation of a humanized anti-HER2
mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor
mAb C225. Oncogene, 18(3):731–8.
Zhang, D. J., Ward, A., Tschulena, U., Bechtel, S., Uhlmann, S., Sahin, O., and
Wiemann, S. (2010). flowDeconvolutor: open-source solution to flow cytometry cell
cycle analysis in R and Bioconductor. submitted.
Zurita, A. J., Troncoso, P., Cardo-Vila, M., Logothetis, C. J., Pasqualini, R., and
Arap, W. (2004). Combinatorial screenings in patients: the interleukin-11 receptor
alpha as a candidate target in the progression of human prostate cancer. Cancer
Res, 64(2):435–9.
172
Die hier vorgelegte Dissertation habe ich eigenständig und ohne unerlaubte Hilfe
angefertigt. Die Dissertation wurde in der vorgelegten oder ähnlicher Form
bei keiner anderen Institution eingereicht. Ich habe bisher keine erfolglosen
Promotionsversuche unternommen.
Heidelberg, den 14.09.2010
Frauke Henjes
